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Kurzzusammenfassung 
Die Modifikation von Peptiden und Proteinen mit Seitenketten-fluorierten Aminosäuren ist eine 
weit verbreitete Strategie um biophysikalische und pharmazeutische Eigenschaften dieser 
anzupassen. Systematische Untersuchungen können dabei wertvolle Einsichten in das Verhalten 
dieser nicht-kanonischen Aminosäuren in natürlichen Proteinumgebungen liefern. Dazu werden 
in dieser Doktorarbeit zwei bewährte Modellsysteme genutzt, um den Einfluss einfacher 
Substitutionen mit sterisch anspruchsvollen und hoch-fluorierten Aminosäuren auf die coiled-coil 
Struktur und Stabilität sowie auf die Stabilität gegenüber Proteasen zu beurteilen. 
Zunächst zeigte der Einbau von Hexafluoroleucin und zwei Trifluorovalin-
Diastereoisomeren an zwei verschiedenen Positionen im hydrophoben Kern eines parallelen, 
heterodimeren coiled-coil Modellsystems, dass diese Aminosäuren problemlos in stabilen, 
dimeren α-helikalen Bündeln akzeptiert werden. Die einfache Substitution von Leucin mit 
Hexafluoroleucin führt zu einem deutlichen Anstieg der thermischen Stabilität, bedingt durch die 
größere Hydrophobie und effiziente Packung.  
Zweitens verbessern fluorierte Leucin- und Isoleucin-Derivate in einigen Fällen die 
Resistenz eines Modellpeptides gegenüber verschiedenen Proteasen. Der Einfluss von Fluor kann 
jedoch nicht verallgemeinert werden, da ebenfalls Destabilisierungen für bestimmte Sequenzen 
beobachtet wurden. Dies könnte durch spezifische Wechselwirkungen zwischen den fluorierten 
Resten und den entsprechenden Enzymbindungstaschen erklärt werden. Bemerkenswert ist, dass 
Trifluoroisoleucin die Peptide gegen die Proteolyse durch alle getesteten Enzyme deutlich 
schützen kann, wenn es N-terminal zur Spaltstelle positioniert wird. 
Schließlich wurden Studien zur Entwicklung stabiler, fluorierter, peptid-basierter HIV-1 
Fusionsinhibitoren durchgeführt. Die Hüllproteinuntereinheit gp41 spielt eine Schlüsselrolle in 
der Infektion der Wirtszelle durch die Ausbildung eines Sechs-Helix-Bündels, welches aus drei 
N-terminalen (NHR) und drei C-terminalen Heptad Repeat (CHR) Sequenzen besteht. Mit der 
Erzeugung von synthetischen, fluorierten CHR-Analoga kann die Bündelbildung und damit der 
Zelleintritt verhindert werden. Das zuvor konzipierte, aus CHR-abgeleitete Peptid C31 dient hier 
als Startpunkt für rationale Substitutionen mit Difluoroethylglycin, Trifluoroisoleucin oder 
Hexafluoroleucin an einer Position, die wichtig für die helikale Bündelbildung ist. In der Tat 
bilden die daraus resultierenden fluorierten C31 Peptide helikale Bündel mit einem NHR-Peptid 
aus, allerdings zeigten die entstandenen Komplexe eine verringerte thermische Stabilität. Obwohl 
die Bindung entropisch nicht begünstigt ist, ermöglicht die hohe negative Enthalpie einen 
spontanen Bindungsprozess. Zwei der fluorierten Analoga weisen sogar eine höhere 
Bindungsaffinität zur NHR-Region im Vergleich zum nativen, nicht fluorierten System auf. 
Zudem wurde ein hetero-tetrameres Gerüst synthetisiert, welches eine trimere Oligomerisierung 
  xiv 
des NHR-Segmentes ermöglicht und für eine genauere Analyse der kinetischen Parameter der 
Helixbildung mittels Oberflächenplasmonenresonanzspektroskopie genutzt werden soll. 
Die Ergebnisse dieser Arbeit tragen so zu einer rationalen Anwendung fluorierter 




  xv 
Abstract 
The modification of peptides and proteins using side-chain fluorinated amino acids is a widely 
used strategy to modulate their biophysical and pharmaceutical properties. Systematic 
investigations can provide valuable insights into the behavior of these non-canonical amino acids 
in natural protein environments. To this end, the research conducted in this doctoral thesis made 
use of two well established model systems to evaluate the impact on coiled-coil structure and 
stability, and proteolytic stability of single substitutions with sterically demanding and highly 
fluorinated amino acids.  
First, the incorporation of hexafluoroleucine and two trifluorovaline stereoisomers at two 
different positions of the hydrophobic core of a parallel heterodimeric coiled-coil model system 
showed that these amino acids are readily accommodated into stable dimeric α-helical bundles. 
Remarkably, the single substitution of leucine with hexafluoroleucine leads to a significant 
increase in thermal stability due to its greater hydrophobicity and efficient packing. 
Second, fluorinated leucine and isoleucine derivatives in some cases improve the resistance 
of a model peptide towards different proteases; however, fluorine’s impact cannot be generalized 
as destabilization was also observed for certain sequences. This might be explained by specific 
interactions between the fluorinated residues and the respective enzyme binding sites. 
Noteworthy is that trifluoroisoleucine is able to significantly protect peptides from proteolysis by 
all tested enzymes when positioned N-terminal to the cleavage site.  
Finally, studies were carried out towards developing stable, fluorinated peptide-based HIV-1 
fusion inhibitors. Envelope protein subunit gp41 plays a key role in host cell infection due to the 
formation of a six-helical bundle consisting of three N-terminal (NHR) and three C-terminal 
heptad repeat (CHR) sequences. By generating synthetic, judiciously fluorinated CHR-analogues 
bundle formation and, therefore, cell entry may be inhibited. The previously designed 
CHR-derived peptide C31 serves as starting point for single substitutions with 
difluoroethylglycine, trifluoroisoleucine or hexafluoroleucine at a position crucial for helix 
bundle formation. The resulting fluorinated C31 peptides indeed undergo helix-bundle formation 
with an NHR-peptide, but the resulting complexes exhibit decreased thermal stabilities. Although 
binding is entropically disfavored, the large negative enthalpy enables a spontaneous binding 
process. Two of the fluorinated analogues exhibit even higher binding affinities to the 
NHR-region compared to the native, non-fluorinated parent. Moreover, a hetero-tetrameric 
scaffold was synthesized that enables a trimeric oligomerization of the NHR-derived segment and 
will be applied in surface plasmon resonance experiments for a more detailed analysis of the 
kinetic parameters underlying helical assembly.  
The results of this thesis will contribute to the rational application of fluorinated amino acids 
to the development of stable, peptide-based drug candidates.  
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Peptides and proteins have various biological functions determined by the physical and chemical 
properties of their amino acid building blocks. Through folding they are precisely arranged in a 
three-dimensional structure.[1-2] α-Helices constitute the most abundant structural folding motif, 
and are thus found to underlie several important intracellular protein-protein interactions 
mediating a number of critical housekeeping events, such as transcriptional control, cellular 
differentiation, and replication, as well as numerous pathogenic processes.[2-5] For example, 
helical bundle formation of surface exposed proteins is a key step in several infection processes 
and enables the entry of viruses like the human immunodeficiency virus (HIV) into host cells. 
Therefore, selective disruption of helix-helix interactions emerged as an excellent strategy for 
drug discovery. 
In the case of HIV infection, its envelope glycoprotein gp41 constitutes as promising drug 
target, as a critical step in the mechanism of cell entry involves a helix-helix interaction between 
the N- and C-terminal heptad repeats (NHR and CHR) of gp41 that form a coiled-coil six-helix 
bundle (6-HB). During the formation of this structure, a pre-hairpin intermediate with a relatively 
long lifetime is formed that can be deactivated by the binding of synthetic peptides derived from 
CHR or NHR to inhibit the formation of the fusion active conformation, and thus, HIV infection 
by interaction with their counterparts in gp41. 
HIV is a retrovirus that exists in two prevalent subtypes (HIV-1, HIV-2) and causes the 
devastating acquired immunodeficiency syndrome (AIDS). Although a 48% decline in AIDS-
related deaths was observed between 2005 and 2016 (from 1.9 million to 1.0 million) that can 
primarily be attributed to a global scale-up of antiretroviral therapy,[6-8] the prevention and 
treatment of HIV still remain challenging. In 2016 there were 1.8 million new infections 
worldwide, adding up to a total of 36.7 million people living with HIV.[8] 
With the current standard of care of at least three antiretroviral drugs, the so-called highly 
active antiretroviral therapy (HAART), the HIV-1 infection is treated and the time until the 
outbreak of AIDS is extended. Currently administered antiretroviral drugs can be divided into the 
following groups of drug substances: nucleoside or nucleotide reverse transcriptase inhibitors 
(NRTIs or NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors 
(PIs), fusion inhibitors (FIs) and integrase inhibitors (INIs). Reverse transcriptase inhibitors and 
protease inhibitors are most common, and only two fusion inhibitors are approved for clinical 
use - among these one peptidic antiviral drug.[9] T20 was approved in 2003 as the first and 
currently only peptidic fusion inhibitor for clinical use.  
The widespread interest in peptides and proteins as highly potent pharmaceuticals relies on 
their inherent biocompatibility as well as their largely unmatched bioactivity, high specificity and 
low toxicity.[10-12] However, the application of peptides as drugs is limited by low bioavailability 
Stabilization of peptides by site-specific incorporation of fluorinated amino acids 
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in vivo, which results from rapid degradation by proteases, slow passive transport in blood, and 
generally low membrane penetration.[13-14] This motivates attempts towards the de novo design of 
peptides and proteins with superior properties such as chemical and metabolic resistance as well 
as thermodynamic stability. It holds also true for T20 that requires frequent high dose 
administration and furthermore some HIV strains are resistant against it.[9] Hence, the 
development of novel peptide-based HIV fusion inhibitors with improved stability and antiviral 
potency is necessary.  
Strategies to improve the properties, especially the proteolytic stability against proteases of 
the blood plasma or digestive system, of peptide-based drugs include PEGylation, 
stapling/crosslinking or cyclization of peptide sequences.[15-17] The latter was used for the design 
of a new potent HIV-1 entry inhibitor VIR-576 that is currently in clinical trials.[18] VIR-576 
exhibits a ring structure established by the formation of a disulfide bond and is able to effectively 
block HIV-1 entry into the host cell by binding to the end of the gp41 fusion peptide, thereby 
inhibiting the anchoring of the virus to the host cell. 
Another strategy to improve pharmacological properties of the peptides relies on the 
incorporation of non-native amino acids such as D-amino acids, N-methylated amino acids, 
α,α-dialkylated residues or β- and  γ-amino acids.[12] Such residues might not be recognized by 
the proteases; thus, no cleavage of the adjacent peptide bond occurs. In these cases, however, the 
residues need to be placed judiciously to maintain the active conformation of a peptide. Therefore, 
the introduction of amino acids that carry heteroatoms in their side chain, which are absent from 
the pool of canonical amino acids has gained much attention. Among these, fluorine has emerged 
as a promising candidate. 
Due to its unique properties, namely its small size, extremely low polarizability, and the 
strongest inductive effect among all chemical elements,[19] fluorine has become a key element for 
modulating the properties of pharmaceuticals and biologically active compounds, exemplified by 
25% of all pharmaceuticals on the market containing fluorine.[20] In this respect, the incorporation 
of side-chain fluorinated amino acids has been established as an efficient strategy to alter distinct 
functionalities of peptides and proteins, such as hydrophobicity, acidity/basicity, and 
conformation and thus can result in advanced pharmacological properties of peptide-based 
drugs.[21] In addition, fluorine addition can have significant effects on protein-protein as well as 
ligand-receptor interactions.  
Nevertheless, general consequences of the hydrogen replacement by fluorine on the structure 
and activity of peptides and proteins are still not completely understood and cannot be 
generalized.[14] Even the incorporation of just one fluorinated amino acid can have a huge impact 
on protein structure,[22] whereas extensively fluorinated amino acids closely preserve and even 
strengthen the structure.[23-24] This makes it difficult to predict the influence of fluorine 
incorporation on protein stability and other pharmacological properties. 
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To fully utilize the power of this unique element one needs to understand the structural 
consequences of incorporating non-canonical side chains into a protein in a more detailed manner. 
To this end, systematic studies of the consequences of fluorination on the interactions of peptides 
with natural protein environments or proteases provide a valuable knowledge base, that can 
ideally be transferred and applied for substitution studies in biologically relevant interaction 
domains, such as gp41 of HIV. 
The ultimate goal is the rational design of proteins using fluorinated amino acids as novel 
building blocks to develop stable peptide therapeutics with improved oral bioavailability, longer 
plasma half-lives, and perhaps even greater selectivity and affinity to their targets than their 
hydrocarbon counterparts. 
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2. Fluorine - a unique element for tuning properties of 
peptides and proteins 
Besides its application as an analytical probe, e.g. in 19F-NMR spectroscopy or positron emission 
tomography (PET), fluorine substituents are widely used for the decoration of organic molecules. 
Especially in medicinal chemistry fluorine introduction is a well-known strategy, but also in crop 
and material science, fluorine has gained much attention in recent years.[25] Fluorine’s unique 
properties and the effect of the resulting carbon-fluorine bond[26] often impart in features that 
cannot be achieved by any other known functional group. Molecular properties such as 
conformation, pKa values of neighboring functional groups or hydrophobicity can be dramatically 
changed upon fluorine introduction and thereby biological half-lives, bioavailability and -activity 
or interactions with proteins, membranes or receptors can be considerably improved.[20, 25, 27] 
Thus, it is not surprising that nowadays around 25% of the marketed drugs contain at least one 
fluorine atom, and they are employed for a wide variety of applications such as depression, cancer, 
and infectious disease therapies.[28-30] 
In this regard fluorine has been proven promising also in the context of peptide and protein 
engineering. Incorporation of fluorinated amino acids can change biophysical, chemical, 
biological as well as pharmacological properties of peptides and proteins.[21] Especially the 
influence on structure, activity, folding, and stability towards thermal and chemical denaturation 
is described in several studies and reviewed extensively by the Koksch group and others.[21, 31-33] 
Within the scope of this doctoral thesis, only aspects regarding the impact of aliphatic, side-chain 
fluorinated amino acids will be discussed in the following. 
2.1 Properties of fluorine and its relevance for medicinal chemistry 
and peptide engineering 
Fluorine is a small atom with a van der Waals radius of 1.47 Å that is between that of oxygen 
(1.52 Å) and hydrogen (1.20 Å).[34] Therefore fluorine is often used as an oxygen- or hydrogen-
mimic in organic chemistry. Especially the substitution of one hydrogen atom with a fluorine 
atom causes only minimal steric perturbation and is considered as shape-conservative or 
bioisosteric.[23-25, 35]  
However, the steric bulk of fluorocarbon groups seems to disproportionately increase with 
the extent of fluorine substitution[14] and is controversy discussed in literature. One reason for this 
might be that the data is always dependent on the applied experimental method, and that its 
subsequent interpretation is often solely based on steric size, disregarding electronic 
contributions, rotation and shape of the considered residues. Thus, the values given in literature 
for the steric demand of a trifluoromethyl group vary from as large as a methyl group[36] up to the 
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size of a sec-butyl or phenyl group.[37] Other studies suggest that the trifluoromethyl group in a 
protein can rather be compared with larger alkyl groups - like an isopropyl group - than with a 
methyl residue,[38] or estimate that the van der Waals volume is close to that of an ethyl group.[39] 
Nevertheless, in addition to its volume, also the shape and flexibility of a substituent have to be 
taken into account, since steric interactions depend on these features.  
Furthermore, fluorine is the most electronegative element (𝜒𝜒 = 4 in the Pauling scale), and 
it has the smallest value of polarizability per molecule volume. This results in a short, strong, and 
very low polarized C-F bond.[40] It is suggested that the increase in bonding strength in comparison 
to a C-H bond may enhance the metabolic stability and thus the bioavailability of a fluorinated 
compound.[41] Moreover, the C-F-bond causes a reduced overall molecular polarizability 
throughout the carbon framework of a fluorinated compound.[14, 42]  
Because fluorine exerts a strong inductive effect, it influences the acidity or basicity of 
nearby functional groups. The pKa values might be changed significantly by several log units, 
depending on the degree and position of the fluorine substitution. The acidity of COOH, 
C-OH and C-H is increased, whereas the basicity of amines is reduced.[43] Moreover, this change 
may have a strong influence on the pharmacokinetic properties of a molecule and its binding 
affinity to receptors since hydrogen bonds and electrostatic interactions play an important role in 
these properties.[20] It is suggested, that the reduced basicity of amines upon fluorination results 
in a better membrane permeability and, therefore, in an improved bioavailability.[44] 
Since hydrogen bonds are essential for the formation on higher-ordered peptide and protein 
structures and they thus provide a significant contribution to the biological function of these 
macromolecules, the value of fluorocarbon-modified amino acids for peptide design and 
engineering might be connected to the ability of fluorine to contribute to the formation of 
hydrogen bonds.[14] This aspect is controversy discussed in literature.[40, 45] Through screening of 
the Cambridge Crystallographic Structural Database and ab initio calculations, it was shown that 
organic fluorine is only a very weak hydrogen bond acceptor.[46] Most of the hydrogen bonds are 
formed between a carbon-bound fluorine and a polarized carbon-bound hydrogen, whereas 
interactions with other functional groups such as amine or hydroxy groups are less common.[47] 
However, these interactions are referred to as weak dipolar interactions rather than hydrogen 
bonds. This may be explained by the high electronegativity and low polarizability of fluorine, 
whereby it does not like to donate its lone electron pairs. In contrast to hydrogen bonding, the 
participation of fluorine in electrostatic/polar interactions is widely accepted and may contribute 
to the enhanced binding affinity of organo-fluorine compounds for the enzyme’s active site.[25] 
For instance, it was demonstrated for a set of fluorine-substituted thrombin inhibitors that 
C-F⋯C=O interactions can play a significant role in protein-ligand interactions and can lead to 
improved binding affinities.[48] 
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Despite the highly dipolar character of the C-F bond, fluorination of an organic compound 
generally results in an increased lipophilicity or hydrophobicity.[42] This may be because fluorine 
lowers the overall polarizability of a molecule and is itself a weak hydrogen bond acceptor. 
Furthermore, fluoroalkyl groups possess larger van der Waal volumes than their non-fluorinated 
analogues. This is described as polar hydrophobicity.[42] Thus, it can be a useful tool to improve 
the membrane permeability or receptor-ligand interactions.[49] However, it must be taken into 
account that fluorination does not always increase the hydrophobicity. While for fluorinated 
aromatic and olefinic compounds the hydrophobicity is increased in comparison to their hydrogen 
analogues, partial aliphatic fluorine substitution might actually reduce rather than increase 
hydrophobicity. An example for this is the terminal mono-, di- or trifluorination of an alkane due 
to the strong electron withdrawing capabilities of the fluorine.[19] Moreover, a critical number of 
fluorine atoms per alkyl chain is required to achieve the so-called hyper-hydrophobicity.[50] One 
reason for the extreme hydrophobicity of highly fluorinated aliphatic hydrocarbons is the low 
polarizability of fluorine. Due to that dispersive interactions with water and other hydrocarbons 
are disfavored. Therefore, perfluorinated compounds tend to segregate from both aqueous and 
hydrophobic environments to form a third, fluorous phase. This is referred to as the fluorous 
effect.[51] 
There a today many marketed drugs containing one or more fluorine atoms, possessing 
increased pharmaceutical effectiveness due to this substitution, and thus underpinning the role of 
fluorine as a key element in drug design. Around one-third of the top-performing drugs that are 
currently on the market contain fluorine atoms in their structure,[28] and some examples of the 
small molecule top-selling, blockbuster drugs that contain this unique element are depicted in 
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Figure 2.1: Fluorine containing drugs. Ledipasvir and Sofosbuvir are used in combination for treatment of hepatitis C. 
Sitagliptin is an oral antihyperglycemic for treatment of diabetes mellitus type 2. It inhibits the dipeptidyl peptidase IV 
(DPP-IV). Fluticasone is a synthetic glucocorticoid and an anti-inflammatory, anti-allergic, and immunosuppressive 
agent that find use, inter alia, in the treatment of asthma or chronic obstructive pulmonary disease. Efavirenz and 
Emtricitabine are antiretroviral medications used to treat and prevent HIV/AIDS. Efavirenz is a non-nucleoside reverse 
transcriptase inhibitor and Emtricitabine a nucleoside reverse transcriptase inhibitor. Risperidone is an antipsychotic 
drug and mainly used to treat schizophrenia or bipolar disorder. Celecoxib is an anti-inflammatory drug and used to 
treat the pain and inflammation of e.g. rheumatoid arthritis. Rosuvastatin is used to treat high cholesterol and related 
conditions, and to prevent cardiovascular disease. 
To sum up, the described unique properties of fluorine made this element an attractive tool for 
medicinal chemists in the rational design of molecules with a beneficial reactivity and biological 
activity. Thus, with the introduction of fluorine atoms different physicochemical and 
pharmacokinetic properties of small, organic molecules can be altered:  
(i) Metabolic stability 
Oxidative metabolism by liver enzymes usually limits the bioavailability of compounds. 
Replacement of an oxidizable C-H group by a C-F group increases the metabolic 
stability, and thus bioavailability of a molecule by blocking metabolically labile 
sites.[20, 25] 
(ii) Acidity/Basicity  
If a fluorine substituent is introduced in proximity to a basic group, its basicity is 
reduced, which may result in an increased membrane permeability and improved 
bioavailability of a molecule.[20, 25] 
(iii) Binding affinity  
Fluorine substituents can modify the binding affinity of a drug candidate by alteration 
of pKa values of adjacent groups or due to a direct interaction of fluorine.[20, 25] 
(iv) Molecular conformation 
Due to steric variations imposed upon fluorine substitution and fluorine’s 
electronegativity, the preferred molecular conformation of a molecule can be 
altered.[20, 25] Electrostatic repulsive or attractive interactions of fluorine or a CF3 group 
with other functional groups in a molecule lead to significant conformational 
changes.[28] 
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(v) Lipophilicity 
For pass through the cell membrane the lipophilicity of a drug molecule needs to be as 
such that it can pass into the lipid core without becoming trapped in it. Using fluorine 
substituents the lipophilicity can be fine-tuned.[25] 
Not only in medicinal chemistry but also for peptide engineering introduction of fluorine atoms 
or fluoroalkyl groups has emerged as a well-established strategy. Several groups took advantage 
of the described unique properties of fluorine to design peptides and proteins with superior 
properties over fully native sequences. Therefore, they introduced fluorinated amino acids into 
various peptide and protein sequences to investigate their influence on structure, activity, folding, 
and stability towards thermal and chemical denaturation.[21, 31-33] Such non-natural building blocks 
are of great interest for the development of highly potent pharmaceuticals and bio-inspired 
materials.[11, 54] Aspects regarding the influence of fluorine on the stability of peptides will be 
discussed in the next sections. 
2.2 Fluorine’s influence on stabilization and folding of coiled-coil 
structures  
A full review on the impact of fluorinated amino acids on peptide and protein properties was 
published in 2012 by the Koksch group.[21] With regard to the fluorinated amino acids used in this 
thesis, the following section briefly summarizes the applications of fluorinated analogues of 
aliphatic amino acids such as leucine, isoleucine or valine with focus on coiled-coil structures.  
2.2.1 The coiled-coil folding motif and its use as model structure 
Isolated α-helices are only marginally stable in solution; thus they are stabilized in proteins by 
being packed together through hydrophobic side chains. These interactions are maximized within 
a helical interface, when the helices are being wound around each other in a superhelix, a so-called 
coiled-coil arrangement.[55] The coiled-coil structure was first postulated in the early 1950s by 
Crick and Pauling & Corey individually through investigation on α-keratin,[56-59] and is found to 
be one of the most abundant folding motifs in nature.[5] Approximately 3-5% of all amino acid 
residues in naturally occurring proteins form coiled-coil structures, as suggested by an analyses 
of various primary sequences.[60] Typically, α-helical coiled coils consist of two to five 
amphipathic right-handed α-helices wrapped around one another to form a left-handed 
supercoil,[61] but also seven-helix coiled-coil arrangements are reported.[62] The individual 
α-helical strands can thereby align in a parallel or antiparallel orientation to each other and the 
helices composing the supercoil can be identical (homotypic) or distinct (heterotypic).[4, 63-64] The 
simplest form is a dimeric α-helical coiled coil as depicted in Figure 2.2 A and B. Whereas regular 
α-helices possess 3.6 amino acids residues per turn, the distortion imposed upon each helix within 
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a left-handed coiled coil reduces this value to around 3.5 and allow the position of the side chains 
to repeat after two turns.[4, 61] This (pseudo-)repetitive sequence of seven amino acids, referred to 
as heptad repeat, is characteristic for coiled coils and usually denoted (a-b-c-d-e-f-g)n in one helix, 
and (a’-b’-c’-d’-e’-f’-g’)n in the other.[65] These seven residues are usually depicted in a so-called 
helical wheel diagram, which gives the arrangement of the residues along the helical axis (Figure 
2.2 D). The number of the heptads n can vary from two in designed coiled coils[66] to 200 in 
natural fibrous proteins.[67] 
 
Figure 2.2: Structure of a classical coiled-coil dimer (PDB code: 2ZTA). A) Side view 
perpendicular to the superhelical axis, and B) top view along the superhelical axis. The 
backbone is represented by ribbons, side chains that make up the knobs-into-holes (KIH) 
interactions as sticks, and the heptad positions a-g colored separately. In this way, the 
hydrophobic core can be easily followed in orange and yellow. C) A single KIH interaction 
between a ‘knob’ from one helix (shown in yellow on the right helix) and a ‘hole’ formed by 
four residues on the other (left helix). D) Helical wheel diagram of a parallel coiled coil 
showing the different recognition motifs. Yellow and orange residues represent hydrophobic 
interactions, coulomb interactions occur between oppositely charged residues (marked in red 
and blue). (Adapted with permission from Testa et. al.[68] Copyright © 2008, Oxford 
University Press) 
Positions a and d are typically occupied by hydrophobic residues, positions e and g by charged 
residues and positions b, c and f by polar or charged residues. Hydrophobic side chains such as 
Leu, Ile, Val, or Met at the a- and d-positions are located on one side of the helix. Thus, in aqueous 
solution, the α-helices of the coiled coil associate via hydrophobic and van der Waals interactions 
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to bury their hydrophobic surface area and form the so-called hydrophobic core.[61, 64] This 
provides the thermodynamic driving force for oligomerization. The side chains facilitate a tight 
knobs-into-holes (KIH) packing, first noted by Crick in 1953.[59] In this arrangement one residue 
(knob) fits into a space generated by four residues of the opposing helix (hole) (Figure 2.2 C). 
This hydrophobic core packing provides the thermodynamic driving force for the formation of 
α-helical coiled coils and is the dominant determinant for coiled-coil stability.[64] Charged 
residues such as Glu or Lys preferably populate the positions e and g of the heptad repeat, which 
flank the hydrophobic core. These residues can form interhelical electrostatic interactions that can 
be attractive or repulsive. Thereby they further contribute to the coiled-coil stability, folding 
specificity (parallel or antiparallel), pairing (homo- or heterotypic) and oligomerization (dimer, 
trimer, etc.).[69-78] If complementary charges in e and g positions are placed accordingly, the 
hetero- and orientation specificity in dimeric coiled-coils can be controlled (Figure 2.3).  
 
Figure 2.3: Orientation and homo/hetero specificity of coiled-coil assemblies specified by charge. N 
and C refer to the N- and C-termini of a peptide chain, respectively. Charge complementarity (matching 
oppositely charged side chains) of the e and g positions can generate different possibilities: parallel 
homodimer, parallel heterodimer, antiparallel homodimer, and antiparallel heterodimer. (Adapted from 
Yu,[64] Copyright © 2002, with permission from Elsevier) 
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The remaining heptad repeat positions b, c and f are solvent exposed and located at the opposite 
side of the hydrophobic core residues, so they are usually occupied by hydrophilic or charged 
residues. These residues mainly contribute to the solubility of the peptides, but are also able to 
stabilize a certain conformation of the α-helical coiled coil through the formation of 
salt-bridges.[79] These intramolecular ionic interactions occur between charged residues in the 
c- and g- or b- and e- positions.[77] 
At the hydrophobic core of dimeric parallel coiled coil, is not only the type of residue 
important (hydrophobic, polar or charged), but also its placement in either a- or d-position. It was 
shown that β-branched hydrophobic residues like Ile and Val provide significantly greater 
stability to the coiled coil than the similarly sized γ-branched amino acid Leu, when placed in 
position a, whereas Leu appeared to provide more stability at position d.[80-82] These positional 
preferences arise from structural differences in the a- and d- positions. Two fundamentally 
different packing geometries occur in a dimeric parallel helix arrangement (Figure 2.4).[78] The 
side chains in an a-position show a structural geometry in which the Cα−Cβ bond vector of the 
amino acid side chain extends parallel to the Cα−Cα helix vector, so that the side chain points 
out of the hydrophobic core (parallel packing). In contrast, in position d, the Cα−Cβ side-chain 
vector extends perpendicular to the Cα−Cα helix vector and thus, directing the side chain into 
the core and directly towards the neighboring helix (perpendicular packing). As a consequence, 
hydrophobic β-branched amino acids are the most stabilizing amino acids in parallel packing 
arrangements, because they project the aliphatic hydrocarbon from the β-carbon atom directly 
into the helical interface, whereas perpendicular packing precludes β-branched residues from 
occupying these sites and γ-branched amino acids are favored.[83-84] In trimeric coiled coils also a 
third way of packing can occur. The Cα−Cβ bond vector of the amino acid side chain forms an 
acute angle (~ 50°) with the Cα−Cα helix vector (acute packing). This is why in this type of 
packing arrangement branched and unbranched residues are nearly equally represented and 
distributed evenly between the a- and d-positions.[85] 
 
Figure 2.4: Schematic drawing of three types of knobs-into-holes packing geometries. The relative positions of the 
Cα–Cβ and Cα–Cα vectors for perpendicular, parallel, and acute knobs-into-holes packing are depicted. (From 
Harbury et al.,[86] Copyright © 1993. Adapted with permission from the American Association for the Advancement 
of Science)  
Since in naturally occurring α-helical coiled-coil structures 80% of the a- and d-positions are 
occupied by hydrophobic amino acid residues, the hydrophobic packing appears to be crucial for 
the stability of the coiled coils.[69, 80] Through the incorporation of unnatural, strongly hydrophobic 
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amino acids in the a- and/or d- position, the stability may be increased even further.[87-88] 
However, the hydrophobic packing does not only influence coiled-coil stability but can also alter 
the structural specificity. For instance, Harbury et al. showed that the coiled-coil structure of 
GCN4 leucine zipper mutants can be either two-, three- or four-stranded depending on the 
positioning of Ile and Leu residues in a or d positions.[85-86] Another example was described by 
Monera et al., who could switch a synthetic coiled coil from two-stranded to four-stranded upon 
the relative positions of Ala residues in the hydrophobic core.[89] Polar amino acid residues fill 
the other 20% of the hydrophobic interaction domain[69, 80] and contribute more to the structural 
specificity (orientation, heterospecificity and oligomerization) and less to the stability.[83-84, 90-91]  
The coiled-coil structure has emerged as one of the most diverse proteins folds in nature and 
is involved in a wide variety of biological functions like membrane fusion, signal transduction, 
and solute transport.[92] These structures enable processes such as muscle contraction, 
transcription and metabolisms, and are part of membrane channels and molecular chaperones, 
which demonstrates the significance of such domains.[4-5, 64, 67] Examples are the transcription 
factor GCN4[93] or viral fusions proteins like the gp120/gp41protein complex of HIV-1[94], which 
is responsible for the entry of the virus into the host cell.  
Due to the described structural simplicity and diverse biological functions, the coiled-coil 
folding motif evolved as excellent target in protein engineering, and with use of a small number 
of quantifiable principles a large structural and functional diversity can be achieved that are not 
possible with other de novo approaches.[4-5, 63-64, 92, 95] For example engineered coiled coils can be 
used for biosensor based applications and affinity chromatography,[96] as drug delivery 
system[64, 97] or as a model system to evaluate the impact of natural and non-natural amino acids 
in peptide structures, e.g. of fluorination on hydrophobic protein-protein interactions.[21] In that 
manner, the VPE/VPK-system was designed in the Koksch group to study the influence of 
fluorinated amino acids in different hydrophobic microenvironments.[79]  
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2.2.2 Globular substitution 
Side-chain fluorinated analogues of aliphatic amino acids such as Ile, Leu and Val (Figure 2.5) 
are the most commonly used building blocks for peptide and protein modifications.[21, 31-33] 
 
Figure 2.5: Side-chain fluorinated analogues of the aliphatic amino acids Val, Ile and 
Leu. The (2S)-form is depicted. 
As described in Section 2.2.1, coiled-coil peptides constitute ideal and simple model systems for 
studying the impact of fluorination on protein-protein interactions. Since the coiled-coil formation 
is mainly driven by the hydrophobic effect, the substitution of residues at the a- and d-positions 
within the hydrophobic core by more hydrophobic fluorinated analogues might create highly 
stable coiled-coil peptides. Many reports indeed demonstrate the stabilization of such structures 
towards thermal and chemical denaturation when fluorine is globally introduced into the 
hydrophobic core.  
In the early 2000s Tang et al. incorporated 5,5,5-trifluoroleucine (53-F3Leu) for Leu at all 
d-positions of a leucine-zipper peptide as equimolar mixture of the (2S,4S)- and 
(2S,4R)-diastereomers using in vivo techniques.[36] By modification of the leucyl-tRNA 
synthetase activity also the incorporation of 5,5,5,5’,5’,5’-hexafluoroleucine (53,5’3-F6Leu) was 
successful.[88] A maximum amount of 92% 53-F3Leu substitution and 74% of 53,5’3-F6Leu 
substitution could be achieved.[36, 88] Analysis by circular dichroism (CD) and ultracentrifugation 
revealed no significant structural difference between the wild-type, non-fluorinated peptide and 
the 53-F3Leu or 53,5’3-F6Leu containing version. Thermal and chemical unfolding studies showed 
that the fluorinated peptides are highly resistant to denaturation, with each 53-F3Leu residue 
accounting for 0.4 kcal mol-1,[36] and each 53,5’3-F6Leu for 0.6 kcal mol-1 of stabilization.[88] An 
increase of 13°C in the melting temperature TM was observed when three fluorine atoms were 
introduced into the Leu side chain, as well as 2.5-fold increased amount of urea was needed for 
denaturation.[36] Adding three more fluorine atoms, enhanced the TM further by 9°C and the 
peptide remained far from complete unfolding even in 8 M urea solution, which is explained by 
the increased hydrophobic character of the additional trifluoromethyl group and suggested a 
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correlation between stability and fluorine content.[88] In another study Tang et al. introduced the 
same mixture of 53-F3Leu at all four d-position Leu residues of a dimeric C-terminal coiled-coil 
subdomain of the leucine-zipper peptide GCN4-p1, a naturally occurring transcription factor 
(Figure 2.6).[87] The authors also generated a fluorinated analogue of the full-length bZip 
transcriptional activation factor. Fluorine introduction retains the dimeric α-helical structure of 
the native peptides, and the fluorinated peptides furthermore exhibited remarkably enhanced 
thermal stabilities, higher resistances towards denaturation, with no loss in DNA-binding affinity 
observed. Molecular dynamics (MD) simulations determined that the coiled-coil binding energy 
is 55% more favorable upon fluorination and indicated that there might be a difference between 
the different isomers of 53-F3Leu.  
 
Figure 2.6: Structure of the GCN4-p1 dimer substituted with 53-F3Leu at the four 
d-positions. The van der Waals radii of the fluorine atoms are depicted as yellow 
spheres. (Reprinted with permission from [87], Copyright © 2001 American 
Chemical Society.) 
Kumar et al. synthesized a highly fluorinated analogue of the GCN4-p1 coiled-coil domain by 
incorporation of fluorinated amino acids in a- as well as in d-positions using solid phase 
synthesis.[98] Four Leu (d-positions) and three Val residues (a-positions) were replaced by 
53-F3Leu and 4,4,4-trifluorovaline (43-F3Val) respectively. The amino acids were mixtures of 
(2S,4S)- and (2S,4R)-53-F3Leu or (2S,3S)- and (2S,3R)-43-F3Val. The single conserved Asn 
residue in a-position was retained to specify oligomerization and orientation.[71, 86, 99-100] As 
concluded by CD spectra, the fluorinated as well as the native peptide are α-helical, while the 
fluorinated analogue possesses a higher level of helicity.[98] In addition, both peptides form dimers 
as determined by sedimentation equilibrium experiments, suggesting that both 53-F3Leu and 
43-F3Val residues are incorporated in the hydrophobic core with only minimal structural 
distortions. The fluorinated peptide is highly stable towards thermal denaturation, exhibiting a TM 
that is 15°C higher than that of the parent peptide with a hydrocarbon core. Interestingly, in 
comparison to the earlier studied analogue described by Tirrell and co-workers, in which only all 
d-positions were substituted with 53-F3Leu, the thermal stabilization is almost equal.[87] The fully 
fluorinated variant was also slightly more stable towards denaturation by chaotropic reagents, and 
the free energy of unfolding was increased by approximately 1.0 kcal mol-1.[98] The authors 
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concluded that the observed stabilization upon fluorine introduction can be explained by the 
segregation of the hydrophobic trifluoromethyl groups from aqueous solvent. 
Since in the described studies diastereomeric mixtures of 53-F3Leu were used, in a more 
recent report the enantiomerically pure (2S,4S)-and (2S,4R)-53-F3Leu residues were incorporated 
separately into the d-positions of the coiled coil to investigate the effects of stereochemistry on 
coiled-coil peptide biosynthesis and stability.[101] Fluorination did not affect the secondary 
structure of the parent peptide, and no difference between the stereoisomers was detected. The 
peptides containing either (2S,4S)- and (2S,4R)-53-F3Leu both stabilize the dimer to a similar 
extent, possessing a 10°C higher TM than that of the native, non-fluorinated analogue. In addition, 
a 1:1 mixture of the (2S,4S)- and (2S,4R)-53-F3Leu substituted variants was investigated that 
exhibited an additional 3°C increase in TM, which is identical to the earlier investigated dimer 
containing the diastereomeric mixture of 53-F3Leu.[36] This result suggests that the fluorinated 
peptides form heterodimers rather than homodimers upon mixing. However, in this studies 
non-purified products and mixtures were used and the level of fluorinated amino acid 
incorporation was in the range of 90% only.[101] 
The Tirrell group studied the influence of the Ile or Val replacement by either 
5,5,5-trifluoroisoleucine (53-F3Ile) or (2S,3R)-43-F3Val, respectively, at the a-positions of 
coiled-coil peptides derived from GCN4 (Figure 2.7).[102] These peptides have been expressed in 
E. coli with extents of residue-specific incorporation of 90 and 88 %, respectively. Both CD and 
equilibrium sedimentation studies showed that the secondary and higher-order protein structure 
is maintained upon fluorine introduction. While the substitution of Ile for 53-F3Ile yielded in an 
increase of 27°C in TM, (2S,3R)-43-F3Val accounted for an only 4°C higher TM compared to the 
Val containing peptide. A similar trend was observed for the stability towards chemical 
denaturation, where the free energy of unfolding was 2.1 kcal mol-1 higher for substitution of Ile 
for 53-F3Ile, and only 0.3 kcal mol-1 higher when Val is replaced by (2S,3R)-43-F3Val. 
Fluorination left the DNA-binding affinities and specificities unchanged compared to those of the 
respective non-fluorinated sequence, which is in agreement with the above described studies by 
Tang et al. on fluorinated variants of GCN4-p1.[87] It is suggested that the great difference in the 
enhancement in stability caused by 53-F3Ile or (2S,3R)-43-F3Val might arise from both entropic 
and packing effects. The steric bulk of the γ-CF3 group presumably leads to steric clashes with 
the helix backbone, resulting in loss of side-chain entropy of Val, and thus a less pronounced 
stabilizing effect.[102] 
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Figure 2.7: Schematic structure of the coiled-coil region of the zipper peptides 
based on the X-ray crystal structure of GCN4. The four a-positions are highlighted 
in yellow, and were mutated to either Ile or Val, and subsequently substituted by 
the fluorinated analogues 53-F3Ile and (2S,3R)-43-F3Val. The conserved Asn residue 
in the a-position of the third heptad repeat was retained in the design of all the 
peptides because of its crucial role in determining oligomerization state, orientation 
specificity, and the overall geometry of the coiled-coil assembly. (Taken from Son, 
Tanrikulu and Tirrell[102] with permission, Copyright © 2006, John Wiley and Sons) 
Kumar and co-workers also designed a peptide H that forms a parallel homodimeric coiled-coil 
assembly, containing Leu at seven out of eight a- and d-positions. Subsequently, these Leu 
residues were replaced by 53,5’3-F6Leu to gain a peptide that is referred to as F.[103-104] The 
peptides used contain an N-terminal Cys residue to enable dimer formation via a disulfide bond. 
A disulfide bound heterodimer of one 53,5’3-F6Leu core peptide and one Leu core peptide HF was 
prepared and its preference for sorting into homodimers was examined by a disulfide-exchange 
assay. Within 30 min an apparent equilibrium was established with only 3% of the initial 
heterodimer remained in solution while the remaining peptides exclusively form HH and FF 
disulfide bridged homodimers (Figure 2.8). All three disulfide bonded dimers HH, FF and HF 
form α-helical structures, and the FF is remarkably more stable towards thermal and chemical 
denaturation than either the heterodimer HF or the hydrocarbon homodimer HH, which show 
comparable values. This stability of the FF assembly was suggested to be partly responsible for 
the observed preference for the formation of homodimers. Sedimentation equilibrium analysis 
revealed that the HH assembly is present as a monomer (one disulfide bonded species with two 
helices), whereas in the FF assembly two disulfide bound peptide dimers align into a putative 
four-helix bundle.[103] The interactions of fluorinated side chains with hydrocarbon side chains 
seem to be disfavored and contribute less to stability, which may be explained with the fluorous 
effect. 
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Figure 2.8: Self-sorting behavior of hydrocarbon- and fluorocarbon-core 
coiled-coil peptides. Covalently bound heterodimer HF undergoes disulfide 
exchange via monomeric peptides to yield covalently bound homodimers HH 
and FF in > 90% yield. Air oxidation of the individual thiol monomers H and F 
produces the same mixture. (Adapted from Yoder and Kumar,[105] with 
permission of the Royal Society of Chemistry, Copyright © 2002) 
The Marsh lab developed a tetrameric, antiparallel coiled-coil model system α4H with Leu in all 
a- and d-positions to systematically investigate the effects of Leu to 53,5’3-F6Leu substitutions on 
the stability and structure of this system.[106-107] The hydrophobic core of this arrangement 
comprises six layers with four Leu residues, and either two, four or all six layers were packed 
with 53,5’3-F6Leu, giving the peptides α4F2, α4F4 and α4F6 (Figure 2.9). It was shown that upon 
fluorine introduction the peptides retain their helical tetrameric structure as intended. NMR 
spectroscopic studies suggested that with an increasing degree of fluorination the peptides exhibit 
a more structured backbone. Furthermore, the free energy of unfolding increased by 0.3 kcal mol-1 
per residue on introducing 53,5’3-F6Leu at the central two layers. Interestingly, a smaller and 
almost linear increase by additional 0.12 kcal mol-1 for each 53,5’3-F6Leu residue is observed 
when packing the further layers. Thus, α4F6 was observed to be ∼ 25% more stable than the 
non-fluorinated α4H. Hence, it was suggested that the stabilization may be attributed to the highly 
hydrophobic nature of 53,5’3-F6Leu rather than to specific fluorine-fluorine interactions between 
these residues within the hydrophobic core. 
 
Figure 2.9: Modeled structures of α4F2, α4F4 and α4F6 peptides showing the 
packing of 53,5’3-F6Leu residues in the hydrophobic cores. The fluorinated side 
chains are highlighted in green. (Reprinted with permission from Lee et al..[106] 
Copyright © 2006, American Chemical Society.) 
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More recent studies on the same system examined the effects of 53,5’3-F6Leu introduction at 
different positions within the hydrophobic core.[108] It was reported that the stabilizing effect of 
53,5’3-F6Leu depends strongly on the positions at which this amino acid is incorporated, and the 
positioning 53,5’3-F6Leu at all a-positions or all the d-positions of the hydrophobic core, thereby 
creating an alternating packing arrangement of Leu and 53,5’3-F6Leu, was found to result in very 
stably folded proteins that exhibit even higher per-residue stabilization than proteins which 
hydrophobic cores are packed entirely with 53,5’3-F6Leu. Thus, it was concluded that the fluorous 
effect does not appear to be primarily responsible for the self-segregating properties observed and 
rather efficient packing of the fluorous amino acid within the hydrophobic core seems to be a 
crucial factor for enhancing protein stability.  
This suggestion was underpinned by high-resolution X-ray structures for different de novo 
designed α4 peptides.[23-24] Analyzing the obtained data revealed that fluorinated amino acids are 
especially effective at stabilizing proteins because, although larger, they closely preserve the 
shape of the natural side chains they replace while increasing the buried hydrophobic surface area. 
Thus, this kind of residue is accommodated within a peptide or protein with only minimal 
structural perturbations. In addition, no evidence was found for the fluorous effect, meaning 
fluorinated residues form favorable contacts with each other, which is a commonly supported 
opinion of why fluorinated residues stabilize peptide structures. This means that the same 
principles that underpin the stability of natural proteins (efficient packing of side chains and 
conventional hydrophobic effects) seem to be responsible for the enhanced stability of fluorinated 
proteins.[24] 
Pendley et al. performed MD simulations on highly fluorinated parallel coiled-coil 
heterodimer that contained 53,5’3-F6Leu at all d-positions and showed that fluorination of Leu 
increases the stability of the helical interactions, thereby enhancing coiled-coil formation.[109] 
To sum up, fluorination of the side chain of aliphatic canonical amino acids can significantly 
increase the stability of coiled-coil peptides and proteins towards thermal and chemical 
denaturation, while usually exerting only marginal structural disturbance. The extent of 
stabilization hereby depends on the identity of the fluorinated amino acid, the substitution 
position, as well as the degree of fluorination. 
However, destabilizations are also observed for global substitutions with fluorinated amino 
acids. Panchenko et al. globally replaced all Leu residues in the enzyme chloramphenicol 
acetyltransferase (CAT) with 53-F3Leu and found that this substitution results in a loss of thermal 
and chemical stability, although the enzyme activity is retained, and the secondary structure 
content greatly improved.[110] A reduced thermodynamic stability for this system was also 
described by others,[111] but it should be noted that CAT is a more complex globular protein. 
Side-chain fluorinated aromatic amino acids resulted in either an increased or a decreased 
stability depending on the substitution position, and degree of fluorination. Whereas 
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pentafluorophenylalanine is usually destabilizing,[112] the highly but not fully fluorinated analogue 
tetrafluorophenylalanine was found to exert a large stabilizing effect.[113] Such fluorinated Phe 
residues are of special interest, because they differ significantly in their electrostatic potential 
from the hydrocarbon analogue, resulting in altered electrostatic interactions or stacking modes. 
That might be used to fine-tune protein folding and stability. Taking advantage of these types of 
interactions protein structures are usually found to be stabilized (vide infra, see Section 2.3). 
2.2.3 Single substitutions  
The above described studies focus on the effects of multiple or global substitutions of amino acids 
by their highly fluorinated analogues, and in the applied coiled-coil systems the fluorinated amino 
acids usually interact with each other. 
In contrast, the Koksch group designed dimeric coiled-coil models, in which single 
substitutions are carried out in only one strand, thus the fluorinated side chain exclusively 
interacts with non-fluorinated side chain so that the influence of fluorination can be investigated 
in a native polypeptide environment.[79, 114-115] For this purpose, fluorinated analogues of 
2-aminobutanoic acid (Abu) were applied (Figure 2.10). 
 
Figure 2.10: Non-canonical amino acids used for single substitutions within the 
hydrophobic core of a coiled-coil dimer: Abu and its analogues MfeGly, DfeGly, 
and TfeGly as well as DfpGly. The (2S)-configuration is depicted. 
In a first study, (2S)-difluoroethylglycine (DfeGly) and (2S)-trifluoroethylglycine (TfeGly) were 
incorporated individually at either position 9 within the hydrophobic core or position 8 within the 
charged surface of a 41 amino acid peptide sequence, that was synthesized via thioester-mediated 
chemical ligation.[114] The developed peptide consists of five full heptad repeats and is able to act 
autocatalytically in templating its own synthesis by accelerating the thioester-promoted 
amide-bond formation. It folds into an antiparallel coiled-coil homodimer,[116] and this antiparallel 
orientation ensures that the fluorinated building blocks exclusively interact with native amino 
acid residues in defined positions at the opposing helix, which are Glu29 in the charged surface 
and Leu30, Leu33, combined with Leu37 for the hydrophobic core. The different synthesized 
peptides were investigated for their coiled-coil peptide formation and stability.[114] The TM values 
were lowered by 5.0-19.5°C upon introduction of DfeGly or TfeGly with the most pronounced 
impact when the Leu residue in position 9 is replaced. Furthermore, it was observed that both 
fluorinated amino acids result in a strong retardation of the self-replication rate relative to the 
control sequence. However, it could be shown that the screens used in this study were sensitive 
enough to detect even the difference of one single fluorine atom within the coiled-coil assembly. 
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In a second study, this library was extended by (2S)-4,4-difluoropropylglycine (DfpGly) and 
the non-fluorinated analogue Abu for comparison.[115] This allows for a systematic study of 
fluorine’s impact in regard to side-chain length and degree of fluorine substitution. As observed 
before, all substitutions of Leu9 in the hydrophobic core strongly destabilize the coiled coil 
towards thermal denaturation compared to the native sequence, lowering the TM significantly by 
14.9-22.3°C. Interestingly, stepwise introduction of fluorine atoms of the Abu side chain slightly 
increases the TM, where the effect for the DfeGly analogue is only small with a 0.4°C enhanced 
TM compared the Abu analogue, while the peptide bearing one more fluorine atom possesses a 
5°C increased thermal stability. A further enlargement due to the incorporation of DfpGly 
however led to a dramatic decreased stability, suggesting that the polarization of hydrogen atoms 
in the neighboring alkyl groups upon fluorine introduction drastically disturbs an efficient 
packing within the hydrophobic core. The replacement of Lys8 in contrast showed a lower impact 
on the thermal stability, reducing the TM by only maximal 5.6°C. This was explained by the loss 
of the stabilizing Lys8-Glu29 salt bridge. In this case all fluorinated peptides show comparable 
thermal stabilities that are even slightly decreased compared to the Abu containing variant. 
 
Figure 2.11: Influence of polarity and spatial demand of different fluoroalkyl 
groups on stability of hydrophobic domains of a coiled-coil peptide. (Adapted with 
permission from reference [115]. Copyright © 2006, John Wiley and Sons) 
In a more recent study, a rationally designed parallel heterodimeric coiled-coil peptide system, 
referred to as VPE/VPK, was used to evaluate the impact of fluorinated amino acid substitutions 
within different hydrophobic protein microenvironments.[79] Therefore, different peptide variants 
were synthesized that contain amino acids with variable fluorine content in either position a16 or 
d19 of the VPK strain within the hydrophobic core. Here, also DfeGly, TfeGly, and DfpGly were 
used, and the non-fluorinated Abu residue was included for comparison. Later the introduction of 
(2S)-4-monofluoroethylglycine (MfeGly) was reported as well.[117] This allowed for the 
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determination of the influence of a gradual increase on the fluorine content, and thus size and 
hydrophobicity of the side chain, on the coiled-coil stability.  
Structural analysis by CD spectroscopy, FRET, and analytical ultracentrifugation of 
equimolar mixtures of VPE with the different VPK analogues indicated that all form stable 
α-helical structures, while maintaining the dimeric oligomerization state and suggest that the 
substitution of Leu19 or Val16 by Abu and its fluorinated analogues only causes minor structural 
perturbations.[79, 117] However, in both substitution positions Abu and its fluorinated analogues 
considerably decreased the thermodynamic stability of the coiled-coil when compared to the 
analogue containing only the canonical amino acids. This effect of the fluorine substitution was 
shown to be position dependent, and the substitution at position a16 seemed to be less tolerated 
than substitution at position d19. While at the central a16 position the stability of the coiled-coil 
dimer increases with the size of the side chain (DfpGly > TfeGly > DfeGly > MfeGly), such a 
correlation could not be detected when these residues were incorporated at the central d19 
position. The result for DfpGly is somewhat contrary to the result for the antiparallel coiled-coil 
system described before, where this residue was found to disturb folding the strongest when 
positioned an a-position.[114-115] The findings obtained for the VPE/VPK system were related to 
the different packing characteristics and relative orientation of the side chains in a- and 
d-positions within the parallel coiled coil.[79, 117] Figure 2.12 illustrates these different packings at 
the two substitution positions exemplarily for TfeGly. In position d19 the highly polarized 
β-methylene group of the studied fluorinated amino acids points towards the interacting 
hydrophobic groups in the opposing VPE strand. In position a16 the bulk of the side chains is 
exposed and the β-methylene groups are turned away from the hydrophobic core. Therefore, the 
fluorine-induced polarity has a stronger destabilizing effect at d-positions, while at a-positions 
the side-chain volume is the crucial factor for coiled-coil stability.  
 
Figure 2.12: Depiction of the different packing and orientation of TfeGly against the 
direct interaction partners at A) position a16 and B) position d19 according to MD 
simulations. The Cβ atoms of the interacting side chains are closer in d- than in 
a-position. The gray arrows display the Cα–Cβ vectors. (Adapted with permission from 




Fluorine - a unique element for tuning properties of peptides and proteins 
 23 
To conclude, single amino acid substitutions with different small, fluorinated Abu analogues 
within the hydrophobic core usually lead to a destabilization of coiled-coil dimers. The effect of 
the fluorine-induced polarity and degree of fluorination on the stability is hereby strongly 
dependent on the characteristics of the microenvironment at the certain substitution position. 
Phage display studies recently showed that with the selection of preferred interaction partners 
of the fluoroalkyl-substituted amino acids evolved microenvironment can be created, which gave 
rise to increased thermal stabilities of coiled-coil systems.[118-119] Thus, the destabilizing effect of 
fluorine introduction can be compensated if correct packing of the fluorinated residue is provided. 
2.3 The impact of CH⋯π interactions on protein stability  
Non-covalent interactions influence biomolecular interactions are important for essentially all 
cellular processes and are also responsible for the folding and stabilization of peptide and protein 
structures.[120-122] Despite interactions such as hydrogen bonds and salt bridges that are widely 
recognized and well-studied non-covalent interactions present in proteins, weak non-covalent 
interactions gradually gaining importance in recent years.[123] Among them are CH⋯π interactions 
that are ubiquitous in chemistry and biology[124] and found in different molecular systems 
including organic crystals, proteins and nucleic acids.[125] In proteins, many CH⋯π interactions 
involving side-chain π-systems are local, and either direct neighbors along the sequence or close 
neighbors in α-helices or β-turns have the tendency to form this kind of interactions,[121] but they 
can be found in almost any type of structural motif.[122] Most CH⋯π interactions hereby occur 
between amino acid residue side chains that are separated by nine or less residues in the sequence. 
They are energetically favorable and can contribute to the overall stability of proteins as well as 
of small molecules.[121-122] They are also known to play an important role in protein-ligand 
interactions,[126] carbohydrate-peptide recognition,[122, 127] and can even build up in whole 
networks.[122, 125] A substantial number of CH⋯π interactions is furthermore found in catalytic 
and ligand binding sites suggesting their possible role in maintaining active site geometry.[122, 125] 
CH⋯π interactions are stable in both polar and non-polar solvents. The overall stabilization 
energy of about 0.5-1 kcal mol-1 per interaction is enough to make it a potentially important 
contributor to the overall protein stability, which is not more than a few kcal mol-1 itself.[121] More 
recent reports state that in typical CH⋯π hydrogen bonds involving aliphatic and aromatic 
CH-groups as the hydrogen donor and a C6 aromatic ring as the CH-acceptor, the stabilization 
energy of a one unit CH⋯π hydrogen bond is ~ 1.5–2.5 kcal mol-1.[122, 127-128] The energy comes, 
essentially, from the dispersion force[124, 128] and the exact value depends on the nature of the 
participating molecular fragments, the CH donor and the π-acceptor groups.[122, 127-128] The 
stronger the proton donating ability of the CH group, the larger the stabilizing effect, meaning 
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that interactions involving aromatic CHs are usually stronger than the aliphatic ones.[127] Thus, 
the CH⋯π interactions are commonly classified as weak H-bonds.[121]  
Screenings of the Protein Data Bank (PDB) revealed that CH⋯π interactions are most 
prominent formed between aromatic CH donor groups and aromatic π-acceptors and between 
aliphatic CH donor groups and aromatic π-acceptors.[121, 125] Among the studied cases, three 
quarters of the Trp-rings, half of the Phe and Tyr-rings and a quarter of the Hi-rings were found 
to serve as acceptors in CH⋯π interactions. Aromatic CH groups, but also the aliphatic side chains 
of amino acid residues Lys, Arg, Met and Pro preferably act as donors. This CH⋯π interactions 
are predominately found in the interior of the protein, however the more hydrophilic the 
participating groups are, the interactions were also found to be located closer to the 
surface.[121-122, 125] 
As many CH⋯π interactions are observed between aromatic CH donor groups and aromatic 
π-acceptors,[129] aromatic-aromatic interactions in proteins were investigated in the recent years 
and in this regard also the impact of fluorination was investigated.[113, 130] Zheng et al. incorporated 
tetrafluorinated Phe residues into the villin headpiece subdomain HP35, a 35-residue α-helical 
protein, which features three interacting Phe residues in the hydrophobic core (Figure 2.13).[113] 
The HP35 domain enables solely edge-to-face interactions: H-4 of F6 packs against the phenyl 
ring of F17 and the H-6 of F10 packs against the π-cloud of F6. The used fluorinated Phe 
substituents exhibit an enhanced hydrophobicity in comparison to the native Phe and the 
remaining hydrogen has an increased partial positive charge.[113] The authors showed the HP35 
variants bearing the tetrafluorinated Phe analogues exhibit increased thermal and thermodynamic 
stability, which was attributed to strengthened CH⋯π interactions. In contrast, the incorporation 
of the pentafluorophenylalanine weakens the protein stability, which is attributed to a potentially 
elimination of CH⋯π interactions. 
 
Figure 2.13: A) Structure of HP35 (PDB code: 1YRF) highlighting the interacting Phe residues 
(F6, F10, and F17) in the hydrophobic core in green. The hydrogen atoms engaging in CH⋯π 
interactions are highlighted in red. B) Structures and space-filling models of the Phe side chain and 
its fluorinated analogues showing the partial charges and electrostatic potentials. Negative 
electrostatic potentials are indicated in red, positive in blue. (Adapted with permission from Zheng 
et al.,[113] Copyright © 2009, American Chemical Society) 
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In 2012, Pace et al. used the model protein system α2D, a 35 residue polypeptide originally 
designed by DeGrado and co-workers[131] to assess the energetic scale of CH⋯π contacts.[120] This 
peptide forms a dimeric four-helix bundle containing two stacked Phe-Phe pairs in the 
hydrophobic core (Figure 2.14).[131] The core was mutated in a way so that it comprises a phenyl 
and cyclohexyl pair. In this conformation, they are forced into a stacking conformation to favor 
CH⋯π interactions.[120] In addition, also a pentafluorophenylalanine moiety (Z) was incorporated. 
It was found that the CH⋯π contact between cyclohexylalanine (Cha) and phenylalanine (F) 
contributes -0.7 kcal mol-1 to the protein stability. In contrast, in the here described case the 
incorporation of pentafluorophenylalanine results in a much smaller change probably due to the 
absence of these favorable CH⋯π contacts. 
 
Figure 2.14: Dimeric structure of the α2D peptide with the Phe residues as sticks 
(left). Electrostatic potential maps for F, Cha, and Z residues that highlight the 
distinct differences in electronics despite their similar size with electron-rich and 
electron-poor regions depicted in red or blue, respectively (right). The F-Cha 
stacking pair in the core of α2D is illustrated was well, with the electron-rich 
π-cloud of F interacting with the partially positive hydrogen atoms of Cha. 
(Reproduced with permission from reference [120], Copyright © 2012, John Wiley 
and Sons) 
Another recognition motif that plays a significant role in protein folding and protein-protein 
interactions is based on the stacking behavior of aromatic rings, often referred to as π-π 
interactions or quadrupole interactions. In this context, the tendency of aromatic and 
perfluoroaromatic molecules to associate with each other is focus of several reports.[130, 132-133] 
Aromatic compounds such as benzene exhibit a negative potential at the π-face and a positive 
potential around the periphery.[133] This electron distribution is referred to as quadruple. On the 
contrary, perfluoroaromatic molecules possess a reversed quadruple with a negative potential on 
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the periphery and a positive potential on the aromatic ring. This might be attributed to the electron 
withdrawing effect of the fluorine atoms, which results in an electrostatic interaction between 
aromatic and perfluoroaromatic compounds that differ from the ones when only non-fluorinated 
aromatics are interacting with each other. The so obtained different preferred stacking modes 
(edge-face, offset-stacked or face-face) can be used to induce strong non-covalent and selective 
protein-protein interactions and to stabilize protein structures.[130, 132-133] These π-π stackings are 
not of crucial importance for the understandings of this dissertation and thus will not be discussed 
further. 
The CH⋯π interactions between aliphatic CH-donors and aromatic π-acceptors are the most 
prominent class of this kind of interactions in protein structures.[121, 125] Besides Lys, Arg, Met 
and Pro side chains, common donors are both methyl groups of Leu and Val, but also other 
aliphatic amino acid residues like Ile and Ala are frequently found to engage in CH⋯π 
interactions. As stated before, interactions generally occur between direct neighbors, but within 
α-helices interactions with a distance of i and i + 4 are almost as often observed.[121, 125] However, 
the significance of aliphatic fluorinated amino acids as donors in such interactions within protein 
systems has been hardly explored so far. It is known, that the incorporation of fluorine results in 
a significant polarization of adjacent CH-bonds,[79] and the hydrophobicity of fluorinated aliphatic 
amino acids should be increased in comparison to their hydrocarbon analogues.[50, 134-136] In line 
with the studies on fluorinated aromatic amino acids by Gao and coworkers,[113, 120, 130, 132-133] the 
fluorination of aliphatic amino acids might also strengthen CH⋯π interactions and thus, protein 
stability might be increased. Hence, the influence of such interactions are probed within the scope 
of this doctoral thesis (see Section 5.4). 
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Figure 2.15: Examples of CH⋯π interaction with aliphatic CH-donors and aromatic π-acceptors. A) Interaction 
between Gln425 and Phe426 at the dimerization interface of the human cellular coagulation factor XIII (PDB code: 
1F13).[137] B) CH⋯π hydrogen bond between methyl group of Leu50 and aromatic ring of Tyr59 in ubiquitin 
(PDB code: 1UBQ).[138] C) Multiple CH⋯π interactions found in the human growth hormone (PDB code: 3HHR). 
Lys179, Arg211, Arg213 and Lys215 are sandwiched by aromatic residues Trp186, Phe225, and Tyr222, and vice 
versa.[139] 
2.4 Influence of fluorine on the proteolytic stability of peptides and 
proteins  
Peptides show generally excellent specificity and high affinity for recognizing and binding to 
their targets and are therefore desirable lead compounds in drug development. However, their 
application as drugs is limited due to several factors such as poor membrane permeability and a 
short half-life attributable in part to low stability in plasma, and sensitivity to proteases; resulting 
in low bioactivity and poor oral bioavailability.[12, 15-17, 140] Strategies to overcome these 
limitations, especially to prolong the half-life and enhance resistance towards proteases, include 
cyclization, stapling of peptide sequences, blockage of C- or N-terminal ends via N-acylation or 
C-amidation, PEGylation, but also the introduction of noncanonical amino acids such as D-amino 
acids, α- or N-methylated amino acids or β-amino acids.[15-17] Here, also fluorinated amino acids 
have found widespread application for improving the resistance of peptides towards proteolytic 
degradation. For instance, sterically constrained α-trifluoromethyl substituted amino acids that 
carry a CF3 group instead of the Cα-proton of proteinogenic amino acids were investigated for 
their potential of peptide stability modification. Due to the incorporation of such amino acids, 
strong conformational restrictions are exerted on a peptide sequence and neighboring substituents 
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experience considerable polarization effects. Both factors usually resulted in an increased 
proteolytic stability of the substituted peptides, but advantageous interactions of the fluoroalkyl 
group with the particular enzyme’s binding site observed in other cases, yielded in a more rapid 
digestion of the fluorinated substrate by the protease.[141-143] 
A more frequently used class of fluorinated amino acids investigated in this purpose are 
canonical, aliphatic amino acids bearing the fluorine substituent in the side chain. Their impact 
on proteolytic stability was investigated for biologically active peptides and model systems, and 
the results are summarized in the next paragraphs.* 
Biologically active peptides 
5,5,5,5’,5’,5’-hexafluoroleucine (53,5’3-F6Leu) was used to improve the potency and proteolytic 
stability of potential therapeutic peptides.[144-146] Meng et al. reported the replacement of two or 
five different residues at the nonpolar face of the antimicrobial peptides buforin II (BII)[147] and 
magainin 2 amide (M2)[148] (Figure 2.16 A and B) by 53,5’3-F6Leu, and analyzed the resulting 
fluorinated peptides for their resistance towards proteolytic cleavage by trypsin, and their 
antimicrobial and hemolytic activity.[144] Almost all of the fluorinated peptides displayed an 
1.4- to 2.3-fold increased proteolytic stability towards trypsin compared to the non-fluorinated 
parent peptides. Only one fluorinated buforin variant was degraded at a slightly faster rate than 
the parent peptide, whereas the highly fluorinated magainin 2 peptide containing five 53,5’3-F6Leu 
residues was extremely resistant. Over 78% of the whole-length peptide still remained in solution 
after 3 h. In contrast, the non-fluorinated magainin 2 is completely digested within 40 min. It is 
suggested that this observation can be attributed to the steric bulk of 53,5’3-F6Leu, leading to a 
occlusion of the fluorinated substrates from the enzyme’s active site.[144] Furthermore, some 
fluorinated peptide showed a different cleavage pattern compared to the non-fluorinated one, and 





* Adapted from S. Huhmann, B. Koksch, Fine-tuning the proteolytic stability of peptides with fluorinated 
amino acids. Eur. J. Org. Chem. 2018, DOI: 10.1002/ejoc.201800803 
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Figure 2.16: Structures and sites of fluorination of different biologically active peptides. 
A) Buforin II series: Leu18 and 19 were substituted with 53,5’3-F6Leu (PDB code: 2RVQ). 
B) Magainin 2 series: sites of fluorination are residues Leu6, Ala9, Ala13, Val17, and Ile20 
(PDB code: 2MAG). C) MSI-78 dimer structure with Leu and Ile residues. D) GLP-1: Ala8, 
Glu9, Gly10, Phe28, Ile29, Leu32 were replaced by 53,5’3-F6Leu (PDB code: 1D0R). (The 
structure of MSI-78 is reproduced with permission from Gottler et al.,[146] Copyright © 2008 
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim) 
Gottler et al. introduced 53,5’3-F6Leu into a synthetic analogue of magainin 2, named MSI-78 
(Figure 2.16 C). The two Leu and Ile residues of the sequence were substituted with this highly 
fluorinated amino acid to produce a peptide referred to as fluorogainin-1. Both peptides were then 
compared for their antimicrobial and hemolytic activity, and proteolytic stability towards trypsin, 
and chymotrypsin.[146] Neither of the peptide showed any hemolytic activity, while fluorogainin-1 
maintained the broad-spectrum antibiotic activity. MSI-78 and its fluorinated analogue were 
unstructured in the absence of liposomes, whereas in their presence the peptides possessed 
an α-helical conformation.[146] Interestingly, the incorporation of 53,5’3-F6Leu residues only 
protects the resulting peptide almost completely against proteolysis by trypsin and chymotrypsin 
in the presence of liposomes. Whereas MSI-78 was fully degraded within 30 min, fluorogainin-1 
remained intact even after 10 h. In contrast, the fluorous peptide was as rapidly degraded as the 
nonfluorinated control in the absence of a membrane environment. These findings are in contrast 
to the observations made for buforin II and magainin 2 described above,[144] where fluorination 
results in an improved proteolytic stability even in the absence of a membrane. Thus, it is 
suggested that 53,5’3-F6Leu introduction itself is not the solely factor responsible for prevention 
of proteolysis.[146] Here, the interaction of the fluorinated peptide with the membrane rather 
accounts for the observed resistance, attributable to a formation of a more stable coiled-coil 
dimer.[146, 149] 
The glucagon-like-peptide-1 GLP-1[7-36] (Figure 2.16 D) is a promising therapeutic for 
treatment of diabetes mellitus type 2, but unfortunately the rapid digestion (t1/2 ≈ 2 min) by the 
serine dipeptidyl peptidase IV (DPP IV) limits its application substantially.[150-152] Thus, 
53,5’3-F6Leu was site-specifically incorporated into this peptide at positions adjacent to the 
cleavage site for proteolysis (Ala8-Glu9) with the aim to improve the resistance towards DPP IV. 
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Furthermore, a double substituted mutant was synthesized, as well as variants containing 
53,5’3-F6Leu at the N-terminal site of GLP-1 to adjust its binding affinity to the corresponding 
receptor GLP-1R.[145] The authors showed that the fluorination did not result in structural 
perturbation as these peptides adopt secondary structures similar to the native GLP-1. It was 
demonstrated that the substitution of the hydrophobic positions 8, 9 and 10 adjacent to the 
cleavage site can lead to a complete resistance towards DPP IV digestion. For some sequences no 
digestion products could be detected even after 24 h. In addition, fluorine introduction left the 
cleavage site between residues 8 and 9 unchanged.[145]  
To summarize, using the highly fluorinated, aliphatic amino acid 53,5’3-F6Leu 
therapeutically valuable peptides can be generated that display higher proteolytic stability while 
retaining their activity. Furthermore, the obtained results indicate that large hydrophobic side 
chains such as that of 53,5’3-F6Leu are well tolerated at different positions within a peptide. 
Another extensively fluorinated amino acid that was used to improve proteolytic stability of 
therapeutically valuable peptides is 4,4,4,4’,4’,4’-hexafuorovaline. In the 1980s the group 
Marshall showed that the incorporation of this amino acid at different positions of the 
angiotensin II peptide enhances the resistance of the gained fluorinated analogues towards 
proteolytic degradation by the enzymes carboxypeptidase A, hog renal acylase, and 
α-chymotrypsin.[153-154] Angiotensin II plays an important role in blood pressure regulation and 
was recently approved by the U. S. Food and Drug Administration (FDA) as a vasoconstrictor for 
the treatment of low blood pressure resulting from septic shock.[155-156] 
Model peptides  
53,5’3-F6Leu was furthermore applied for investigations on the impact of fluorination on the 
stability of an de novo designed model 4-α-helix bundle α4H (Figure 2.17).[157] The Leu residues 
in the hydrophobic core (three a- and three d-positions) of this peptide were entirely packed with 
53,5’3-F6Leu to produce an extensively fluorinated analogue referred to as α4F6. Both peptides 
were compared for their ability to resist proteolytic degradation and unfolding by fluorinated and 
nonfluorinated solvents. α4F6 is more stable towards unfolding by organic solvents than α4H, and 
19F-NMR studies demonstrated that this peptide does not exhibit a self-segregating behavior as 
assumed by the fluorous effect. Although both peptides have several potential cleavage sites for 
either chymotrypsin or trypsin, α4F6 resists proteolysis by these proteases much better than α4H. 
The latter was almost completely digested already after 15 min when incubated with trypsin, and 
in the case of chymotrypsin within 2 h. In contrast, less than 50% of the full-length α4F6 were 
digested by trypsin after 110 min, and hardly any degradation was detected by chymotrypsin. This 
is somewhat surprising as introduction of 48 trifluoromethyl groups in α4F6 can be considered 
quite an extreme modification, also regarding the fact that the side chain of 53,5’3-F6Leu is ~ 30% 
(32 Å3) larger than that of Leu[24]. The observed differences might be explained by the greater 
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hydrophobicity of 53,5’3-F6Leu,[135] leading to an increased thermodynamic stability of the 
fluorinated peptide α4F6 compared to the non-fluorinated parent peptide α4H, rather than the 
fluorous effect, or the inability of proteases to accommodate fluorinated substrates.[157] Such 
thermodynamic stabilizations upon a global substitution of the hydrophobic core of a protein were 
described previously.[88, 104, 107] 
 
Figure 2.17: Left: Tetrameric structure of α4H (PDB code: 3TWE). Leu residues are marked in green and were 
globally substituted with 53,5’3-F6Leu. Right: Primary structures of FA peptide library. Positions are named according 
to Schechter and Berger nomenclature.[158] Substitution positions Xaa are marked green; with Xaa = Abu, DfeGly, or 
TfeGly. 
The described experiments of fluorine substitution in biologically active peptides suggested that 
highly fluorinated amino acids such as 53,5’3-F6Leu generally improve the proteolytic stability 
rather than reduce it, as there are only a few examples of the latter case.  
In order to verify whether small, aliphatic fluorinated amino acids can also enhance the 
proteolytic stability of peptides, the Koksch group performed systematic studies with the help of 
a model peptide library.[159-160] Therefore, a model peptide FA was designed that consists of 10 
amino acid residues and comprises the substrate specificities of different serine and aspartate 
proteases. The fluorinated analogues of (S)-2-aminobutanoic acid (Abu), 2-amino-4,4-
difluorobutanoic acid (DfeGly) and 2-amino-4,4,4-trifluorobutanoic acid (TfeGly), were 
individually incorporated at the P2, P1’, or P2’ positions located adjacent to the cleavage site and 
substitute an Ala residue of the native sequence (Figure 2.17). Comparison to the corresponding 
peptides containing the hydrocarbon analogue Abu enabled the distinction between the effects 
resulting from either steric or electronic effects. The proteolytic stability of the resulting peptide 
library was investigated towards human blood plasma and elastase[159], as well as α-chymotrypsin 
and pepsin[160] and evaluated using an analytical RP-HPLC assay with fluorescence detection, and 
cleavage sites were identified by ESI-ToF analysis.  
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The influence of fluorination on plasma half-lives was observed to be position dependent. 
While fluorinated Abu analogues in P2 position maintained or decreased the half-life up to 
2.3-fold, the substitution of the P1’ position resulted in a 1.7- to 2.1-fold increased stability 
compared to the hydrocarbon analogue Abu. In the case of the P2’ substituted peptides, however, 
fluorination either improved or decreased the half-life of the peptide depending on the fluorine 
content. In the case of incubation with isolated elastase, this phenomenon was observed for the 
fluorine substitution in P2, and P1’. Here, incorporation of TfeGly results in an increase in 
stability whereas DfeGly leads to decreased stability compared to the peptide containing Abu. 
Noteworthy, the TfeGly containing peptides showed almost completely resistance, only up to 
7.5% were degraded after 120 min incubation. The opposite is observed for the impact of 
fluorination in P2’ position. Here, introducing DfeGly slightly increased the stability of the 
resulting peptide, whereas TfeGly produced a peptide less resistant towards digestion by 
elastase.[159] 
In a second study, these peptides were exposed to α-chymotrypsin and pepsin.[160] When 
incubated with α-chymotrypsin, fluorine introduction reduced the rate of hydrolysis compared to 
the corresponding Abu analogue in only one case, that is when DfeGly is positioned in the P2 
position of FA. Here, the resistance towards α-chymotrypsin hydrolysis was enhanced by a factor 
of ~ 2.5. All other fluorinated peptides of this library were more prone to hydrolysis by 
α-chymotrypsin. The observations made for the P2’ substitution correlate with the increase in 
hydrophobicity for the fluorinated Abu analogues,[50] underpinning the hydrophobic character of 
the S2’ subsite of the enzyme.[161-162] For pepsin digestion the observed effects are different, here 
TfeGly is able to protect the peptide against digestion in all substitution positions when compared 
to the non-fluorinated peptide containing Abu in the respective positions. On the contrary, DfeGly 
effectively stabilized the peptide against pepsin only in P2’. Remarkably, pepsin seems to disfavor 
the fluorinated side chain in P2’ position, as only up to 5% of the peptides are digested within 
120 min.[160] 
In brief, a significant increase in proteolytic stability towards either α-chymotrypsin or 
pepsin was observed in only half of the investigated cases. A remarkably increased resistance 
with a greater than 50% gain in stability was shown for two cases: fluorination at P2’ in the 
context of pepsin digestion.[160] These systematic studies revealed that the impact of fluorine on 
the proteolytic stability depends on the particular enzyme, the position of the substitution relative 
to the cleavage site and the fluorine content of the side chain. Moreover small, aliphatic 
fluorinated amino acids significantly increase the proteolytic stability only in a few cases. 
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Aromatic, side-chain fluorinated amino acids 
In addition to the aliphatic, fluorinated amino acids derivatives, also aromatic fluorinated amino 
acids have been the subject of studies regarding their impact on peptide proteolysis. These were 
mainly performed in the context of globular proteins,[163-164] but these class of amino acids found 
also use in small peptides to modulate stability and potency.[165-167] In this cases, neither a global 
nor a single substitution with aromatic, fluorinated amino acids is able to increase stability of a 
globular protein or small peptide towards different proteases, but rather the stability is maintained 
or reduced. This is in huge contrast to the observations made for highly fluorinated and bulky 
fluorinated amino acids like 53,5’3-F6Leu described above that are able to protect a peptide from 
digestion by various proteases. 
Nevertheless, the effect of incorporation of side-chain fluorinated amino acids on resistance 
towards proteolytic degradation cannot be generalized and is far from being predictable, and 
consequently needs to be studied always case-by-case. Depending upon the substitution position, 
the chemical nature and fluorine content of the amino acid side chain, as well as the particular 
protease used, the proteolytic stability of peptides and proteins can be modified in various ways. 
Even a single substitution with a minimally fluorinated amino acid bearing a small side chain can 
have a dramatic effect on proteolytic stability.  
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3. HIV-1 and its entry into the host cell 
The infection with the human immunodeficiency virus (HIV) causes over time acquired 
immunodeficiency syndrome (AIDS). The HIV infection leads to a progressive failure of the 
cellular immune function, and as a consequence AIDS is characterized by increased susceptibility 
to life-threatening opportunistic infections and a higher incidence of cancers.[9] Due to a global 
scale-up of antiretroviral therapy, with nowadays ~ 46% of HIV-1 infected people worldwide 
covered, annual deaths from AIDS-related causes have decreased by 48% from 2003 until 
2016.[6-7] In highly active antiretroviral therapy (HAART), first introduced in 1995, three or four 
antiretroviral therapeutics are combined that target different stages of the retrovirus life-cycle 
(entry, reverse transcription, integration and maturation). Usually two nucleoside/nucleotide 
reverse transcriptase inhibitors (NRTI/NtRTI) are applied together with one protease inhibitor or 
a non-nucleoside reverse transcriptase inhibitor (NNRTI).[9, 168] These drugs can stop ~ 99% of 
viral replication, changing HIV infection from a deadly to a chronic disease. 
Although HAART is generally effective in most patients, severe side effects, resistance 
development and high costs restrict its efficacy considerably.[9, 168-176] Moreover, there were more 
than 1.8 million new cases of HIV-1 infection diagnosed worldwide in 2016, which means about 
5000 new infections each day.[6-7] Hence, there is still need for further expanding treatment and 
identifying new drugs that could enhance the efficiency of HAART. Elucidation of the whole 
machinery underlying the entry process has provided insights into a new type of drugs, which 
block HIV entry.[168] Such inhibitors of viral fusion target different receptors and proteins 
involved in the several stages of the entry mechanism (CCR5, CXCR4, gp120 and gp41) and are 
applicable in combined therapies or when resistance to other antiretroviral drugs 
appears.[168, 177-178] Moreover, since they act before the virus enters the cell, they could have the 
same pre-exposure prophylactic potential as vaccine-induced immunity.[169] In this context, 
especially the development of fusion inhibitors that target the gp41 region of HIV-1 gained 
widespread interest as gp41 directly mediates fusion of the viral with the host cell’s membrane 
by formation of a 6-HB.[94, 176, 179-182] Aspects regarding this topic will be discussed in the 
following sections.  
3.1 Entry mechanism of HIV-1 
The structure of a human immunodeficiency virus (HIV) is depicted in Figure 3.1. For membrane 
fusion with a target cell only the HIV-1 envelope glycoprotein is required. It is initially generated 
as the fusion-incompetent precursor gp160, which is extensively glycosylated and proteolytic 
cleaved to generate two non-covalently associated subunits - a surface subunit gp120 and a 
transmembrane subunit gp41.[94, 179, 183] 
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Figure 3.1: Structure of the human immunodeficiency virus (HIV) in cross section. The 
virus is surrounded by an envelope membrane in which the complex of the viral 
glycoproteins (gp120/gp41) is embedded. The viral capsid (core) with the genome is 
located in the interior. It contains two copies of single stranded RNA, which interact with 
the viral nucleoproteins to form the nucleocapsides, and the viral enzymes protease, reverse 
transcriptase and integrase. The link protein connects the capsid with the membrane. 
(Adapted from Löffler.[184] Copyright © 2008, Springer Medizin Verlag, Heidelberg) 
The process of HIV entry into the host cell can be divided into three principal events (see 
Figure 3.2):[176] 
(i) Viral particle attachment to the host cell 
(ii) Binding to a seven-transmembrane chemokine co-receptor 
(iii) Fusion of the viral and cellular membranes 
The entry of HIV into the target cell is initiated by attachment of the envelope glycoprotein gp120 
to the cellular receptor CD4 on the target cell surface. Thus, HIV preferably infects cells with 
strong CD4 expression such as helper T cells and macrophages. The binding to CD4 initiates a 
structural rearrangement in gp120, leading to the formation and exposure of the co-receptor 
binding site. In humans, CCR5 or CXCR4, both seven-transmembrane proteins of the chemokine 
receptor family, act as co-receptors. The co-receptor binding induces further conformational 
changes in gp120 that result in the exposure of the gp41 and its insertion into the host cellular 
membrane, leading to viral entry.[94, 176, 179, 183, 185-186] 
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Figure 3.2: Mechanism of HIV entry. HIV entry begins with the attachment of the envelope glycoprotein gp120 to a 
CD4 molecule (binding site for CD4 is shown in yellow) on a target cell. Binding to CD4 induces conformational 
changes in gp120 which exposes the V3 loop and co-receptor binding site (gray). Engagement of these CD4-induced 
epitopes with the chemokine co-receptors initiates further rearrangements leading to the uncovering of the gp41 fusion 
peptide. Once exposed, the fusion peptide inserts into the host cell membrane leading to destabilization of the lipid 
bilayer. The N-terminal (blue) and C-terminal (purple) helices of gp41 form a hairpin structure by folding onto each 
other, thereby creating a stable six-helix bundle. This leads to the approximation of viral and cellular membranes, which 
results in membrane fusion. (Adapted with permission from Esté and Telenti,[187] Copyright © 2007 Elsevier Ltd.) 
Current models suggest that upon interaction of gp41’s amino terminus, referred to as fusion 
peptide, with the target cell’s membrane a pre-hairpin intermediate of gp41 is produced, that spans 
both viral and cellular membranes.[179, 186-188] This pre-hairpin intermediate then folds into a 
six-helix bundle (6-HB) core structure by interaction of the N-terminal and C-terminal heptad 
repeat regions (NHR and CHR, respectively) of gp41. The formation of this 6-HB presumably 
induces the membrane fusion as it brings the viral and host cell’s membrane in close proximity. 
As a result, a fusion pore develops that grows rapidly.[176, 186, 189] It is assumed that several fusion 
proteins may act cooperatively for creation of this pore.[189-190] The viral capsid, containing the 
genome, is then able to pass through this pore and into the host cell cytoplasm. The 6-HB is 
extremely stable and probably represents the most thermodynamically favorable structure of 
gp41. It is likely that the free energy released during this bundle formation overcomes the 
unfavorable process of putting two phospholipid membranes into close proximity and promotes 
the pore growth.[179, 191-192] 
As the 6-HB structure of gp41 is highly stable, it is unlikely to be disrupted. Therefore, and 
since it has a relatively long lifetime of several minutes, the pre-hairpin intermediate became an 
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attractive target for inhibitory peptides (see Section 3.3). Binding of peptides to this pre-hairpin 
structure inactivates gp41 and prevents its conversion to the fusion-active conformation.[179, 183, 193]  
3.2 gp41’s core structure 
The gp41 subunit is a type I transmembrane protein composed of extracellular and transmembrane 
region, and a cytoplasmic tail.[176, 194] Its extracellular domain, also denoted as ectodomain, 
contains different functional regions - a hydrophobic, Gly-rich fusion peptide; an N-terminal 
heptad repeat (NHR) and a C-terminal heptad repeat (CHR) that are linked via a loop containing 
a disulfide bond and a Trp-rich region.[194] Over the last decades, several crystallographic studies 
were performed to determine the exact structure of HIV gp41.[94, 185, 188, 195] The NHR- and 
CHR-regions associate to form a complex, which was identified as a six-stranded helical bundle 
that presumably represents the core of the fusion-active state of gp41.[94] This bundle consists of 
three NHR-helices forming a central parallel, coiled-coil trimer. Three CHR-helices wrap around 
the outside of this central coiled-coil trimer in an antiparallel orientation (Figure 3.3 A).[94, 185] 
Thus, the 6-HB can also be described as a trimer of heterodimeric subunits or 
trimer-of-hairpins.[179] 
The overall dimensions of this complex comprise a cylinder measuring ~ 35 Å in diameter 
and ~ 55 Å in height.[94] The residues at the a- and d-positions of the N-terminal heptad repeat are 
predominantly hydrophobic, but also a few buried polar interactions are present in the central 
trimer (Figure 3.3 B).[94] A comparison with the sequence of gp41 in SIV shows that these 
residues are highly conserved. The characteristic knobs-into-holes packing of coiled coils occurs 
where the NHR-trimer demonstrates exclusively “acute” packing geometry, similar to that found 
in the GCN4 isoleucine-zipper trimer.[85, 94]  
Residues at the a- and d-positions of the CHR-derived peptide pack against residues at the 
e- and g-positions of the NHR-derived peptide, thereby stabilizing the CHR/NHR-complex 
through predominately hydrophobic interactions. The central coiled-coil NHR-trimer shows three 
grooves on its surface, referred to as hydrophobic pocket, where the CHR-helices pack into. The 
residues lining these grooves, as well as the residues that are projecting into it, are highly 
conserved as shown by comparison of the HIV-1 and SIV sequence (see Figure 3.3 B). Each 
groove on the surface of the NHR-trimer has a particularly deep cavity (~ 16 Å long, ~ 7 Å wide, 
and 5-6 Å deep) and accommodates three hydrophobic residues from the interacting 
CHR-sequence, Ile635, Trp631, and Trp628. These residues are crucial for stabilizing the helical 
hairpin structure of the gp41 ectodomain core. In addition to these extensive hydrophobic contacts 
within the cavity, a salt bridge between Lys574 of NHR and Asp632 of CHR seems also important 
for the NHR/CHR interaction.[94] 
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Figure 3.3: A) End-on view (top) and side view (bottom) of the N36/C34 complex of the HIV-1 gp41 six-helix bundle. 
N36 helices are depicted in blue, the C34 helices in purple. N36 and C34 are peptides derived from the NHR- and 
CHR-regions of gp41. The amino termini of the N36 helices point toward the top of the page, while those of the C34 
helices point toward the bottom. The C34 helices are oblique orientated relative to N36. At the top of the complex, C34 
is slightly titled toward the left N36 helix, while at the bottom of the complex, it is slightly titled toward the right N36 
helix. B) Helical wheel representation of N36 and C34. The view is from the top of the complex. The residues at each 
position are colored according to their conservation between HIV-1 (HXB2) and SIV (Mac239): red – identity; 
black – conservative change; turquoise-green – non-conservative change. The N36 helices interact through 
knobs-into-holes packing interactions at the a- and d-positions (colored yellow). Positions of the N36 and C34 helices 
that occupy the interhelical space between two N36 helices and one C34 helix are marked in green. (Adapted from 
reference [94], Copyright © 1997 Cell Press, with permission from Elsevier.) 
An electrostatic potential map of the central NHR-coiled-coil trimer reveals that its surface is 
largely uncharged. The grooves responsible for interaction with the CHR-region are 
predominantly lined by hydrophobic residues, which probably lead to an aggregation of the 
NHR-peptides upon exposure to solvent. On the contrary, acidic residues on the outside of the 
CHR-peptide helices result in a much higher charged surface of the 6-HB complex. This explains 
the enhanced solubility of the heteromeric complex compared to the central coiled-coil trimer.[94] 
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3.3 Inhibition of cell fusion 
As mentioned above gp41 initiates the fusion of HIV and its target cell. Several conformational 
rearrangements of this protein subunit are involved in the mechanism of cell fusion - a crucial 
step is the peptide-peptide interaction between the NHR- and CHR-regions forming a coiled-coil 
6-HB. During formation of this structure, a pre-hairpin intermediate with a lifetime of many 
minutes occurs (see Chapter 3.1). Here, the NHR- and CHR-regions are not associated, thus 
making these regions an attractive target for the development of HIV fusion and entry 
inhibitors.[94, 179, 183, 193] Synthetic peptides derived from CHR or NHR can inhibit the formation 
of the fusion-active conformation, and thus, HIV-1 infection in a dominant-negative 
manner[179, 196-197] by binding to their respective counterpart regions in gp41 at this intermediate 
stage (Figure 3.4).  
 
Figure 3.4: Schematic representation of the HIV-1 viral fusion mechanism and its disruption by a decoy CHR-helix 
shown in green. (Adapted from Bird et al.[13]) 
Since the early 1990s several synthetic peptides derived from the NHR- and CHR-regions of the 
HIV-1 envelope glycoprotein transmembrane unit gp41 were developed and shown to have potent 
anti-HIV activity. Most of the investigated fusion inhibitors are CHR-peptides due to their 
stronger inhibitory potency compared to NHR-peptides, which probably can be attributed to the 
tendency of NHR-derived sequences to aggregate.[179, 198] Among these, T20 (Fuzeon®, 
enfuvirtide) and C34 were extensively studied and possess low nanomolar antiretroviral 
activities.[94, 176, 178, 198-201] T20 is a 36 amino acid peptide and corresponds to the residues 638-673 
of gp41 (Figure 3.5).[200] It does not include the pocket-binding sequence 628-635. However, the 
interaction of this pocket-binding domain (PBD) in the CHR with the pocket-forming domain in 
the NHR (amino acid residues 565-581) appears to be substantial for stabilization of the 6-HB. 
Residues Ile635, Trp631 and Trp628 of CHR have been shown to insert into the NHR-pocket 
making extensive hydrophobic contacts.[94, 193, 202] T20 furthermore contains a highly hydrophobic 
Trp-rich region at its C-terminus, which enables its binding to the lipid membrane of the host cell. 
Thus, the membrane might serve as a reservoir for the drug and renders the interaction with other 
segments of gp41 possible, accounting for its high anti-HIV activity.[203-204] C34, a 34 amino acid 
peptide comprising residues 628-661 of gp41 (Figure 3.5), contains in contrast to T20 the pocket-
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binding sequence 628-635, so it can interact with the hydrophobic pocket of the NHR-trimer to 
form a stable 6-HB complex.[198] 
 
Figure 3.5: Sequence and interaction of the CHR- and NHR-region of gp41. Heptad repeats shown in black. Dashed 
lines between the NHR- and CHR-regions indicate the interaction between the residues located at the e-, g- and a-, d-
positions in NHR and CHR, respectively. The interaction of the pocket-binding domain (PBD, in blue) in the CHR 
with the pocket-forming domain (in red) in the NHR is critical for 6-HB formation. Region immediately adjacent to 
the PBD (in green) is important for stabilization of the gp41 core structure. This motif may interact with the residues 
in the pocket-forming domain in the NHR and the downstream motif (AVERY) as shown by the dashed green 
lines.547GIV549 motif (in purple) is responsible for development of drug resistance. The Trp-rich domain (in orange) 
has a tendency to bind to lipid membranes. The regions of peptides derived from the NHR- or CHR-region are shown 
above or below the sequence, respectively. (Adapted from He et al.)[199] 
In 2003 T20 was approved as the first and currently only peptide-based HIV-1 fusion inhibitor 
used in clinic.[199, 205-207] Unfortunately, its application has been limited as acquired resistance is 
possible. The development of drug resistance can be attributed to mutations in a 10 amino acid 
region between residues 547 and 556 within the gp41 NHR-region that forms part of the binding 
site for T20, with the 547GIV549 motif playing a predominant role.[194, 208-212] In addition, the 
manufacturing procedure of T20 is expensive and complex,[213-214] and in vivo proteolysis of T20 
is rapid. The latter is limiting bioavailability and thus high subcutaneous injections with high 
dosages are required twice daily.[9, 13, 215] C34 displays both potent anti-HIV activity as well as 
reduced susceptibility to the evolution of resistant viruses. However, its poor solubility under 
physiological conditions might prevent its use as a promising drug candidate.[216] Therefore a new 
generation of fusion inhibitors with improved antiviral activity and pharmacokinetic profile needs 
to be developed. 
Nearly all CHR-derived peptides reported to date correspond to residues 628-673 of 
gp41.[181-182, 194, 202] Especially the PBD (residues 628-635) is important for the inhibitory activity 
of CHR-derived peptides as the residues Trp628, Trp631, and Ile635 contribute substantially to 
the stability of the 6-HB.[193, 217-218] Moreover, salt bridges between Asp632 of CHR and Lys574 
of NHR, as well as Ile642 are critical for viral entry and inhibition.[196, 217, 219-221] Thus, and due to 
the lack of the PBD in T20, C34 has been widely used as a template for engineering CHR-derived 
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fusion inhibitors with enhanced pharmacokinetics. Table 3.1 summarizes some of these peptides 
that possess potent antiretroviral activity, also against virus mutants resistant to T20 or C34. 
Table 3.1: Examples of peptides derived from the CHR-region of gp41 that possess highly potent inhibitory activity 
against HIV-1 fusion.[181-182] Peptides are generally acetylated at the N-terminus and amidated at the C-terminus to 
enhance stability. Bold letters indicate substitutions for native residues, and lower-case letters indicate D-amino acids. 
The pocket-binding domain (PBD) residues are marked in red, and residues of the lipid-binding domain (LBD or 
MPER) are highlighted in blue.[181-182] 
peptide sequence gp41 residues references 
T20, 
enfuvirtide YTSLIHS LIEESQN QQEKNEQ ELLELDK WASLWNWF 638-673 
[200-201] 
C34 WMEWDRE INNYTSL IHSLIEE SQNQQEK NEQELL 628-661 [198] 
MT-C34 MTWMEWD REINNYT SLIHSLI EESQNQQ EKNEQELL 626-661 [222] 
C34M2 WMEWDRE INNYTSL IHSLIEE SQNQQeK NEkELL 628-661 [223] 
C34M3 WeEWDRE INNYTSL IHSLIEE SQNQQeK NEkELL 628-661 [223] 
sifuvirtide SWETWER EIENYTR QIYRILE ESQEQQD RNERDLLE  117-115a) [224] 
SJ-2176 EWDREIN NYTSLIH SLIEESQ NQQEKNE QEGGC 630-659 [225-226] 
C43 INNYTSL IHSLIEE SQNQQEK NEQELLE LDKWASL WNWFNITN 635-677 
[227] 
C42 NNYTSLI HSLIEES QNQQEKN EQELLEL DKWASLW NWFNITN 636-677 
[227] 
SC34EK WZEWDRK IEEYTKK IEELIKK SQEQQEK NEKELK (Z = Nle) 628-661 
[228]  
SC29EK WEEWDKK IEEYTKK IEELIKK SEEQQKKN 628-656 [229]  
MTSC22 MTWEEWD KKIEEYT KKIEELI KKS 626-649 [230-232] 
HP23 EMTWEEW EKKIEEY TKKIEEI LK 625-647 [230-231] 
CP621-652 QIWNNMT WMEWDRE INNYTSL IHSLIEE SQNQ 621-652 [194] 




T2635 TTWEAWD RAIAEYA ARIEALI RAAQEQQ EKNEAAL REL 626-663 
[234-235] 
T2544 MTWEAWD RAIAEYA ARIEALI RAAQEQQ EKNEAAL REL 626-663 
[234]  
T649 WMEWDRE INNYTSL IHSLIEE SQNQQEK NEQELLEL 628-663 [209, 236-237] 





a) The numbering is according to the gp41 CHR-sequence of HIV-1 subtype E from which sifuvirtide 
is derived. b) T1249 is composed of sequences derived from HIV-1, HIV-2, and SIV and consists of a 
PBD, a truncated CHR-region and an LBD. 
A key strategy used to improve anti-HIV activity of CHR-derived peptides is the introduction of 
salt-bridge structures, thereby creating electrostatically constrained peptides like SC34EK, 
SC29EK, T2635 and sifuvirtide (Table 3.1).[224, 228-229, 234] In such peptides, Glu and Lys pairs are 
placed in i and i + 4 positions at the solvent-accessible site of the helical bundle while the residues 
critical for the interaction with the NHR-region remain unchanged (Figure 3.6). The electrostatic 
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interactions introduced by Glu/Lys substitutions enhance the α-helicity and water solubility of 
the peptides. Moreover, a thermal stabilization of the CHR/NHR complex is usually 
observed.[216, 228-229] The increased α-helical structure is proposed to be a key factor for improving 
antiviral activity to a low nanomolar range.[228-229] Isolated CHR-derived peptides are generally 
unstructured in solution, while they adopt nearly full α-helical structures when interacting with 
the NHR to form a 6-HB.[233, 241] Due to the loss of entropy while generating a fixed helical 
structure out of an unstructured conformation, binding of CHR to the NHR-region exacts a large 
energetic penalty.[233] Hence, enhancing the helicity of the peptide fusion inhibitor may improve 
its antiretroviral potency by increasing its binding affinity to NHR.[216] 
 
Figure 3.6: A) Helical wheel representation of the 6-HB structure. Amino acid residues at positions a, d, e 
and g of CHR interact with NHR. Residues in solvent-exposed positions of CHR are substituted with Glu 
or Lys to form salt-bridges. B) Design concept of incorporating the Glu/Lys motif at solvent-accessible 
sites. The α-helical CHR-peptide could be divided into interaction (orange) and solvent (turquoise green) 
sites. X indicates the original amino acids of the CHR-sequence. Only amino acid residues at solvent 
exposed positions are substituted with Glu or Lys at i and i + 4 position. (Adapted from Nishikawa et al.,[228] 
Copyright © 2009 with permission from Elsevier)  
He et al. investigated the upstream sequence of the pocket-binding domain (PBD) in the CHR 
and found that the 621QIWNNMT627 motif, immediately adjacent to the PBD, is critical for the 
formation and stabilization of the gp41 6-HB core.[194] CHR-derived peptides containing this 
motif, e.g., CP621-652, showed high thermal stabilities and nanomolar anti-HIV activity in a 
dose-dependent manner, also against T20- and C34-resistant mutants, presumably due to the fact 
that they target different sequences of the gp41 NHR. As reported before, when positively or 
negatively charged residues (Lys or Glu, respectively) were introduced additionally at i and i + 4 
positions into this peptide, promoting the formation of salt-bridges (peptide CP32M, Table 3.1), 
a much-improved antiviral activity against some T20-resistant viruses, with IC50 values in the 
picomolar range, was observed.[199] More recently, Chong et al. showed that Met628 and Thr627 
of the 621QIWNNMT627 motif are key residues for HIV-1 entry and inhibition.[202] The researchers 
determined the high-resolution crystal structure of a peptide containing this domain complexed 
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by NHR and observed that 621QIWNNMT627 does not maintain a fully α-helical conformation. 
Instead, the Met628 and Thr627 form a unique hook-like structure referred to as M-T hook 
(Figure 3.7). This M-T hook is crucial for stabilizing the interaction between the pocket-binding 
residues from the CHR and the pocket region on the NHR-trimer. Mutation studies demonstrate 
that an absence of these hook residues significantly destabilizes the interaction of NHR- and 
CHR-peptides and reduce the anti-HIV activity of latter. By incorporating the M-T hook residues 
at the N-terminus of known CHR-derived peptides, like C34 or sifuvirtide, the binding affinity 
and thermostability of the 6-HB core could be enhanced, and these peptides exhibited 
significantly increased antiviral activity.[222, 242-244] This structure is furthermore promising to 
overcome drug resistance. Molecular dynamic simulations revealed that the increased affinity and 
stability of ligands with such a M-T hook structure can be attributed to the formation of more 
stable hydrogen bonds compared to ligands that do not possess this structural feature.[245] 
 
Figure 3.7: Structure of the 6-HB formed by CP621-652 and T21, derived from the CHR- and NHR-region of 
gp41, respectively (top). The T21 trimer is colored light gray, CP621-652 peptides are colored in marine blue, 
the 621QIWNNMT627 motifs of CP621-652 are highlighted in orange. Hydrogen bond interactions observed 
between Asp632 and Lys574, and between His643 and Gln567 are indicated by dashed lines. A portion of the 
above 6-HB structure is magnified in the gray box and is illustrated with a wall-eye stereo image. (bottom). 
Residues Thr627 and Met626 form a hook-like structure (highlighted in orange) that stabilizes the interaction 
between T21 and CP621-652. The Thr627 residue terminates the α-helical conformation of the N-terminus of 
the CP621-652 peptide. The hydroxyl group of the Thr627 side chain accepts a hydrogen bond from the 
NH-group of Glu630, directing the N-terminus of the CP621-652 peptide away from the T21 trimer. The side 
chain of Met626 caps the hydrophobic pocket on the T21 trimer. Dashed lines indicate the hydrogen bonds 
between the residues. (Adapted with permission from Chong et al..[202] Copyright © 2012, The American 
Society for Biochemistry and Molecular Biology) 
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Gochin et al. found that both specific and non-specific interactions can form a basis for inhibitor 
affinity of CHR-derived peptides.[221] Classic effects such as electrostatic forces, specific van der 
Waals interactions, entropy, and amphiphilicity all seem to play key roles in binding. However, 
especially a negative net charge of - 2 or - 3 in combination with non-specific hydrophobic 
interactions and high helical content is crucial for the affinity of CHR and NHR and thus for the 
antiretroviral potency.[221] Besides that, the authors also examined the upstream region of the 
CHR-sequence and found that specific salt-bridges and hydrogen-bond networks may occur in 
following regions: Arg579 of the NHR could form intermolecular salt-bridges or hydrogen bonds 
to Glu620 and Asn624 of CHR, respectively, as well as an intramolecular hydrogen bond with 
Gln575. This underlines the findings of He et al. described above that an extended interaction site 
may be necessary to obtain low nanomolar inhibitory potencies.[194, 199] 
Studies by the Gellman group furthermore suggest that the affinity between individual 
CHR-helices and the complementary groove in NHR depends upon interactions distributed across 
an extended protein interface.[246] Even though their results showed very high binding affinities 
within the hydrophobic pocket, also residues downstream (C-terminal) of the PBD contribute 
significantly to the stability of the six-helix assembly.  
Peptide drugs have an intrinsic weakness due to rapid proteolysis and thus, limited 
bioavailability. Unnatural building blocks may be used to overcome this poor in vivo stability and 
might even lead to oral bioavailability. Bird et al. inserted backbone crosslinks, referred to as 
chemical staples, into HIV-1 fusion inhibitors T649 and T20 at i and i + 4-positions (schematic 
representation in Figure 3.8).[13] The stapled peptides exhibited improved antiviral activities even 
against T20 resistant strains and showed remarkable protease resistance. The latter can be 
attributed to the strengthening of the overall α-helical structure and complete blockage of peptide 
cleavage at the sites localized within or adjacent to the i and i + 4-crosslinked regions, which 
slows down the kinetics of proteolysis. 
 
Figure 3.8: Schematic illustration of peptide stapling. α,α-Disubstituted non-natural 
amino acids containing olefinic side chains are incorporated at two or more i and i + 4 
positions in the peptide chain. Crosslinking occurs by ruthenium-catalyzed ring-closing 
olefin metathesis, resulting in an increased helicity of the peptide. (From Walensky et al..[247] 
Adapted with permission from American Association for the Advancement of Science, 
Copyright © 2004.) 
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A different chemical crosslink was introduced by the group of Kim to improve the inhibitory 
potency of short CHR-peptides, whose sequence corresponds to the HIV-1 gp41 residues 
626-639.[233] A diaminoalkane crosslinker was used to stabilize the helical conformation of the 
peptide, yielding C14linkmid (Table 3.1). As expected, the peptides bind to the gp41 hydrophobic 
pocket and the short linear peptide showed no significant inhibitory activity, while the constrained 
peptide C14linkmid inhibited HIV fusion at micromolar potency. Additionally, the authors 
observed that not the peptides with the greatest α-helicity were the most potent inhibitors, but 
rather those that best balance the changes in binding enthalpy and entropy. 
An alternative approach to enhance the resistance to proteolytic degradation is the 
substitution with D-amino acids. In 1999, Eckert et al. used mirror-image phage display to identify 
peptides composed of D-amino acids that are able to bind to the hydrophobic pocket of gp41 
NHR.[197] These peptides additionally contain two Cys residues that form an intramolecular 
disulfide bond to create a cyclic structure. Therefore, they are practically insensitive to proteolytic 
digestion. Unfortunately, these D-peptides inhibit HIV-1 entry with only modest potency. Eight 
years later Welch et al. used the consensus sequence CX5EWXWLC identified from the phage 
screen to discover D-peptide pocket-specific inhibitors of entry (PIE) with improved antiviral 
potency.[248] For this purpose, the researchers developed a constrained library in which the six X 
residues were randomized while the other consensus positions (underlined) were fixed. A family 
of D-peptides with enhanced potency was identified and surprisingly, the most potent D-peptides 
found were missing two of the randomized residues (CX3EWXWLC). The best inhibitor among 
these proved to be ~ 15-fold more potent, and a trimeric version of this PIE showed an IC50 value 
of 250 pM, which means an 40,000-fold increase in antiviral potency compared to D-peptides 
previously reported by Eckert et al.. Bahraoui and co-workers site-specifically incorporated 
D-amino acids into C34, to yield peptides C34M2 and C34M3 containing either two or three 
D-residues, respectively (Table 3.1).[223] Both peptides are able to inhibit HIV-1 replication with 
an efficiency similar to that of the native C34 sequence, consisting of solely L-amino acids, while 
being more resistant to proteolytic degradation. In contrast, an all-D-amino acid containing C34 
showed no antiviral activity.  
All the results described demonstrate that D-peptides can form specific and high-affinity 
interactions with gp41.[223, 248] The non-natural D-amino acids are readily accommodated within a 
peptide sequence without altering its structure and judiciously placed, even only few D-residues 
may improve inhibitory activity. Unlike natural L-peptides, D-peptides are resistant to proteolytic 
digestion and have the potential for oral bioavailability, extended persistence in circulation and 
reduced immunogenicity.[248] Thus, such non-natural building blocks show considerable potential 
for the development of peptide-based highly potent anti-HIV-1 drugs and other therapeutic 
agents.[223, 248] 
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To summarize, several CHR-derived peptide sequences have been generated and those 
peptides with a length of 30 residues and longer are usually significantly more potent compared 
to short peptides and small molecules. This fact can be attributed to the large, shallow and 
hydrophobic intermolecular binding interface of the gp41 fusion complex.[13, 246] However, long 
peptides are not orally bioavailable and must be administered via injection. Furthermore, the 
length of peptide closely relates to difficulty and cost of its production, thus still making the 
development of short-peptide inhibitors attractive. Unfortunately, their low binding affinity and 
poor inhibitory potency creates an obstacle to the development of a small orally bioavailable 
HIV-1 entry inhibitor,[233] but in the last decade several short peptides with stabilized α-helical 
conformations and moderate inhibitory efficiency have been reported.[233, 249-250] Hence, the 
inability of CHR-derived peptide inhibitors to bind to the corresponding NHR-region cannot 
exclusively be attributed to their sequence length. 
Taking all the above described findings into account, a CHR-derived peptide that includes 
the downstream as well as the upstream region of the PBD was previously designed in the Koksch 
group (Table 3.2).[251] Its ability to bind to the NHR-derived peptide T21 was investigated by CD 
spectroscopy and a N-PAGE experiment. Gained results suggest hetero-oligomerization and 
formation of a helical bundle. Moreover, the helical content as well as the thermal stability are 
considerably increased in comparison to the C34/N36 complex. The highly conserved 
Trp628-Trp632-Ile635 motif of the PBD constitutes the center of this peptide and was chosen as 
a starting point for substitution studies carried out in this doctoral thesis (see Section 5.4).  
Table 3.2: Sequence of the CHR-derived peptide C31. 
peptide sequence 
C31 
620                                                                         650  
EQIWNNMTWMEWDREINNYTSLIHSLIEESQ 
A more recent evolved class of fusion inhibitors are the so-called anchoring inhibitors that target 
the highly conserved fusion peptide of HIV-1 gp41. While T20 and other CHR-derived peptides 
inhibit formation of the hairpin which is able to trigger the membrane fusion, anchoring inhibitors 
directly block the insertion preventing the anchorage of gp41 into the cell membrane, which is 
the previous stage of the hairpin formation (Figure 3.9). Münch and colleagues screened a 
comprehensive peptide library generated from human hemofiltrat and identified a 20 residue 
peptide, referred to as VIRus-Inhibitory Peptide (VIRIP), corresponding to a C-proximal cleavage 
fragment of α1-antitrypsin, the most abundant circulating serine protease inhibitor 
(Table 3.3).[252] The researchers found that VIRIP is highly potent inhibitor for a wide variety of 
HIV-1 strains including those resistant to common antiretroviral drugs. This peptide blocks HIV-1 
entry by specifically interacting with the gp41 fusion peptide and additionally, the antiretroviral 
potency of VIRIP was greatly improved by changing specific amino acid side chains and/or 
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particular structural features such as charge and peptide chain rigidity.[252] An about two orders 
of magnitude increased anti-HIV-1 activity compared to the natural form was observed for VIRIP 
derivatives, e.g., VIR-576, containing an intramolecular cyclic motif by a disulfide bond 
(Table 3.3). For this, a Cys residue was introduced into the VIRIP sequence, resulting in peptides 
with similar potency as T20. VIR-576 was later selected for clinical development and its safety, 
pharmacokinetics, and antiviral efficacy were determined in a short-term monotherapy with 
treatment-naïve HIV-1 patients.[18] VIR-576 was well tolerated and reduced the plasma viral load 
by more than one order of magnitude. These findings show that inhibitors targeting the fusion 
peptide, thereby preventing virus particles from anchoring to and infecting host cells, offer great 
prospects for the development of a new class of antiviral drugs. 
 
Figure 3.9: Schematic representation of modes of action of T20 in comparison with VIR-576. The 
fusion inhibitor T20 binds to the NHR-region of HIV-1 gp41 and thereby prevents the formation of 
the 6-HB hairpin structure required for membrane fusion (top). VIR-576 is an anchoring inhibitor 
that binds to the hydrophobic gp41 fusion peptide and blocks its insertion into the host cell membrane 
(bottom). (From Forssmann et al..[18] Adapted with permission from the American Association for 
the Advancement of Science.) 
Table 3.3: Sequences of the anchoring inhibitors VIRIP and VIR-576. 
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3.4 Multimerization of gp41-derived peptide inhibitors 
Multivalent binding is based on multiple simultaneous molecular recognition processes and plays 
a crucial role in biological processes by establishing strong, but also reversible interactions 
between two units, such as receptor and ligand or virus and host cell.[253] Here the multiple 
additive (in some cases cooperative) interactions between a large number of individual, mutually 
binding partners result in dramatically enhanced binding. In the case of virus infection such 
interactions initially lead to a stable adhesion since the virus has a high affinity for the multivalent 
binding sites of the cell surface. In this regard, monovalent drugs can only be effective in very 
high doses, resulting in a widespread interest for engineering multivalent molecules as drug 
candidates. Such molecules may allow for strong binding to the recognition sites on the virus or 
host cell, thereby preventing infection.[253] This section shortly summarizes the research reported 
in recent years on the development of multimerized HIV-gp41-derived peptides with possible 
application as fusion inhibitors and vaccines. Especially the trimerization of CHR- or 
NHR-peptides represents a promising approach as it mimics their native conformation in the 
pre-hairpin intermediate of gp41. 
As already briefly mentioned above, Welch et al. observed that trimeric versions of D-peptide 
pocket-specific inhibitors of entry such as PIE7 show improved antiviral potency compared to the 
monomeric analogue.[248] The trimer was produced by connecting two PIE7 peptides with the 
N-terminal Lys residue to a central PIE7 peptide with two Lys at the N-terminus via bis-PEG9 
NHS ester crosslinks (N9N(PIE7)3). More recently, the same research group reported the design 
and characterization of a new pocket-specific D-peptide, denoted PIE12-trimer.[254] To this end, 
linker optimization was performed first by relocating Lys to the C-terminus of the PIE and using 
a shorter PEG5 crosslink. This resulted in PIE peptides with a C5C-linkage, which show enhanced 
potency compared to the N9N linkage (N9N(PIE7)3 vs C5C(PIE7)3; Table 3.4). Second, optimizing 
the flanking residues of the PIE7 core sequence (CDYPEWQWLC) yielded in peptide PIE12 with 
improved binding affinity to the gp41 pocket. A combination of these findings yielded the 
PIE12-trimer C5C(PIE12)3 that exhibits ~ 100,000-fold enhanced target binding affinity, a 
significantly broadened inhibitory potency, and a dramatically improved resistance profile 
compared to that of the previously described D-peptides, as well as those of T20.[254] 
Table 3.4:Trimeric D-peptide inhibitors and antiviral potency against HXB2 and JRFL HIV-1 





N9N(PIE7)3  (KGACDYPEWQWLCAA)3 0.3 220 [248] 
C5C(PIE7)3 (GACDYPEWQWLCAAGK)3 0.1 6.7 [254] 
C5C(PIE12)3 (HPCDYPEWQWLCELGK)3 0.5 2.8 [254] 
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Francis et al. described an optimization of the PIE12-trimer synthesis by using a modular PEG 
scaffold.[255] This approach greatly improves yield and the scaffold furthermore allows to 
conjugate the peptide trimer to different membrane-localizing groups, e.g., cholesterol or alkyl 
chains (Figure 3.10), resulting in up to ~ 160-fold increased potency and retention of 
PIE12-trimer’s resistance profile. Pessi and co-workers used a similar approach and synthesized 
dimeric cholesterol-tagged fusion inhibitors (Figure 3.10).[256] For this purpose, two 
Cys-containing C34 peptide chains were conjugated to a maleimide-functionalized core that bears 
a cholesterol group. The resulting dimer shows highly potent antiviral activity in the picomolar 




Figure 3.10: A tetrameric conjugate bearing three PIE12 peptide chain and a cholesterol moiety separated by a PEG 
scaffold (top left).[255] A dimeric cholesterol-tagged fusion inhibitor via a trivalent scaffold comprising two C34 
peptides (bottom left).[256] Schematic representation of a cholesterol containing scaffold carrying peptide-based fusion 
inhibitors (right). The peptides can bind to the pre-hairpin intermediate of gp41 thereby preventing the formation of 
the 6-HB required for membrane fusion. It is assumed that the cholesterol tag as lipophilic moiety interacts with the 
membrane and facilitates the accumulation of the inhibitor peptide at the fusion site, resulting in improved antiviral 
potency. (Adapted with permission from Francis et al.,[255] Copyright © 2012, American Chemical Society.) 
The group of Tamamura designed a novel three-helical bundle mimetic that corresponds to the 
trimeric form of native N36 and evaluated its inhibitory activity against HIV-1 infection.[257] The 
trimer triN36e (Figure 3.11 A) was synthesized by conjugating N36, containing a Cys residue at 
the N-terminus, to a three-armed aldehyde scaffold using thiazolidine ligation. TriN36e showed 
only modest anti-HIV-1 activity, however the potency was threefold higher than that of 
unconjugated N36. The same researchers also reported an trimeric from of C34, denoted triC34e 
(Figure 3.11 B), which shows a 100 times improved inhibitory potency compared to the 
corresponding C34 monomer.[258] In this approach, a Gly thioester was added to the C-terminus 
of C34 and the resulting C34 strands were coupled to a three-armed Cys scaffold via native 
chemical ligation. The authors also generated a C34 dimer by using the same template with a 
three-armed cysteine scaffold.[259] In this case, unprotected C34 thioester was coupled, 
stoichiometrically to the template, followed by carboxymethylation of the free thiol groups with 
iodoacetamide to produce the dimer diC34e (Figure 3.11 C). The anti-HIV activity of diC34e is 
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approximately equal to that of the trimer triC34e. In the same manner, also dimeric and trimeric 
variants of T20 were synthesized that also showed increased fusion inhibitory activity compared 
to the corresponding monomeric T20.[259] 
 
Figure 3.11: Structures of dimers or trimers of CHR- or NHR-derived peptides.[257] A) Trimeric N36, triN36e. 
B) Trimeric C34 conjugate triC34e.[258] C) C34-derived dimer diC34e. The thiol groups were capped by 
iodoacetamide (R = CH2CONH2).[259] D) Bivalent CHR-peptides. 6-aminohexanoic acid, alanine or triethylene 
glycol were used as linker.[260] E) Structure of three-helix bundles mimicking the HIV membrane fusion-state 
proteins. NHR or CHR are N36, C34 or T20.[261] 
Ling et al. reported other dimeric CHR-derived peptides as fusion inhibitors using an bivalent 
drug design approach.[260] First, the CHR-derived peptides were modified N-terminally with a 
linker and Cys residue and two CHR-domains were afterwards crosslinked via a disulfide bond 
(Figure 3.11 D). The crosslinked, bivalent peptides showed improved inhibitory activity against 
HIV-1 fusion compared to the respective monomer and in few cases the determined values are 
close to one of the high active peptidic fusion inhibitor C34. Tam and Yu described a facile 
ligation approach to prepare trimeric NHR- and CHR-peptides of gp41 as fusion-state protein 
mimetics that may be useful as inhibitors and vaccine candidates for blocking HIV infection.[261] 
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peptides, which contain a Cys residue at the N-terminus, to an three-armed aldehyde scaffold. 
This resulted in different three-helix bundle fusion-state protein mimetics (Figure 3.11 E), but 
their antiviral potency was not determined within the reported study. The peptide scaffold also 
enables to incorporate T helper epitopes for synthetic vaccines or other peptide cargoes for testing 
other biological functions. 
The group of Kim designed a small protein, denoted 5-Helix, which should bind tightly and 
specifically to the CHR-region of gp41.[262] It is composed of five of the six helices that form the 
6-HB core of gp41 connected with short peptide linkers (Figure 3.12 A). The 5-Helix lacks the 
third CHR-peptide and thus indeed binds to the CHR-region of gp41 with high affinity, resulting 
in potent, nanomolar inhibitory activity against diverse HIV-1 strains. In contrast, a control 
protein, in which six helices form the entire trimer-of-hairpins structure, does not bind 
CHR-peptides and displays no appreciable inhibitory activity. 
 
Figure 3.12: A) A schematic model of the 5-Helix protein. Three NHR-derived (N40, orange) and two CHR-derived 
peptide segments (C38, turquoise green) are alternately linked (N40-C38-N40-C38-N40) using short Gly/Ser peptide 
sequences (gray loops). N40 corresponds to residues 543-582 of gp41 and C38 is derived from residues 625-662. The 
sequences of the linkers are: N-to-C linker, GGSGG; and C-to-N linker, GSSGG. (Adapted from Root et al.[262] with 
permission from The American Association for the Advancement of Science, Copyright © 2001.) B) Structure of 
NCCG-gp41 with exposed N35 portion. By linking N35 to the N-terminus of N34(L6)C28 and substituting Leu576, 
Gln577 and Ala578 of N35 with Cys, Cys and Gly, respectively, three molecules of N34(L6)C28 segments in 
NCCG-gp41 can form a 6-HB, while the three N35 molecules form a helical trimer which is stabilized by three 
intermolecular disulfide bonds. (Reprinted with permission from Louis et al.[263] Copyright © 2001.) C) HR121 and 
HR212 constructs and schematic models of the trimers. The sequences of NHR (HR1) and CHR (HR2) for constructing 
HR121 and HR212 are peptides N34 (residues 546-579 of HIV-1 gp41) and C34 (residues 628-661), respectively. 
(Adapted from Ni et al.[264] with permission from Elsevier, Copyright © 2005.) 
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Louis et al. reported the design and characterization of a chimeric protein, referred to as 
NCCG-gp41, derived from the ectodomain of HIV-1 gp41 (Figure 3.12 B).[263] This molecule 
features an exposed trimeric coiled-coil structure of N35 derived from the NHR-region of gp41 
(residues 546-580). The helical, trimeric conformation is stabilized by fusion to the N-terminus 
of the minimal thermostable ectodomain N34(L6)C28 of gp41 and three engineered 
intermolecular disulfide bridges. N34(L6)C28 consists of N34 (residues 546-579 of HIV-1 gp41) 
and C28 (residues 628-655) that are covalently linked by L6, a six-residue loop with the sequence 
SGGRGG.[195, 265] The exposed trimeric coiled-coil domain of NCCG-gp41 targets the CHR-region 
of gp41 in its pre-hairpin intermediate and possesses potent inhibitory activity at nanomolar 
concentrations against HIV-1 envelope-mediated cell fusion. 
Ni and co-workers designed two recombinant proteins, denoted HR121 and HR212 
(Figure 3.12 C).[264, 266] HR121 consists of two N34 molecules derived from the NHR (also 
referred to as HR1) region of gp41, and one molecule of C34 derived from the gp41 CHR- (or 
HR2) region. These peptide sequences are linked in the order NHR-CHR-CHR. The other peptide 
HR212 contains two C34 and one N34 peptide connected in the order CHR-NHR-CHR. In this 
design three heptad repeats (two NHR- and one CHR-peptide or one NHR- and two 
CHR-peptides) are linked by flexible linkers so that the NHR- and CHR-peptides in each protein 
are able to associate and form a hairpin structure.[266] Consequently, three molecules of the protein 
can form a stable 6-HB with three free NHR- or CHR-peptides exposed (Figure 3.12 C). These 
exposed peptides can bind to the counterpart regions in HIV-1 gp41, thus inhibiting 
gp41-mediated membrane fusion. Both proteins HR121 and HR212 showed potent inhibitory 
activity with IC50 values in low nanomolar range, comparable to the potency of T20. Other 
advantages of this recombinant proteins are that they could be abundantly expressed and easily 
purified, which may reduce the cost of production compared to the synthetic peptides. 
In conclusion, with the different strategies to obtain multimerization of CHR- or 
NHR-derived described above, e.g., flexible PEG spacers, disulfide bonds, three-armed 
cysteine-scaffolds, short peptide linkers or recombinant protein expression, binding affinities and 
antiretroviral activities can be significantly improved. The obtained findings may serve as basis 
for the design of novel peptide-based anti-HIV-1 therapeutics, and trimeric C34 and N36 
derivatives may additionally be applied in the development of HIV-1 vaccines.[257, 267-268] Recently 
is was also shown that multimerization strategies can be applied to enhance the potency of small 
molecule gp41 inhibitors.[269] 
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4. Aim of the study 
The aim of the current study is the design of novel active peptides that specifically bind to the 
gp41 region of the envelope protein of HIV-1 and thereby prevent the fusion of viral and cellular 
membrane. Therefore, peptide C31, previously developed in our group and derived from the 
CHR-region of the wild type sequence of the gp41 core of HIV-1, which was previously shown 
to interact with the corresponding NHR-region, will be substituted with different fluorinated 
amino acids at a central position. Specifically, the three fluorinated amino acids 
difluoroethylglycine (DfeGly), 5,5,5-trifluoroisoleucine (53-F3Ile) and 5,5,5,5’,5’,5’-
hexafluoroleucine (53,5’3-F6Leu) will replace an Ile residue, and the peptides are to be synthesized 
via solid phase peptide synthesis. Subsequently, their folding characteristics and thermal 
stabilities are to be investigated via CD spectroscopy to determine the influence of the fluorination 
on the interaction with the NHR-derived counterpart. Also, ITC measurements will be carried out 
to determine the thermodynamic parameters of the peptide/peptide interaction. Furthermore, for 
a more detailed investigation on the binding kinetics of the new CHR-peptide analogues, an 
SPR-based assay will be conducted. To this end, a hetero-tetrameric scaffold will be designed and 
synthesized, which on the one hand effectively presents the NHR-derived peptide as a trimer and 
on the other hand enables immobilization on the surface of an SPR chip. 
To gain insights into how sterically demanding, highly fluorinated amino acids behave 
and how they influence the stability of peptides when it comes to single amino acid substitutions, 
initial studies should be performed using two well established model systems to evaluate both 
thermal stability and stability towards proteolytic digestion. 
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5. Results and Discussion 
Parts of the results presented in this chapter were published in the following peer-reviewed 
reports: 
• H. Erdbrink, E. K. Nyakatura, S. Huhmann, U. I. M. Gerling, D. Lentz, B. Koksch, C. 
Czekelius, Synthesis of enantiomerically pure (2S,3S)-5,5,5-trifluoroisoleucine and 
(2R,3S)-5,5,5-trifluoro-allo-isoleucine. Beilstein J. Org. Chem. 2013, 9, 2009-2014. 
(Section 5.1) 
• J. R. Robalo, S. Huhmann, B. Koksch, A. Vila Verde, The Multiple Origins of the 
Hydrophobicity of Fluorinated Apolar Amino Acids. Chem 2017, 3, 881-897. 
(Section 5.1) 
• S. Huhmann, E. K. Nyakatura, H. Erdbrink, U. I. M. Gerling, C. Czekelius, B. Koksch, 
Effects of single substitutions with hexafluoroleucine and trifluorovaline on the 
hydrophobic core formation of a heterodimeric coiled coil. J. Fluorine Chem. 2015, 
175, 32-35. (Section 5.2) 
• S. Huhmann, A.-K. Stegemann, K. Folmert, D. Klemczak, J. Moschner, M. Kube, B. 
Koksch, Position-dependent impact of hexafluoroleucine and trifluoroisoleucine on 
protease digestion. Beilstein J. Org. Chem. 2017, 13, 2869-2882. (Section 5.3) 
Results that are not part of these publications are evaluated and discussed in additional sections. 
5.1 Hydrophobicity and α-helix propensity of fluorinated amino acids 
The side-chain size, or rather shape and hydrophobicity of an amino acid as well as its intrinsic 
propensity for a certain secondary structure, e.g., α-helix propensity, are important factors for 
peptide and protein folding, such as the formation of helical assemblies, and are thus also crucial 
for the interpretation of the results presented in this thesis. These properties have been extensively 
studied in our group for side-chain fluorinated amino acids.[50, 134-135, 270] The following section 
summarizes the results for the fluorinated amino acids used in this study and describes newly 
gained insights in the multiple origins of the hydrophobicity of these amino acids. 
5.1.1 Hydrophobicity of side-chain fluorinated amino acids 
The relationship between side-chain volume and hydrophobicity of side-chain fluorinated amino 
acids was investigated by plotting their retention times from an RP-HPLC experiment against 
their calculated side-chain van der Waals volumes (Figure 5.1). The non-polar character of the 
reversed-phase column used in this experiment provides a hydrophobic environment.[271] The 
accuracy of this method was validated in prior studies by our group.[50, 117] 




Figure 5.1: Retention times of Fmoc amino acids plotted against the van der Waals volume of their side 
chains.[50, 134-135] The van der Waals volumes of the amino acid side chains were calculated according to Zhao et al.[272] 
Non-fluorinated amino acids and the correlation between them are depicted in black. Fluorinated amino acids are 
presented in green. A version of the figure containing all fluorinated amino acids studied by our group is published in 
reference [31]. 
The retention time of non-fluorinated aliphatic amino acids increases non-linearly with increasing 
side-chain volume.[50, 135] As expected, the enlargement of the aliphatic side chain results in an 
increase of hydrophobicity. The retention times of the fluorinated amino acids do not fit into this 
correlation.[50, 134-135] A significant increase in the van der Waals volume is observed with each 
addition of a fluorine atom. The fluorinated amino acids relevant for this thesis are all more 
hydrophobic (as indicated by the increased retention time) than their native, non-fluorinated 
analogues. The hydrophobicity and side-chain volume of DfeGly lies in between the values 
obtained for Abu and Val.[50] (3S)-, and (3R)-43-F3Val are comparable to Leu and Ile with regard 
to side-chain volume as well as hydrophobicity. A slight difference is determined for both 
isomers, which might be attributed to the orientation of the side chain.[134] The fluorinated 
analogue of Ile, 53-F3Ile, is similar in size but at the same time much less hydrophobic than 
2-Aha.[135] On the contrary, 53,5’3-F6Leu is similar to 2-Aha in hydrophobicity while exhibiting a 
much larger volume.[135]  
It has been suggested that there are two effects that determine the overall hydrophobicity of 
the side-chain fluorinated aliphatic amino acids.[50] 
(i) The solvent-accessible surface area is increased when a hydrogen atom is substituted 
by a fluorine atom, leading to an increase in hydration energy. 
(ii) The C-F bond is more polarized than the C-H bond, resulting in energetically more 
favorable electrostatic interactions of the fluorinated group with the solvent.  
Thus, the fluoroalkyl side chains possess two opposing physicochemical properties: 
hydrophobicity and polarity. The combination of both leaves fluorinated amino acids less 
hydrophobic than their surface area would suggest.[135] Recently it was shown that this explanation 
is insufficient.[136] The group of Ana Vila Verde used molecular dynamics simulations and the 
gained results were compared to the experimental data obtained from the RP-HPLC experiment 
established by our group. Changes in the surface area of an amino acid upon fluorination have 
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only a secondary contribution to the changes in the hydrophobicity. Differences in hydration free 
energy arise primarily from steric hindrance and changes in the number of hydrogen bonds formed 
between backbone amine and carbonyl groups with water. The total number of backbone-water 
hydrogen bonds was found to decrease upon fluorination and correlates well with the observed 
increase in amino acid hydration free energy.[136] The smallest contribution to the free energy 
comes from changes in the dipole moment. Furthermore, it was found that changes in hydration 
free energy upon fluorination depend strongly on the identity of the amino acid and the orientation 
of the fluorinated side chain as in the case of (3S)-, and (3R)-43-F3Val. These results are supported 
by earlier quantum mechanics and molecular dynamics studies that showed that fluoromethylated 
groups establish hydrogen bonds to water molecules, which are weaker than that of 
non-fluorinated side chains in native protein environments.[50] 
5.1.2 α-helix propensity of side-chain fluorinated amino acids 
The α-helix propensity of fluorinated amino acids was determined using methods established by 
the Cheng group.[273-274] Therefore, the amino acid of interest is incorporated at a guest 
position (X) of an α-helical alanine-based model peptide with the sequence 
Ac-YGGKAAAAKAXAAKAAAAK-NH2 (K-X). The helical content of the peptides is then 
evaluated by CD spectroscopy and the mean residue ellipticity at 222 nm is used to calculate the 
fraction helix fhelix from which the α-helix propensity ω of the amino acids is determined applying 
modified Lifson-Roig theory (Table 5.1).[275-277] 
Table 5.1: Ellipticity [θ] at 222nm from normalized CD data, fraction helix fhelix 
and α-helix propensity ω of K-X peptides for selected natural and fluorinated 
amino acids. 
amino acid [θ]222nm fhelix ω 
Abu[273] -18100 ± 200 0.522 ± 0.006 1.22 ± 0.14 
Val[270] -13054 ± 452 0.38 ± 0.01 0.41 ± 0.04 
Ile[135] -13813 ± 156 0.40 ± 0.01 0.52 ± 0.05 
Leu[273] -17400 ± 200 0.502 ± 0.006 1.06 ± 0.12 
DfeGly[134] -13969 ± 569 0.40 ± 0.02 0.497 ± 0.060 
(3S)-43-F3Val[270] -2685 ± 526 0.08 ± 0.01 0 
(3R)-43-F3Val[270] -3887 ± 547 0.11 ± 0.02 0 
53-F3Ile[135] -10776 ± 216 0.31 ± 0.01 0.26 ± 0.03 
53,5’3-F6Leu[273] -8720 ± 200 0.251 ± 0.006 0.128 ± 0.023 
Chiu et al. showed that fluorinated amino acids generally exhibit lower α-helix propensities 
compared to their hydrocarbon analogues.[273-274] We expanded these studies with other 
fluorinated amino acids and observed the same trend.[134-135, 270] The introduction of two fluorine 
atoms into the Abu side chain results in a slightly reduced propensity for an α-helical structure, 
and the value obtained for DfeGly is comparable to Ile or Val.[134] (3R)- and (3S)-43-F3Val does 
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not display any α-helix propensity at all.[134, 270] Val is known to prefer β-sheet conformations[278] 
and the fluorination of one of the two β-methyl groups increases this effect even further. The 
close proximity of the large CF3-group to the peptide backbone prevents the formation of 
α-helical structures, and hence explains the absence of a α-helix propensity of the two 43-F3Val 
diastereomers.[270] This is supported by the findings for 4’3-F3Ile.[270] A complete loss of helix 
propensity is reported in this case as well, and also here, the β-methyl group is replaced by a 
CF3-substituent.[270] In contrast, it was observed that 53-F3Ile, in which the γ-CH3 group is replaced 
with CF3, still exhibits some α-helix propensity, namely half the value for Ile.[135] 53,5’3-F6Leu 
has an 8-fold reduced α-helix propensity compared to Leu.[273] 
The dramatic decrease in α-helix propensity of an amino acid upon fluorination is generally 
attributed to burial of the fluorinated side chain within the unfolded state of the peptide, as solvent 
exposure of these side chains in the monomeric helical state would be unfavorable due to the 
hydrophobic nature of the fluorinated amino acids.[273] In addition, the steric demand of the side 
chains is another factor that must be considered. For instance, amino acids that are branched at 
the β-carbon atom like Val or Ile have reduced α-helix propensities compared with the 
β-unbranched Leu as these side-chain atoms come into close proximity with the peptide 
backbone.[278] This effect is strengthened by the observations made for 43-F3Val and 4’3-F3Ile that 
carry the voluminous CF3 group at the β-carbon.[270] Here, the close proximity of this sterically 
demanding group to the peptide backbone seems to prevent the formation of α-helical structures 
as these amino acids possess no α-helix propensity.[270]  
It remains to be elucidated to what extent the α-helix propensity influences the protein 
stability at buried positions, e.g., within the hydrophobic cores of proteins, such as the 
hydrophobic pocket of gp41 of HIV-1, since the observed decrease in α-helix propensity might 
be caused by unfavorable solvent interactions at exposed positions of the monomeric K-X peptide. 
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5.2 Effects of hexafluoroleucine and trifluorovaline on the hydrophobic 
core formation of a heterodimeric coiled coil 
The results presented in this section were originally published as: 
S. Huhmann, E. K. Nyakatura, H. Erdbrink, U. I. M. Gerling, C. Czekelius, B. Koksch, Effects 
of single substitutions with hexafluoroleucine and trifluorovaline on the hydrophobic core 
formation of a heterodimeric coiled coil, J. Fluorine Chem. 2015, 175, 32-35. 
The original paper including supporting information is available at: 
https://doi.org/10.1016/j.jfluchem.2015.03.003 
Copyright © 2015 Elsevier B.V.. 
Individual contributions 
S. Huhmann synthesized the fluorinated VPK peptides, performed CD, and SEC/SLS 
experiments, and wrote the manuscript. E. K. Nyakatura had the project idea, synthesized the 
unmodified VPK and VPE peptides, and helped with the analysis of the results. H. Erdbrink, U. 
I. M. Gerling, and C. Czekelius provided the fluorinated amino acids. 
Paper summary 
Modifying peptides and proteins with fluorinated amino acids allows for modulation of their 
biophysical and pharmaceutical properties, and, therefore, biological activity.[21, 31-33] Systematic 
investigations that are based on model systems, which mimic natural protein-protein interaction 
domains, for instance the coiled-coil folding motif, can help to provide valuable insights into how 
side-chain fluorinated amino acids behave in natural protein environments. 
Several prior studies focused on the global substitution of the hydrophobic core with 
fluorinated analogues of hydrophobic amino acid residues, namely Leu and Val, and showed that 
the resulting coiled-coil systems display increased thermal stabilities. The enhanced stability was 
primarily attributed to hydrophobic effects.[21, 23-24, 35-36, 87-88, 98, 102-103, 105-106, 108] In contrast, work 
from the Koksch group placed emphasis on single amino acid substitutions by small, minimally 
fluorinated building blocks within the hydrophobic core. A coiled-coil model system developed 
for this purpose, named VPE/VPK, served as the scaffold. It was found that these modifications 
can lead to thermal destabilization,[79, 114-115] and that the degree of destabilization depends on how 
efficiently fluorinated residues pack against neighboring side chains.[118-119, 279-280]  
The goal of this study was to examine whether single substitutions with sterically demanding, 
highly fluorinated side chains are able to stabilize the hydrophobic core of such structures. Thus, 
53,5’3-F6Leu and two different diastereomers of 43-F3Ile were incorporated into the parallel 
heterodimeric coiled-coil model system VPE/VPK (Figure 5.2) to replace their natural analogues 
Leu or Val at the hydrophobic core positions d19 and a16, respectively, within VPK. The effect 
of these substitutions on coiled-coil structure and stability was evaluated by applying CD 
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spectroscopy (secondary structure, thermal denaturation), and size exclusion chromatography in 
combination with static light scattering (oligomerization state). 
 
Figure 5.2: Helical wheel representation of the parallel VPE/VPK 
heterodimeric model system.[79] 
The results demonstrate that although fluorinated amino acids generally possess distinctly lower 
helix propensities than their hydrocarbon counterparts,[134-135, 270, 273-274] the fluorinated VPK 
peptides form stable α-helical bundles with VPE showing slightly higher helical contents, while 
maintaining the parental dimeric oligomerization state (Table 5.2). The VPE/VPK-53,5’3-F6Leu19 
dimer exhibits a higher thermal stability (74.4°C vs. 70.7°C for the parent VPE/VPK system), 
while the melting points of the VPE/VPK bundles containing either (3R)-43-F3Val16 or 
(3S)-43-F3Val16 at position a16 are similar or somewhat lower (70.8°C and 67.5°C, respectively). 
As in the used model system, the fluorinated amino acids exclusively interact with natural 
residues of VPE, the increase in thermal stability upon 53,5’3-F6Leu introduction might be 
attributed to the greater hydrophobicity and efficient packing within the hydrocarbon side chains 
in the hydrophobic core, resulting in the highly favorable burial of the bulky hydrophobic 
fluorinated side chain. On the contrary, due to the shorter side chain of the 43-F3Val residue, the 
fluorine content and packing behavior seem to contribute less to hydrophobic core formation. 
Table 5.2: Theoretically and experimentally determined molecular weight, helical content fH, melting temperature 














VPE/VPK 7576 7578 ± 16 64 70.7 ± 0.3 11.1 ± 0.1 
VPE/VPK-53,5’3-F6Leu19 7684 7685 ± 40 69 74.4 ± 0.3 11.9 ± 0.3 
VPE/VPK-(3R)-43-F3Val16 7630 7674 ± 121 71 70.8 ± 0.2 11.1 ± 0.2 
VPE/VPK-(3S)-43-F3Val16 7630 7634 ± 15 73 67.5 ± 0.3 11.3 ± 0.2 
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In conclusion, the same principles that underpin the stability of natural proteins, which are 
efficient packing and hydrophobicity of side chains,[24] appear to determine whether fluorine 
substitution within a hydrophobic protein environment can enhance the stability of peptide 
structures. Even single substitutions with highly fluorinated amino acids can expand the 
hydrophobic core sequence space of coiled-coil based peptides, when correct packing and steric 
demands are considered. 
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For copyright reasons, the article is not included in the online version of this thesis. 
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5.3 Position-dependent effect of sterically demanding, and highly 
fluorinated amino acids on the proteolytic stability of a model 
peptide 
The results presented in this section were originally published as:  
S. Huhmann, A.-K. Stegemann, K. Folmert, D. Klemczak, J. Moschner, M. Kube, B. Koksch, 
Position-dependent impact of hexafluoroleucine and trifluoroisoleucine on protease digestion, 
Beilstein J. Org. Chem. 2017, 13, 2869-2882. 
The original paper with supporting information is available at: 
https://doi.org/10.3762/bjoc.13.279 
This paper is an open access article and reproduced under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0). This license is subject to 
the Beilstein Journal of Organic Chemistry terms and conditions (http://www.beilstein-
journals.org/bjoc). 
Individual contributions 
S. Huhmann synthesized the FA peptide, its analogues containing 53-F3Ile, and Ile, and performed 
the enzymatic digestion assay for these peptides. Furthermore, S. Huhmann wrote the main part 
of the manuscript. K. Folmert synthesized the six Leu and 53,5‘3-F6Leu containing peptides, as 
well as FA, and carried out the enzymatic digestion studies for the Leu/53,5‘3-F6Leu series. 
J. Moschner synthesized the amino acid Fmoc-53,5‘3-F6Leu. A.-K. Stegemann, D. Klemczak, and 
M. Kube repeated the enzymatic digestion assay for all peptides and performed the analysis of 
the cleavage patterns by mass spectrometry during bachelor thesis/research internship in the 
group of Prof. Dr. B. Koksch under supervision of K. Folmert and the author of this thesis. In 
addition, A.-K. Stegemann wrote some parts of the publication. 
Paper summary 
Peptide-based drugs are promising lead structures for the development of new drug candidates 
typically benefitting from high binding affinity and selectivity for their target. Their application, 
however, is limited as peptides suffer from rapid digestion by proteases or poor membrane 
permeability resulting in low bioactivity and poor oral bioavailability.[12, 15-17, 140] Several 
strategies to overcome these limitation, especially to prolong half-life and enhance resistance 
towards proteases, are based on the modification of peptides with non-natural building 
blocks.[15-17] Among these, the incorporation of fluorinated amino acids is of particular interest, 
since the decoration of small molecules with fluorine substituents is a widespread strategy in 
medicinal chemistry to modulate numerous molecular properties. Fluorine’s high 
electronegativity, small size, low polarizability and strong inductive effect can lead to changes in 
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molecule conformation, pKa values of neighboring functional groups, and, thus, the way in which 
a molecule interacts with a protein or receptor or permeates a membrane. As a consequence, 
pharmacokinetics and biological half-life can considerably change.[20, 25, 27-30] In light of these 
facts, several studies are focused on incorporation of fluorinated building blocks into peptides and 
proteins with the intention of improving or tuning their properties.[21, 31-33] For example, 
fluorinated amino acids have been shown to improve the proteolytic stability of peptides and 
proteins, though this is not always the case.[144-146, 157, 163-164] For a detailed discussion regarding 
this topic see Section 2.4. 
In an attempt to understand fluorine’s impact on the proteolytic stability of peptides in more 
detail, Koksch et al. established a systematic study. Therefore, a 10-amino acid model peptide, 
named FA, was designed comprising substrate specificities of different serine and aspartate 
proteases.[159-160] In initial studies, Ala residues at the P2, P1’ or P2’ positions, which are at or 
adjacent to the cleavage site, were substituted by DfeGly, TfeGly or Abu individually. The 
proteolytic stability of the resulting peptide library was investigated against human blood plasma 
and elastase,[159] as well as α-chymotrypsin and pepsin.[160] In only about 25% of all cased a strong 
increase in proteolytic stability upon introduction of fluorine was observed, while a strong 
destabilization was determined for almost the same amount of peptide substrates. In all other 
cases, no or only a small impact on protease resistance was detected, when fluorinated amino 
acids were introduced into the peptide chain. 
The objective of the study presented here, as a follow up to the previous results, was to 
evaluate the influence of the sterically demanding, highly fluorinated amino acids 53-F3Ile and 
53,5‘3-F6Leu on the proteolytic stability of the model peptide FA. As this project was conducted 
in cooperation with K. Folmert, who studied the 53,5‘3-F6Leu/Leu containing variants as part of 
her doctoral thesis,[281] the results for the 53-F3Ile/Ile substituted analogues are discussed again 
separately in the following paragraphs. 
53-F3Ile and Ile were singly substituted for Ala at positions P2, P1’, and P2’, yielding six 
modified FA analogues (Table 5.3). All peptide substrates, including FA as reference, were 
subjected to degradation by treatment with α-chymotrypsin, pepsin, elastase or proteinase K. The 
digestion process was followed over a time period of 24 h by an analytical RP-HPLC assay with 
fluorescence detection, and the cleavage products were identified by ESI-ToF mass spectrometry. 
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Table 5.3: Names and amino acid sequences of the studied peptides. The substitution 
positions are marked as Xaa with Xaa = Ile or 53-F3Ile. Positions are named according to 
Schechter and Berger nomenclature.[158] 
     cleavage site 
⇓     
   P3 P2 P1 P1’ P2’ P3’ P4’  
FA Abz K A A F A A A A K 
P2-XaaFA Abz K A Xaa F A A A A K 
P1’-XaaFA Abz K A A F Xaa A A A K 
P2’-XaaFA Abz K A A F A Xaa A A K 
Both P2 modified peptides were more stable than FA against digestion by α-chymotrypsin 
(Figure 5.3). Ile seems to be not that preferred as Ala in the P2 position, and the introduction of 
three fluorine atoms strengthens this effect with a 50% gain in stability towards α-chymotrypsin. 
The fluorinated P2 peptide was not digested at all after 24 h, suggesting that 53-F3Ile is not favored 
within the S2 pocket of α-chymotrypsin. Substitution of Ala in P1’ gave peptides that were more 
resistant towards proteolytic degradation. Again, fluorine modification led to less efficient 
degradation. In the case of the P2’ modified variants, Ile introduction slightly accelerates 
proteolysis by α-chymotrypsin compared to FA, while 53-F3Ile has a protective effect in this 
position. Analysis of the cleavage products by ESI-ToF mass spectrometry confirmed that 
position P1 bearing Phe is the main cleavage site for α-chymotrypsin (Figure 5.5). 
 
Figure 5.3: Digestion of peptide substrates by α-chymotrypsin and pepsin. The data shown 
represent the average of three independent measurements. Errors are derived from the standard 
deviation. 
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In the pepsin digestion assay, the control peptide FA is almost fully digested after 24 h 
(Figure 5.3). Except for P2-53-F3IleFA, the same holds true for the modified variants as also these 
peptides are digested completely, even faster than FA. P2-53-F3IleFA instead is fully resistant to 
pepsin, still 100% of the full-length peptide is detected after 24 h. Thus, fluorination shows only 
a protective effect when introduced N-terminal of the cleavage site. Observed digestion products 
corresponded to the expected cleavage pattern with Phe in the P1 position (Figure 5.5). In 
addition, for P2’-53-F3IleFA two further peptide bonds were found to be cleaved by pepsin. 
Substitution of Ala by Ile or 53-F3Ile in position P2 results in increased stability towards 
elastase digestion, while 53-F3Ile provides the best protection (Figure 5.4). Introduction of three 
fluorine atoms into Ile yields an about 35% gain in stability. Also in the P1’ position, Ile seems 
not as preferred as Ala, while 53-F3Ile shows a comparable amount of digestion to FA. That means 
fluorination of the P1’ residue does not protect the peptide from digestion by elastase. The 
opposite is observed for P2’ modified peptides. Whereas P2’-IleFA is almost completely 
degraded by elastase after 24 h, substitution by 53-F3Ile slows down the digestion process with an 
observed stabilization of around 37%. As the peptide substrates have Ala as the main residue 
present, multiple cleavage fragments are observed, consistent with the substrate specificity of 
elastase that preferably hydrolyzes peptide bonds C-terminal to uncharged non-aromatic amino 
acids and mainly between Ala-Ala or Ala-Gly bonds.[282-283] Thus, none of the peptide fragments 
detected corresponded to a Phe in the P1 position. 
 
Figure 5.4: Digestion of peptide substrates by elastase and proteinase K. The data shown 
represent the average of three independent measurements. Errors are derived from the standard 
deviation. 
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When incubated with proteinase K all peptides except for one were almost fully digested within 
24 h (Figure 5.4). Although fluorination of Ile in either the P2, P1’ or P2’ positions reduced the 
reaction velocity, only P2-53-F3IleFA was still present in a reasonable amount with 47% of the 
full-length sequence detectable after 24 h. This is a remarkable observation, as proteinase K 
possesses a broad substrate specificity, high activity and is able to digest numerous proteins even 
in the presence of detergents.[284] Due to the enzyme’s broad specificity, cleaving peptide bonds 
C-terminal to a number of amino acids, multiple cleavage patterns were detected for the 
substituted variants (Figure 5.5). As in the case of elastase, cleavage mostly occurred C-terminal 
to Ala.  
 
Figure 5.5: Cleavage positions observed in the digestion of peptide substrates. Cleavage sites that are not marked with 
a certain amino acid were detected in all P2, P1’ or P2’ modified peptides. 
In brief, 53-F3Ile introduction helps to protect the peptide against proteolysis by α-chymotrypsin 
in all modified positions when compared to the Ile containing analogues (Figure 5.6). For the 
other three enzymes a strong stabilization towards proteolytic digestion is only observed for 
fluorination of Ile N-terminal to the cleavage site. Remarkably, there is only one case 
(P1’-53-F3IleFA for elastase), in which the incorporation of fluorine atoms renders the peptide 
substrate significantly more prone to degradation. Furthermore, the P2-53-F3IleFA peptide is an 
outstanding example for the protective effect that fluorine introduction can account for. This 
peptide is the most resistant substrate towards digestion by all the four proteases investigated (see 
Figures 5.3 - 5.4). 
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Figure 5.6: Dimension of stabilization or destabilization upon 53-F3Ile incorporation compared to the 
non-fluorinated analogues containing Ile for all four different enzymes studied and measured after 24 h 
of incubation. 
Although in most cases an increase in proteolytic stability upon the introduction of fluorine into 
the Ile side chain was observed, the more rapid proteolytic digestion compared to the non-
fluorinated control in other cases point to fluorine specific interactions of the substrate with the 
respective enzyme binding site. Sterically demanding, fluorinated amino acids such as 53-F3Ile 
are not solely excluded from but can even be well accommodated by the active site. However, the 
results demonstrate that 53-F3Ile holds potential for engineering proteolytically stable 
peptide-based drug candidates. 
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Rapid digestion by prOleases limits the applicati n of peptides as therapeutic . One strategy lo increase the prote lytic stability f 
peptidlls i the modification with 0uorinated amino ac ids. Thi s study present a yste matic investigation of the effects of 0uori-
nated leucine and isoleucine derivatives on the prOleolytic stability ofa peptide that was designed to comprise substrate specifici-
ties of di(ler<ml proteases. Therefore, leuci:ne, isoleucine, and their side-chain Uuori.nated variants were site-specifically i:neo<p0rat-
ed at di(ferent p0 ition ofUus peptide resulting in a library of 13 distinct peptides. The tability of Uiese peptide towards prote 1-
ysis by a-chymorrypsi:n, pepsin, proteinase K, and elastase was studied, and this process was followed by an FL-RP-HPLC assay in 
combination wi U1 mass spectromeny. In a few cases, we observed an exceptional i:ncrease in proteolytic stability up0n introduction 
of the fluorine substituents. The opposite phenomenon was observed in other cases, and this may be explained by specific interac-
tions of 0uorinated residues with the respective enzyme binding sites. Noteworthy is that 5,5,5-lri0uoroisoleucuie is able to signifi-
cantly prOlect peptide from pr teol)' i by all enzyme· included in thi study when positioned -1enni11al to the cleavage ·ite. 
These results provide valuable infonnation for the application of 0uorinated amino acids in U1e design of proteolytically stable 
peptide-based pharmaceuticals. 
Introduction 
Peptide-based drugs are promising pharmaceuticals since they 
offer several odvanlage including high selectivily, speci ficily, 
and efficac y for recogiuzing and binding to their t rgel ( 1-6). 
However, their application as drugs is often limited due to low 
ora l bioovoil abil ity and a short half-life all rib1tloble in parl t 
protease of the digestive system and blo d pl, sma (1-8]. Effi-
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cient approaches to overcome these limitations have been de-
veloped including the incorporation of non-natural amino acids, 
such as D-amino acids, backbone-extended or chemically modi-
fied amino acids [I]. In this regard, the incorporation of fluo-
rine into amino acids has become a promising strategy. Fluo-
rine's unique properties, namely low polarizability, a strong 
inductive effect, and high electronegativity, as well as its small 
size, result in strong, short C- F bonds and perturb the acidity 
and basicity of adjacent functional groups. Moreover, these 
changes may strongly influence hydrogen bonding and electro-
static interactions that are crucial for binding to receptors or, in 
context of protease stability, enzymes. Thus, when introduced 
in the form of fluorinated amino acids, this unique element can 
alter the biophysical, chemical and pharmaceutical properties of 
proteins and peptides including their interaction with proteases 
[9,1 O]. 
Several laboratories have focused on introducing highly fluori-
nated analogues of hydrophobic amino acids and have studied 
the effects on stability of the resulting proteins towards thermal 
and chemical denaturation [9,11-22]. These studies prompted 
further investigation into the extent to which fluorinated amino 
acids stabilize peptides and proteins against proteolytic degra-
dation in particular. Meng and Kumar reported that the incorpo-
ration of 5,5,5,5 ' ,5' ,5'-hexafluoroleucine (H!Leu) into the anti-
microbial peptides magainin 2 amide and buforin enhanced 
their resistance towards proteolytic degradation by trypsin [23]. 
They also introduced H!Leu into the glucagon-like-peptide-1 
(GLP-1), which is an attractive lead compound for the treat-
ment of diabetes mellitus type 2. Unfortunately, the clinical use 
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phenylalanine variants into the histone acetyltransferase protein 
tGN5 resulted in destabilization in a chymotrypsin digestion 
assay [30]. Substitution of tryptophan, tyrosine, and phenylala-
nine residues in a glycosylation-deficient mutant of Candida 
antarctica lipase B, CalB N74D, by their monofluorinated ana-
logues, left !lie resistanc e to proteolytic degradation by 
proteinase K unchanged [3 I] . Incorporation of a -fluoroalkyl-
substituted amino acids can also lead to proteolytically stable 
peptides, and proteases can even be used to synthesize a-fluo-
roalkyl-substituted peptides [32-38]. 
These results indicate that the influence of fluorinated amino 
acids on the proteolytic stability of peptides and proteins 
remains difficult to predict. In an attempt to systematically 
study the influence of fluorinated amino acids on the proteo-
lytic stability of peptides, a IO-amino acid peptide (FA) was 
previously designed in our group, comprising the substrate 
specificities of the proteases a-chymotrypsin and pepsin 
[39,40]. 2-Aminobutanoic acid (Abu) and its fluorinated ana-
logues 2-amino-4,4-difluorobutanoic acid (DfeGly) and 
2-amino-4,4,4-trifluorobutanoic acid (ffeGly) were individu-
ally incorporated at either the Pl , the Pl ' or the Pl ' position 
[41] to give nine different analogues of FA In prior studies, we 
observed that the introduction of fluorine atoms into the Abu 
side chain can significantly improve or dramatically reduce 
resistance to hydrolysis by different enzymes and human blood 
plasma, depending upon the fluorine content of the side chain, 
the position of the substitution relative to the cleavage site and 
the particular protease (39 ,40]. 
of the wild-type peptide is severely hampered due to rapid Here, we extend these studies to include highly fluorinated, 
digestion ("2 min) by the serine protease dipeptidyl peptidase sterically demanding H!Leu, and 5,5,5 -trifluoroi soleucine 
[24-26]. Satisfyingly, the fluorinated GLP-1 analogues (Tflle) and to investigate their effects on proteolytic stability 
displayed higher proteolytic stability against this enzyme [27]. towards the serine proteases a-chymotrypsin, elastase, and 
Usually, the enhanced proteolytic stability of fluorinated 
peptides is explained by their greater hydrophobicity and altered 
secondary structure compared to the parent, non-fluorinated 
peptide. A further reason is the increased steric bulk of the fluo-
rinated amino aci4 meaning protection from protease degrada-
tion is a result of the steric occlusion of the peptide from the 
active site [23,28]. In contrast, the Marsh lab found that the 
introduction ofH!Leu into the antimicrobial peptide MSI-78 
only renders it more stable towards proteolysis by trypsin and 
chymotrypsin in the presence of liposomes [29]. In the absence 
ofliposomes, the fluorinated variants were as rapidly degraded 
as the non-fluorinated control, suggesting that the incorporation 
of H!Leu is not the only factor that prevents the peptide from 
being digested by proteases [29]. Fluorinated aromatic amino 
acids were also investigated regarding their impact on peptide 
proteolysis. For instance, incorporation of monofluorinated 
proteinase K, and the aspartate protease pepsin. 
Results and Discussion 
Peptide design and structure 
To elucidate the impact of fluorination on proteolytic stability 
we previously designed the peptide FA (Figure lb) that 
comprises the substrate specificities of a-chymotrypsin and 
pepsin [39,40]. Consequently, the Pl position is occupied by a 
phenylalanine residue. Lysine residues were introduced at both 
ends of the peptide sequence to enhance solubility, and 
a-aminobenzoic acid (Abz) at the N-terminus serves as a fluo-
rescence label. Alanine residues in positions P3, P3', and P4' 
act as spacers as the peptide binds in an extended conformation 
to the enzyme 's active site [42]. The positions P2, Pl' and P2' 
at or adjacent to the cleavage site [4 I] carry the key residues for 
the recognition of the substrate by the protease and serve as 
substitution sites. 
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FaCrrOH P2-XaaFA P1 '-XaaFA 
CF3 NH2 P2'-XaaFA 
4 
(112.86 A3) 
Bel/stein J. Org. Chem. 2017, 13, 2869--2882. 
P3 P2 P1 P1' P2' P3' P4' 
Abz K A A F A A A A K 
A bz K A Xaa F A A A A K 
Abz K A A F Xaa A A A K 
Abz K A A F A Xaa A A K 
Figure 1: (a} Structures of isoleucine (1), leucine (2), and their fluorinated ana logues 5,5,5-trifluoroisoleucine (3 , Tflle} and 5,5,5 ,5' ,5',5'-hexafluoro-
leucine (4, Hfleu}. The van der Waals volumes given in parentheses correspond to the side cha ins (starting at a-carbon), and were calculated accord-
ing lo Zhao et al. (43]; (b) Names and amino acid sequences of the stud ied peptides; the substitution positions are marked as Xaa; Xaa = Leu, Hfleu, 
l ie or Tflle . Positions are named according to Schechter and Berger nomenclature [41]. 
The alanines at P2, Pl ' or P2 • positions were substituted indi-
vidually with either T!Ile or H!Leu (Figure 1 a). Ile and Leu 
variants \Vere al:;o incl uded in lhis study as non- iluorinated 
controls. This led to a library of 12 FA variants (Figure lb). 
Leu and 11e are larger and more hydrophohic than A la . The 
flnorinated amino acids arc even larger and more hydrophobic 
than their hydrocarbon analogues l44,45J. Furthermore, fluo-
rine substitution has been shown to polarize neighboring C-H 
bonds (here U1c y-hydrogem) that co uld affect noncovalcnl 
ir1teractions [9,11]. Since tl1e amino acids used here (Figure l a) 
differ in thcir degree of Ouorination, spatial demand and hydro-
phobici ty , il is cxpcL'.lc<l that they wi ll have diITcrcnt impm.:Ls on 
the enzyme' s bindir1g pocket, reflected by different behavior in 
the proteolysis assay . 
Determination of proteolytic stability 
All peptides were inc ubated with the four di fferent proteases 
and their proteolytic degradation was followed over a penod of 
24 h. Both, a-chymotrypsm [46-49] and pepsin [50-54] are well 
characterized diges tive proteases They are , logethe r ,vith 
trypsin, the m.31.11 enzymes of the human digestive system. Elas-
tase }XJssesses a \vide substrate specifici ty for non-aromat ic, 
neutral s ide chains [55,56] and -is found in the human pancreas 
and in blood scrum. Protcinasc K, an enzyme widely used for 
inact ivation and degradation studies of proteins, was included 
here since it shows a broad substrate specificity and high activi-
ty and. Urns, is abk lO digcst numerous: nalive proteins:, even in 
the presence of detergents [57]. These fmu· enzymes have dif-
ferent preferences al their subsi tes, thus providing a broad scope 
for our invest igations 
The course of proteolytic digestion was characterized by an an-
alytical HPLC-assay wiU1 fluorescence detection [3 9,40]. For 
quant irication of suhstrnte <legrndation, integrntion of lhe corre-
sponding HPLC peak was conducted. Cleavage products were 
identi fied hy ESI - To F mass spec trometry (see Supporting 
lnfonnation r·ile l , Tab1es S4-S7). Figure S2 (Supporting Infor-
mation File 1) shows the time course of all of the <ligcstion ex-
perim ents. A detailed description o f the results for the indi-
vidual en7.ymes is given in the following section s. 
Proteolytic stability towards a-chymotrypsin 
(EC 3.4.21.1) 
a-Chymo lrypsin is a serine cndopcptida8e \vith broad spc1..:i -
ficity. It preferably cleaves peptide bonds C-tenninal to large 
hydrophobic residues such as pheny1alanine, tyro sine, trypto-
phan~ and lencine in the Pl position. Secondary hydrolysis also 
occurs at the carbonyl end of isoleucine, methionine, serine. 
threonine , val ine , his tidine, glycine.,. and alanine 14 7,58-601. 
The S2 subsite of a -chymotrypsin genernlly prefers to accom-
modate hydrophohic resid ues l 59,61 J. We observed that the 
11norinatcd P2 variants show a smaller amount of digestion after 
120 min compared to the ir hydrocarbon analogues, while all 
variants are more stable than the control FA (Figure 2). After 
24 h, all P2 peptides cxccpl for P2-Lcul'A arc still more stable 
than F/1. lncotporation of Leu into P2 leads to complete prote-
olysis compared to FA, in which Ala occupies this position. 
llowevcr, incorporntion of six nuorim.: subslitucnts into Leu (re-
sulting in HfLeu) results in an almost 100% gain in proteolytic 
stabili ty . lie is not as highly pre ferred in P2 as Leu, but also 
here the introduction o f three lluorine :;ubsli tuents lead:; to a 
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Figure 2: Percentage of substrate rema ining after incubation for 120 min (left) and 24 h (right) with a-chymotrypsin in 10 mM phosphate buffer, 
pH 7 .4, at 30 ~c. The data shown represent the average of three independent measurements. Errors are derived from the standard deviat ion. 
50% ga in in stabili ty . P2-HlL-cuFA and P2-TfllcFA arc not ESI- ToF mass analysis confinns that the posit ion P l bearing 
digested at all , suggesting that 1-111..eu and Tille are not favored Phe is the main c leavage si te for a-chymotrypsin (Figure 3). 
within the S2 pocket of o.-chymotr)l)Sin. Cleavage C-tenninal to Leu and HtLeu in Pl ' -LeuFA and Pl•-
P l ' -substituted peptides are all more stable tO\vards digestion 
thllll the control peptide FA, while Leu seems to provide the 
best protection from proteolysis. Here. introduction of fluorine 
makes the peptide prone to degradation. The opposite is true for 
Ik- as Tille kads to k ss efficient dcgr.c1dation. The Sl ~ ::mbsite 
of a-chymotryps in usually accommodates hasic residues with 
long side chai.ns [59,62,63]. Ile, as a branched amino acid, is 
obviously nol ,vcl1 .c1ccommodatcd in this posi tion for stcric 
reasons. A further increase in 8ide chain volume \1.rith Tflle 
exacerba tes this effect. In the case of I-I!L-cu, however, fluorine 
ll1Lcul:A is tilso observed (Figw-c 3, sec Supporting lnformu-
tion Fi le I , Table 84), which means that the cleavage site ·was 
shifted towards the C-tcrminus by one residue. This is likely a 
consequence of u-chymot.rypsin 's preference for not only aro-
matic re f. idues hut alflo bulky hydrophobic residues in the S 1 
pock cl , thus, Ilfl.eu is 1:tr..·-cepte<l by the P 1 binding pock cl of 
c1.-chymotrypsin. 
substituen ts seem to engage in favorable interactions ·with FA 
amino acid residues of the binding site , thus making Pl' -
llfLcuFJ\ a bcucr s Libstnttc lhan the non-11Lwrinatcd Leu 
peptide. Several such interactions are possible, as described in 
our previous work [39,40,64] 
The S2' subsite of a-chymotrypsin exhibits a hydrophobic char-
.c1clcr and thus prcfors to acc-Oinmodat(.· hydrophobic- residues 
f59,6Sl- Hmvever, the more hydrophobic peptides P2'-LeuFA, 
P2'-I-IIL-euFA, P2 '-IleFA, P2' -TllleFA are more stable agamst 
diges tion by u-chymot.rypsin compared Lo 1:A after l 20 min of 
mcuhation. After 24 h, only the fluorinated analogues are less 
degraded than the control FA Full length P2 ' -HJLcuFA and 
P2'-Ttl leFA are present at percentages up to 44% and 24%, re-
spectively, whi le subst1tut10n by Leu and Ile in P2 ' positton 
leads Lo 1::1ccek-rated proteolysis compared lo l-'A. Thus, bo th 




Figure 3: Cleavage positions observed in the digestion of library 
pept ides with a-chymotrypsin 
Tn summary., the introduction of fluorinated Leu and I leana-
logues into a a-chymotrypsin specific peptide sequence can 
2872 








Beilstein J. Org. Chem. 2017, 13, 2869- 2882. 
improve proteolytic stability mainly at the P2 and P2' positions, as well as Ile are well accommodated in the S2 subsite of 
with the strongest effects observed for the P2 position. pepsin. In contrast, Tille, although smaller than H!Leu [44] , 
<locsn~t appear to fit well into the S2 pocket of pepsin 
Proteolytic stability towards pepsin 
(EC 3.4.23.1 ) 
Pepsin is au aspaitic endopeptidase and one of the main diges-
tive enzymes in humans. It exlubits specificity for hydrophobic, 
espi.:cially aromatic residues like Phc, Trp, and Tyr at the Pl 
and Pl ' positions l50-54J. It has an extended active site that can 
bind at least seven residues (66,67] , and peptide bond cleavage 
occm·s N-tenninal to the residue at po sition P 1. 111e cleavage 
efficiency heavily depends upon the identity of this amino acid, 
with Phe and Leu being the most favored res idues. At the PI ' 
posit ion aromatic amino acid residues are preferred, however, 
the influence of the P l ' position on proteolytic cleavage is not 
as significanl f68]. Pepsin typically docs not cleave at Val , A la, 
or Gly linkages (60]. 
The S2 subsite ol pepsin preferentia11y accommodates l1ydro-
phobic residues such as Leu, Ala or norleucine as well as the 
fl- branched species Ile and Val , but can a lso bind charged 
rcsidLtcs [69,70 1. Except for P2-TnlcFA, we observed that the 
P2-modified peptides arc degraded more rapid ly than the 
control peptide FA and thal these pepli<les are almost or com-
pletely degraded after 120 min (Figure 4). For example, where-
as after 24 h FA i s a lso a lmost completely degraded, 
P2-TfTlc FA is still detected al a level of 100%. Incorporation of 
Leu or Ile leads lo complete proteolysis. Remarkably, the intro-
duc tion of six fl uorine atom s into Leu doesn' t t:hange this be-
havior. In shat}) contrast yet equally remarkable, the incorpora-
tion of three llnonne substituents into Ile results 111 a I 00% gam 
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To compare the Pl ' substituted peptides, only Pl ' -H!LeuFA 
shows the same persistence after 120 min as the control peptide 
FA, while all other sequences are digested taster. Herc, the 
introduction of fl uorine into LeL1 seems to stabilize the peptide 
by about 20%. Interestingly, after 24 h this trend is reversed, 
and the Pl '-HfLeuFA peptide is destabilized to an amoUI1t of 
17% compared to the hydrocarbon analogue, but both peptides 
are somewhat more stable than the control FA. The incorpora-
ti on of TIT ie into this posi ti on doesn ' t show a significant 
impact. Although the fluorine substi tuents slow d0\\11 tl1e diges-
tion process (see Supporting Infonuation File I, Figure S2b), 
the Tllle contnimng pcphde as well as its hydrocarbon ana-
logue are fully digested after 24 h . The Sl ' subsite has hydro-
phobic dmraclcr and lhus prc f(.TS lo accommodate hydrophobic 
or aromati c residues l7 1J . lie and Tflle are obviously well 
accommodated in this J:X)Sition, while Leu and HfLeu are not. 
The S2 ' subsite of pepsin favors hydrophobic amino acids, but 
also accepts charged polar amino acids like G Ill and Thr 
[52,72J After 1211 min peptides 1'2 '-1.euFA, 1'2'-llel'A and 1'2 '-
Tfllef A are degraded faster than the control FA. Instead, !'2 ' -
HfLeuFA is only digested up to 5%. This eflCct is even more 
prono ,mced after 24 h. While all other PI ' subst ituted peptides, 
along with the control peptide FA, arc almost or completely 
diges ted, Pr -11n,euFA is still present lo abo ut 76%. In this 
case tluorination leads to protect ion against proteolysis by 
pepsin. Hlleu 1s obviously not well accommodated in this posi-
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Figure 4: Percentage of substrate remaining after incLi bation for 120 min (left) and 24 h (right) with pepsin in 10 mM acetate buffer, pH 4.0, at 30 .. C . 
The data shown represent the average of three independent measurements. Errors are derived from the standard deviation. 
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three fluorine atoms into Tie slows dm.vn proteolysis, a lthough 
both peptides arc completely digested after 24 h 
For almost all peptides of our ltbrary, we observed the expected 
cleavage pullcm \vith Phc in the Pl position (Fig ure 5, sec Sup-
porting Infonnation Fi le I, Table S5). Only P2 ' -HfT .euFA is not 
hydrolyzed al the designed cleavage site, instead cleavage 
occ urs exclusively N-term inal lo the Hll.eu residue, thus 
demonsb·ating that HtLeu occupies the P-1 ' position. In the case 
of P2 ' -Tflk we found two fur ther peptide bonds tha t arc 
cleaved by pepsin, namely N-tenninal cleavage to TfTle and to 
Phe. These findings indicate fhat the SI' subsite accommodates 
bulky hydrophobic residues more readily than docs the S2' site 
BeilsteinJ. Org. Chem. 2017, 13, 2869--2882. 
tional cleavage site at ,.vhich the peptide bonds LeuP1'-AJaP2 ' , 
and HfLcuP1 ·-AlaP"2' arc hydrolyzed, respectively, which means 
that the cleavage site was shifted tm:vards the C-tem1inus by one 
residue. This cleavage pattern was also detected for a-chymo-
trypsin bcfon:, and indicates that lllLc u is well acc-cplcd by 
pepsin in its S 1 hinding site_ Furthermore" we identified a 
second cleavage site forP2-H1LeuFA at which the peptide bond 
N-terminal to Phe is proleo]ytically cleaved as wel l. This means 
that the cleavage site is shifted such that HtLeu occupies the P l 
..-iml Phc the Pl ~ position. llov.-·cver, this pcrfoctl:-,' matches the 
specificity of pepsin that prefers hulky hydrophobic and aromat-
ic amino acids both up- and d0\-\11Stream of the scissile bond. 
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specific. peptide sequence can improve the proteolytic- stability 
at the P2' position, whereas the incorporat ion of a fluorinated 
Il e mto the P2 position shows the strongest effect in protection 
from proteolysis. 
Proteolytic stability towards elastase 
(EC 3.4.21.36) 
Elastase is a seiine endopeptidase. and has a ,:vide specificity for 
non-aromatic Lll1c-hargcd side chains. l l preferentially cleaves 
pept ide bonds C-terminal to small uncharged non-aromatic 
amino acid residues such as glycine, alanine and serine, but also 
valine. leuc im:, isoleucine l56,73J. l ts binding si te extends over 
eight suhsites (SS to Sl , and S I. to S.l') [74]. 
The fact that in this study larger and more hydrophohic amino 
acids [44,45] were introduced may explain why degradation of 
mosl of the variimls during the lirst 120 min of incubation \vith 
elasta:-:e i::; hard ly observed (Figure 6)- Only P2'-LeufA, P2' -
100 
90 + + 
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Figure 6 : Percentage of substrate remaining after incubation for 120 min (left) and 24 h (right) with elastase in 100 mM Tris/HCI buffer, pH 8.4, at 
37 •c. The data shown represent the mean of three independent measurements, Errors are derived from the standard deviation. 
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Il eFA, and [)2 ' -Tfll eFA \.Vere somewhat di gested during th is 
time,. hmvever, .-1 11 of U1e modifi ed peptides are more stable than 
the control FA 
Aller 24 hal l P2 peptide variants a.re more sta ble than the 
control 1-<"A (Figure 6t whil e Tt11e provides the best protection 
from elastase digestion. Leu and Ile are not qui te as preferred in 
P2 position as is Ala. fl uorination of Leu leads to an increase in 
stability of around 19%. \Vith 35%) this effect is even higher 
when three fl uorine atoms are introduced into Ile . 
Modification of the Pl ' postion renders Pl ' -Htl ,cuFA and Pl ' -
Il el'A more stable than the control peptide !'A, while P l'-
J"fll eFA is comparably stable. Incorporation of Leu into Pl ' 
leads to complete di gestion. However_ introduci ng six fluorine 
a toms into Leu results in an 85% gain in stability. The opposite 
is observed for Il e, \\rhcre Tflle accelerates enzymatic degrada-
tion. 
Except fo r P2' - ll el-'A_ all P2 ' modified variants arc more stable 
compared to the cont ro l peptide !'A aller 24 h. Leu 1s not as 
preferred in this positi on as A la. Introduction of fluo rine 
strengthens this effect and effectively doubles the stabili ty . In 
contrast , introduction of Ile leads to almos t complete proteol-
ysis. However, substi h.ltion by Ttll c slows dO\"Vtl the degrada-
ti on rate and results in a stabiliza ti on of around 37%. In P2 ', 
!l uorination shm-vs in both cases a prolecti ve effect towards 
hydrol ys is by elastase. 
Elastase preferably hydro lyses pep tide bonds C-t.erminal to 
uncharged non -aromati c ami no acids and main ly hch-vccn 
A la- A la and A la--Gly bonds [56,73]. Smee Ala IS the ma111 
residue present in the peptides stud ied here,. we observed 
various cleavage products in the ESI- Tor· analysis ( Figure 7, 
see Supporting Information l'ilo 1, Table S6). !'or none of the 
peptides were fragments with Phc in tl1 e P I position observed. 
Since clastasc has a constricted SI pocket, the binding of aro-
matic amino acids at Pl is deleterious [75]. Ilere, we also ob-
served that I ,cu appears to never occupy the P l posi ti on, al-
though it is known to occupy this position in other substrates 
[73]. Interes tingly~ the l.:: trger lluorinated variant was found in 
the Pl position in one case, whi le li e and its fluorinated ana-
logue occupy th is posit.ion in two of the three peptide ana-
logues . 
The S2' subsit.e or elast.ase has a marked specifici ty for Ala, and 
Beilstein J. Org Chem 2017, 13, 2869- 2882 
Figure- 7: Cleavage positi ons for digestion of the different peptides 
w ith elastase. 
The S l ' subsite usually prefers Lys residues, and to a lesser 
extent Ala or Glu l74~76J. lndccd, we found a fragment cleaved 
off correspondrng to a Lys in P l ', but priman ly detected frag-
ments with Ala in Pl ' and also Phe that was even more favored 
than Lys. We observed that lie as well as its flu orinated ana-
logue Tlile are not accommodated in this subsite~ probably due 
to their B-branchcd topology 
The SJ' pocket in elastase is known to have a high aromatic 
specificity L74J. Interestingly, in our cases Phc in P3' was less 
favored. Instead, mainly Lys occupied thi s position 
Ala is favored in P2. Its carboxyl group can fonn a hydrogen 
bend with the amide nit rogen or Gly193 in the S2 pocket, and 
A la's methyl group laces the solvent [76]. 
Occupation of the S4 subsite is important for ellicient catalysis 
l76,77J. Thus clastase might not easily spli t the fi rst three bonds 
at the amino terminus ofa peptide chain, since interactions of a 
resid ue with S4 is necessary [77]. Indeed, we only observed a 
low amount of cleavage proximal to the N-terminus, whi le 111ost 
of the hydrolysis OCClffred at the C-lerminal end of the peptides. 
The SJ subsi tr.: seems to accommodate bul kier hydrophobic 
amino acids well , as we observed cleavage products containing 
Ile and Leu in P3 posihon for all the peptides modified with 
these residues, as well as their fluorinated analog ues for two of 
the three substi tuted peptides each. 
can accommodate bulkier resi dues only with some dif fi culty [n summary, introduction of Htl ,cu in di fferent positions of a 
l74J. Thus. ,vc did not find the fl uorinated am ino ac id s Hfl ,cu pepti de can enhance the proteolytic stability up to 85% com-
and IHie binding lo the S2' subsite of the enzyme as expected, pared lo the corresponding Leu analogues. Replacing Ile ,vith 
whereas for the Leu and Uc variants thi s was ohscrvcd only in Tfl lc can increase the stabili ty against elastasc as welL al-
one case each. though not as elli cie ntly as IIlLe u. 
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Proteolytic stability towards proteinase K 
(EC 3.4.21.64) 
Pro lei,rnse K is a non-specific serine endopeplidase and the 
main proteolytic enzyme produced by the fungus Tritirachium 
album Limber [78]. It has a broad substrate specificity , cleaving 
peptide bonds C-tenninal to a muuber of amino acids, lmwever, 
prefers aromatic or aliphatic hydrophobic ammo acids in posi-
tion Pl f57,78]. forthennore, Ala is favored in posi tion P2 and 
enhances cleavage efficiency l79,80J. Proteinase K possesses a 
very high proteolytic activity [79]. Its active center contains an 
extended binding region consisting of several subsites, at least 
four or five subsites on the N-tenmnal side of the scissile bond 
(S 1 to S4/S5) and lhrcc subsitcs C-tcrminal to the scissilc bond 
(SI ' to S3 ') [81-83j. The "bottom" of substrate recognition site 
is predominantly hydrophobic and there is evidence that not the 
sequence of the substrate is of importance .in the recognition but 
only the 1•olume of the side chains [84]. 
Suhstitulion o f Ala in position P2 with Ile and Leu leads to a 
greater or comparable amount of degradation after 120 min. 
Introducing tluorinc atoms in both cases slows down the diges-
tion process, most prornmnced for P2-TflleFA with a gain or 
60% in stability compared to its non-tluonnated analogue. Ile ,s 
not preCerre<l to the ex tent lhal Leu is, and the introduct ion or 
fluorine e1ilm11ces tl1is effect. W11ile all other peptides are ahnost 
completely or entirely degraded alter 24 h, P2-TtlleFA is the 
only peptide that is sti ll kfl after 24 h of incubation (figure 8). 
l ntrodLtction of Leu at the Pl ' posilion leads to an amounl or 
digest ion comparable to Fi\ after 120 min. fluoriuation of the 
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this position is not as prefetTed as is Leu and this enhances the 
stability to a small extent compared to FA. Introdnc.ing three 
iluorine atoms al the lie side chains strengthens the stahi1ity 
against proteil1ase K even further. 
As already observed for the other two Leu containll1g peptides, 
also snbstitution of Ala at position P2 ' with Leu does not 
change the resistance t1gains l prolcinasc K significantly. Tntcr-
esting]y , when six fluorine atoms are introduced, the digestion 
process is faster and P2'-HfLeuFA is almo st completely 
degraded after 120 mil1. The opposite is observed for the tluori-
nation of I.le. Wru.le Pl '-IleFA is as stable as FA, P2 '-TllleFA 
shows a small gain in stability of arOLmd 12%. 
Tims, in the case of Pl ' as well as P2 ' peptide variants, only 
!luorinntion of Ile leads to a slower digestion by protcinasc K, 
while introducing even more fluorine atoms into the Leu side 
chain leads to more rapid hydrolysis compared to the non-fluo-
rinated analogues. Ile seems in a11 investigated cases not as 
prefened as Leu, since less efficient digestion is observed. 
Introduction of three lluonne atoms even enhances this protec-
tive effec t. 
Hased on the wide subs trate specificity of proteinase K and its 
preference for alanine, and since our studied peptides have a 
high number of alanine residues present, there are multiple 
cleavage si lcs possible in addi tion to the designed si lc bcl\vcen 
PhcPl and XaaP1 · Indeed, multiple cleavage patterns arc ob-
served, especially deavage C-tenninal lo Ala (f-igure 9, see 
Supportil1g Jnfonnation file I, Table S7). Thus, /\la mainly 











Figure 8: Perceniage of substrate rema ining after incLibation for 120 min (left) and 24 h (right) with proteinase Kin 50 mM Tris/HCI buffer , containing 
10 mM CaCl2 pH 7.5, al 37 °c. The data shown represent the mean of three independent measurements. Errors are deri\led from the standard devia-
tion. 
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Figure 9: Cleavage positions found with proteinase K. 
to u greuter extenl. Alu i::; most el.Teclive in P2 f80l as the S2 
subsi le is u small and narro\v clcil. which limits the possibili-
ties for effective side chain suhstitu tions [79]. However, Tie and 
Tl.Ile are we11 accepted here. A negative or pos1t1 vecharge at S2 
is not preferred and hampers the fo rmation of the enzyme sub-
strate compl ex [82]. Tims, it can be concluded that J.ys is 
poorly accepted at this position . Hfl .eu, the most stericall y 
bulky amin o acid investigated here, is not observed to occupy 
the S2 subsite. Instead, Htl.eu is mainly found to bind to the S 1 
pocket. Leu is also found to occupy the SJ site of protcinasc K, 
"\-vhich is la rge an d has ma.inly hydrophobic character 
[82,83.85]. II docs not impose too strong stcric limitations on 
tl1c amino acid side chain but prefers hydrophobic and aromat ic 
residues, wi th a speci(ici ly J.Or Ala f7 8,8 1,83,86l Cha rged side 
chains of Olu and Lys arc very poorl y act",cptcd, as are 
0-brnnched functional groups, because the ent rance to the S 1 
subsi te is too narrow to allow the ir passage f79l Thu s, J.ys 1s 
nut obst: rved to occupy the Sl subsite. Nei ther Ue nor Tflle can 
be accommodated by the SI pocket due to th eir P-branching. 
Phe is found in Sl in only two cases in our srudy, and mainly 
occupies the S3 and SJ ' pockets. The S3 pocket has a wide 
specificity due to its location at the protein surface, but exhibits 
preference for aromatic side chains in P3 (Trp, Phc) [79]. S I ' 
shows a slight preference- for smaller residues like Ala and Uly, 
but also bulkier residues such as Phe and Leu are hydrolyz.ed to 
a significant cx1cnt (8 1] . In this study Leu apparently docs not 
bind to the S 1 • site at all , and thi s is a lso true of Tflle. Addition -
all y. Lys is not \\·ell accommodated here. Phe is a lso found to 
oc-cupy S4 lo a grcut extent, and this subsitc is k.J10\v11 to have an 
affin ity for aromatic groups, especia11 y a marked preference for 
Phe f7 9l S4- P4 in te raction s are prim aril y hydrophobic in 
nan.ire [79], which might explain why we observed that Lys is 
only poorly accepted in this position. The S3 subsi te cannot be 
Beilstein J Org_ Chem 2017, 13, 2869-2882 
defined as a " cleft" or "pocket" [79]. Th e P3 res idue of the 
peptide substrate lies on th e protein surface and the side chain 
of P3 should be directed toward the solvent [79]. This arrange-
ment might explain the broad specificity of S3 [79]. We ob-
served that all the residues used in this study can occupy the P3 
position, main ly Phe and Lys. Leu, Ile and T(]Je arc also found 
to a great extent in P3. 
In sum mary, lluorin ation o l" an Tie residue N-lerminul lo the 
cleavage site c..:an help to protect a peptide against prolcolysis by 
proteinase K . Due to its broad specifi city and high activ ity, 
proteinuse K typically digests peptides qu ickl y f5 7l Thi s was 
also observed in this work in experim ents in ,vhich all peptides, 
except for P2-Ttll eFA, a remarkably stable species, were com-
pletely degraded after an incubation time of 24 h. 
Conclusion 
The bulky side-chain fluorinated amino acids IJJLcu and Tfllc 
have lht: power to sig11i (ican t\ y stabi lize peptides aguinsl proko-
lytic degradation . The impac t of their inc..:orporation on the 
proteol yti c stab ility of pepti des does not fo ll ow a general trend 
but rather depends on a comb ina ti on of !actors includi ng the 
nature of the lluorinated amino at: id, the sub stitution position 
rela ti ve to the cleavage si te and the sru di ed protease. Also, in 
contrast to proteo lytic studies published before f23 ,27,28l, the 
expectati on of a general increase in proteolytic stability as a 
result of steric occlusion of the peptide from the active site upon 
incorporation of stcrica lly demanding fluorinated amino acids 
could not be verified based on the results of our current study. 
We found a significan t stabiliza tion towards proteolysis in 13 of 
a total of24 peptides of the library studied here upon iutroduc-
lion o r eithe r H(Leu or Tflle (Figure 10). Hmvever , \Ve ob-
served that even these sterica lly demanding i1 uorinated am ino 
acids show in some cases favorable interactions ,vith the en-
zymes bindi ng sites resu lting in a more rapid digestion as the 
non-fluorina ted l',On trol. 
The introducti on of flu ori nated J .eu and lle analogues into P2 
and P2 ' position improved the proteolytic stabil ity towards 
u-chymotryps in. \~/hen introduced in the Pl ' position a stabi-
lization was sti ll observed for Tille, ,vhil c incorporation of 
llfLcu made the- peptide more prone to proteolytic diges ti on 
compared lo the non-fluorinated contro l. Incorpora tion of 
HlLeu had a significantly stabilizing clicct towards hydrolysis 
by pepsin on ly in P2' position , while Tflle develops a protec-
ti ve effect only when incorpornted in P2 position . 
As both , elastase and proteinase K possess a broad specificity, 
preferr ing C-term inal cleavage to A la, we observed here a 
rather unspecific cleavage pattern for both enzymes with 
mu ltiple c leavage products, in wh ich the intended designed 
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Figure 10: Dimension of stabilizat ion or destabilization upon Tflle or Hfleu incorporation compared to the non-fluorinated analogues conta ining lie or 
Leu, respective ly, fo r all fou r different enzymes stud ied here and measured after 24 h of incubation. 
cleavage si te with Phe in P l positi on wasn 't affected. Hmvever, 
we obs erved that the introducti on of HfLeu has a general 
protect ive effect against degradati on hy ela::.tase, whereas the 
effect of Tille depends on the subs tituti on positi on. Although 
the introduction of 11uorine substihtents generally affected the 
rntti of hydrolysis by protc inas1: K, only flu urination of an lie 
residue )l°-tenninal to the cleavage site effectively protected the 
peptide from digestion. Particularly noteworthy is the effect of 
tluorination of the Ti e side chain in P2 position. The P2-1'tlleFA 
peptide \-\•'as the most rcs istau t substrate towurds protcolysi::i by 
all four proteases applied in thi s study. In contrast, destabi li7a-
tion due to iluorinat ion was only observed when Tille and 
IltLeu were incorporated into the P l ' position. 
1n future studies, we will focus on a more precise characteriza-
tion of the interact ion of fluori nated substrates with proteolJ1ic 
en 7. ymes to whi ch multiple fac tors con tribute. The steric 
dc,mmd or confonn ation of the side chain, hydrophobiL)ily, fluo-
rine induced pol arity and significant pKa-value changes of 
neighboring groups l9, I0J can lead Lo iluorinc-specific interac-
tions between substrate and enzyme binding sites as \\.'ell as to 
an exc lusion of the cleavage-relevant peptide bonds from the 
acti ve si te . 
Furthennore, our investigations show th a1 fluo rine's impact on 
proteolytic stabi lity needs to be investigated al\vays case-by-
case as there is no general trend to he concluded. Nevertheless, 
the results of thi::i current study provide valuable knowledge on 
how bulky fluorinated amino acids c,m help to increase the 
protcolyti Li stability of pcpti1.ks, and show that upon smart 
design , these fluorinated am ino ac ids can be used to engineer 
peptide drug candidates. 
Experimental 
Materials 
Fmo c-L- amino al,.': id s were purchas ed from ORPEGEN 
Peptide Chemicals GmbJI (Heidelberg, Germany). Fmoc-
Lys(Boc)\.Vang resin v;rns from Novabiochem (Merck Chemi-
cals GmbJ-1, Darmstadt, Gennany) . .A...11 solvents were used from 
VWR (Dannstadt, Gennany) without further purific ation. All 
other chem icals were hought from Acros (Creel, Belgium), ahcr 
GmbH (Karl sruhe, Germ any), 11uoroc11cm (Hadfie ld, Uni wd 
Kingdom), VWR (DannsL1dt, Gemrnny) or Merck (Darn1stadt, 
Ucm1any) at high est conunerc.ially available purity and used as 
such. A detailed synthetic strn te.gy fo r fmoc-Tflle-OJ-1 is de-
scribed in literature r44l For the synthesis of Fmoc-HfLeu-OH 
see Supponi ng Tnfomlation Fi le I . 
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Peptide synthesis, purification and 
characterization 
Peptides were synthesized manually in a 0 .05 mmol scale 
on a solid support by means of an Fmoc/ tert-butyl protecting 
group strategy on a preloaded Fmoc-Lys(Boc)Wang resin 
(0 .57 mmol/g loading) using 10 mL polypropylene reactors. 
HfLeu containing peptides were synthesized with an Activo-
Pl 1 automated peptide synthesizer (Activotec, Cambridge, 
United Kingdom). Couplings of non-fluorinated amino acids 
were performed in dimethylformamide (DMF) with the Fmoc-
L-ainino acid, 1-hydroxybenzotriazole (HOB!) andN,N '-diiso-
carbodiimide (DIC) in an eight-fold excess with respect to the 
resin amount. In order to ensure completion of the reaction the 
couplings were performed twice for 1 h each. The fluorinated 
amino acids and coupling reagents l-hydroxy-7-azabenzotri-
azole (HOAt)/DIC were used in 1.2-fold excess, and the cou-
pling was carried out manually one time overnight. In the case 
of an insufficient coupling, the coupling was repeated for 3 h 
with 0.5 equivalents. Prior to the Fmoc deprotection of the fluo-
rinated amino acids, free N-termini were capped by adding a 
mixture of acetic anhydride (Ac20 , 10% (v/v)) andN,N-diiso-
propylethylarnine (DIPEA, 10% (v/v)) in DMF (3 x 10 min). 
Fmoc deprotection was achieved by treatment with 20% (v/v) 
piperidine in DMF (3 x 10 min). All peptides were N-termi-
nally labeled with a-aminobenzoic acid (Abz) to enable photo-
metric detection. The resin was washed between each step with 
DMF and dicholoromethane (DCM, 3 x 2 mL each). After the 
synthesis, the peptides were cleaved from the resin by treat-
ment with a solution (2 mL) containing triisopropylsilane (TIS, 
10% (v/v)), water (1% (v/v)), and trifluoroacetic acid (TFA) 
(8 9% (v/v)) for 3 h. The resin was washed twice with TF A 
(I mL) and DCM (I mL) and excess solvent was removed by 
evaporation. The crude peptide was precipitated with ice-cold 
diethyl ether (80 mL), and after centrifugation dried by 
lyophilization. Purification of the synthesized peptides was per-
formed on a LaPrepZ low-pressure HPLC system (VWR, 
Darmstadt, Germany) using a Kinetex RP-Cl 8 endcapped 
HPLC column (5 µM, 100 A, 250 x 21.2 mm, Phenomenex®, 
USA). A Security GuardTM PREP Cartridge Holder Kit 
(21.20 mm, ID, Phenomenex®, USA) served as pre-column. As 
eluents deionized water (Milli-Q Advantage® AI0 Ultrapure 
Water Purification System, Millipore®, Billerica, MA, USA) 
and acetonitrile (ACN), both containing 0.1 % (v/v) TFA were 
used. HPLC runs were performed starting with an isocratic 
gradient of 5% ACN over 5 min, flow rate: 10 mL/min, contin-
uing with a linear gradient of 5- 70% ACN over 25 min, flow 
rate: 20.0 mL/min. UV-detection occurred at 220 mn. Data 
analysis was performed with an EZChrom Elite-Software 
(Version 3.3.2 SP2, Agilent Technologies, Santa Clara, CA, 
USA) . The fractions containing pure peptide were combined, 
reduced in vacuo and lyophilized to give the peptides as a white 
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powder. The purity of the peptides was controlled by analytical 
HPL C (LUNA™ C8 (2) column, 5 µm, 250 x 4.6 mm, 
Phenomenex®, Torrance, CA, USA) , and the products were 
identified by high-resolution ESI- ToF- MS (see Supporting 
Information File I). 
Protease digestion assay 
All peptides employed in the degradation studies were used as 
the TFA salts obtained after lyophilization. Stock solutions of 
Cl- chymotrypsin (from bovine pancreas, EC 3 .4 . 21 1, 
2'40 .0 units/mg of protein, Sigma Aldrich, St. Louis, MO, 
USA), and pepsin (from porcine stomach mucosa, EC 3.4.23.1 , 
2'2 50 uuits/mg of protein, Sigma Aldrich, St. Louis, MO, USA) 
were prepared at concentrations of 1 mg/mL in phosphate 
buffer (10 mM, pH 7.4), or in acetate buffer (IO mM, pH 4.0), 
respectively. For proteinase K (from tritirachium album, EC 
3.4.21.64, 2'30 uuits/mg of protein, Sigma Aldrich, St. Louis, 
MO, USA) and elastase (from porcine pancreas, EC 3.4.21.36, 
6.2 uuits/mg of protein, Sigma Aldrich, St. Louis, MO, USA) 
stock solutions were prepared also at concentrations of 
1 mg/mL in tris/HCl (5 0 mM) + CaCI2 (10 mM) buffer (pH 
7.5), or in tris/HCl buffer (100 mM, pH 8.4), respectively. 
Peptides (0.002 mmol) were prepared as stocks in DMSO 
(100 µL) and incubated with the respective enzyme at 30 °C 
(for a-cliymotrypsin and pepsin) or 37 °C (for proteinase Kand 
elastase) with shaking at 300 rpm in a thermomixer over a 
period of 24 Ii. The reaction mixture consisted of DMSO 
(15 µL) , corresponding buffer (25 µL), peptide solution (5 µL) 
and the corresponding enzyme solution (5 µL). The concentra-
tion of enzyme was optimized so that the hydrolysis of the 
control peptide FA was about 40% after 120 min. Aliquots of 
5 µL were taken at fixed time points (0, 15, 30, 60, 90, 120 min 
as well as 3 hand 24 h) and either quenched with ACN contain-
ing 0.1% (v/v) TFA (95 µL) , in the case ofa-chymotrypsin, 
proteinase Kand elastase, or 2% aqueous ammonia (95 µL), in 
the case of pepsin. All samples were subjected to analytical 
HPLC on a LaChrom-ELITE-HPLC-System equipped with a 
fluorescence detector (VWR International Hitachi, Darmstadt, 
Germany). A monolithic reversed-phase C8 Chromolitli® Per-
formance HPLC column (100 x 4.6 mm, Merck KGaA, Darm-
stadt, Germany) was used to resolve and quantify the products 
of digestion. The used system and gradients are described in 
detail in Supporting Information File I. Detection based on the 
Abz label was carried out using a fluorescence detector with 
),_ex ~ 320 mn and J..,m ~ 420 nm. In all cases, the peaks corre-
sponding to the starting materials (full-length peptides) or the 
N-tenninal fragments (products) were integrated and used to de-
termine the velocity of the reaction (see Supporting Informa-
tion File I). The FA peptide was used as a reference. Each frag-
ment cleaved from the full-length peptide was identified by 
ESI- ToF mass analysis on an Agilent 6220 ESI- ToF-MS spec-
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trometer (Agilent Technologies, Santa Clara, CA, USA, see 
SuppOrting Inf, rmati n Fi le 1). Al l experiments were per-
fo rmed in triplicate. 
Supporting Information 
Supporting Information File 1 
Characterization and identification ofsyntliesized peptides, 
characterization of the enzymatic digestion reactions, and 
idenlificati n ofpc leolytic cleavage products, HPl,C 
meUlOds, and synthesi protocol for Frnoc--H!Leu-OH. 
[http://www.beilstein-journals.mg!bjoc/coment/ 
supplememary/ l 860-5397-13-279-SI .pdt] 
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Synthesis of Fmoc-Hfleu-OH 
General information 
All reactions were run under an argon atmosphere unless otherwise indicated. Room 
temperature refers to 22 °C. Reagents and anhydrous solvents were transferred via 
oven-dried syringe or cannula . Flasks were flame-dried under vacuum and cooled 
under a constant stream of argon. Reactions were monitored by thin layer 
chromatography using Merck KGaA silica gel 60 F2s4 TLC aluminium sheets and 
visualized with eerie ammonium molybdate, vanillin staining solution or potassium 
permanganate staining solution. Chromatographic purification was performed as 
flash chromatography on Macherey-Nagel GmbH & Co. KG silica gel 60 M, 0.04-
0.063 mm, using a forced flow of eluent (method of Still). Concentration under 
reduced pressure was performed by rotary evaporation at 40 °C at the appropriate 
pressure . Yields refer to chromatographically purified and spectroscopically pure 
compounds. NMR measurements were recorded on a JEOL-ECX400 (operating at 
400 MHz for 1H NMR, 101 MHz for 13C NMR and 376 MHz for 19F NMR). Chemical 
shifts o are reported in ppm with the solvent resonance as the internal standard. 
Coupling constants J are given in Hertz (Hz). Multiplicities are classified by the 
following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, br = broad or 
m = multiplet and combinations thereof. High resolution mass spectra were obtained 
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Compounds 3 to 7 were synthesized according to literature [1 ,2] . Obtained NMR data 
(1H, 13C, and 19F) are consistent with literature [1,2]. 
Synthesis of Fmoc-Hfleu-OEt (8) 
(S)-7 (1.04 g, 3.89 mmol) was dissolved in 10% Na2CO3, aq (4 ml) and cooled to 
0°C. Dioxane (1 ml) was added and the suspension was stirred for 15 min at O °C 
after which FmocOSu (1.44 g, 4.28 mmol) was added. The mixture was stirred for 3 h 
at O °C and at room temperature overnight. The reaction was diluted with H2O 
(50 ml) and extracted with Et2O (4 x 25 ml). The combined organic layers were 
concentrated in vacuo and the residue was subjected to column chromatography (n-
hexane/Et2O, 3: 1) to give (S)-8 (1 .12 g, 2.29 mmol, 59%) as a waxy solid. 
TLC: R1 = 0.45 (n-hexane/Et2O, 5: 1 ). 
1H-NMR (400 MHz, CDCb): o = 7.77 (d, J = 7.5, 2H); 7.58 (d, J = 7.2, 2H); 7.40 (t, 
J = 7.5, 2H); 7.32 (t , J = 7.0, 2H); 5.40 (d, J = 7.50, 1 H); 4.47 (dt, J = 20.0; 13.40, 
3H); 4.32 - 4.18 (m, 3H); 3.18 (s, 1 H); 2.40 (d, J = 14.5, 1 H); 2.05 (d, J = 10.0, 1 H); 
1.30 (t, J = 7.1 , 3H). 
13C-NMR (101 MHz, CDCl3) o = 170.68, 143.75, 143.53, 141.45, 141.44, 140.84, 
130.32, 127.92, 127.90, 127.19, 127.17, 125.07, 124.98, 120.32, 120.15, 120.11, 
67.29, 62.53, 51 .96, 47.21, 37.15, 27.27, 14.13. 
19F-NMR (376 MHz, CDCb): o = -67.27 - -67.44 (m), -67.63 - -67.79 (m). 
HRMS calculated for C23H31 F6NNaO4 [M+Nar: 512.1267; observed : 512.1294. 
Synthesis of Fmoc-Hfleu-OH (9) 
A solution of (S)-8 (55.0 mg, 11.2 mmol) in HClconc (2 ml) was stirred at room 
temperature for 24 h. The crude product was lyophilized and purified via a 
LaPrep~ low-pressure HPLC system (\/\/1/R, Darmstadt, Germany) using a Kinetex 
RP-C18 endcapped HPLC-column (5 µM, 100 A, 250 x 21.2 mm, Phenomenex®, 
USA). Deionized water and acetonitrile (ACN), both containing 0.1 % (v/v) TFA 
served as eluents. A linear gradient of 30-100% ACN + 0.1 % (v/v) TFA over 18 min 
with a flow rate of 20.0 ml/min was applied . UV-detection occurred at 280 nm . This 
gave (S)-9 (36.3 mg, 7.87 mmol, 70%) as a white powder. 
1H-NMR (400 MHz, DMSO-D6): o = 7.82 (d, J = 7.6, 2H); 7.77 (d, J = 8.7, 1 H); 7.63 
(d, J = 7.5, 2H); 7.36 (t, J = 7.4, 2H); 7.26 (t, J = 7.4, 2H); 4.35 - 4.23 (m, 2H); 4.17 (t, 
J = 6.7, 1 H); 4.04 (br, 1 H); 2.30 - 2.17 (m, 1 H); 2.13 - 2.01 (m , 1 H). 
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13C-NMR (101 MHz, DMSO-D6): o = 175.95 (s); 158.87 (s) ; 144.17 (s); 144.10 (s); 
141 .23 (s); 141 .22 (s); 128.27 (s); 128.25 (s); 127.62 (s); 127.61 (s); 125.69 (s); 
125.69 (s); 125.63 (s); 125.61 (s); 120.65 (s); 120.61 (s); 66.23 (s); 51 .54 (s); 47.11 
(s); 29.52 (s) ; 26.34 (s). 
19F-NMR (376 MHz, DMSO-D6): o = -65.91 - -66.13 (m); -66.38 - -66.62 (m). 
HRMS calculated for C21 H17F6NO4 [M+Nat: 484.0954; observed: 484.0942. 
Peptide synthesis, purification and characterization 
Peptide synthesis 
Peptides containing HfLeu were synthesized on an Activo P11 Automated Peptide 
Synthesizer (Activotec, Cambridge, United Kingdom) working under nitrogen 
atmosphere. All other peptides, either non-fluorinated or Tflle containing, were 
synthesized manually under standard conditions. 
Peptide characterization 
High resolution mass spectra were recorded on an Agilent 6220 ESI-ToF LC-MS 
spectrometer (Agilent Technologies Inc. , Santa Clara , CA, USA) to identify the pure 
peptide products. The samples were dissolved in a 1 :1 mixture of water and 
acetonitrile containing 0.1 % (v/v) TFA and injected directly into the spray chamber by 
a syringe pump using a flow rate of 10 µL min-1. A spray voltage of 3.5 kV was used, 
the drying gas glow rate was set to 5 L min-1 and the nebulizer to 30 psi. The gas 
temperature was 300 °c. 
To verify purity of the synthesized peptides analytical HPLC was carried out on a 
Chromaster 600 bar DAD-System with CSM software (VWR/Hitachi, Darmstadt, 
Germany). The system works with a low-pressure gradient containing a HP LC-pump 
(5160) with a 6-channel solvent degasser, an organizer, an autosampler (5260) with 
a 100 µL sample loop, a column oven (5310) and a diode array flow detector (5430). 
A LUNA TM C8 (2) column (5 µm, 250 x 4.6 mm, Phenomenex®, Torrance , CA, USA) 
was used. As eluents water and ACN , both containing 0.1 % (v/v) TFA were used , the 
flow rate was adjusted to 1 ml/min and the column was heated to 24 °C. The used 
gradient method is shown in Table S1. The UV-detection of the peptides occurred at 
220 nm. The data were analyzed with EZChrom Elite software (version 3.3.2, Agilent 
Technologies, Santa Clara, CA, USA). 
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Table S1 · Used linear gradient for the purity determination of the synthesized 
peptides. 
Time [min] Water+ 0.1 % (v/v) TFA [%] ACN + 0.1 % (v/v) TFA [%] 
















Table S2: Identification of the synthesized peptides by ESI-ToF mass spectrometry and analytical RP-HPLC. 
Peptide Retention time [min] Charge m/z calculated m/z observed 
FA 10.597 +1 967.5364 967.5396 
+2 484.2721 484.2736 
P2-LeuFA 12.500 +1 1009.5463 1009.5849 
+2 505.2956 505.2970 
P2-HfLeuFA 12.393 +1 1117.4622 1117.5306 
+2 559.2573 559.2691 
P2-lleFA 12.137 +1 1009.5463 1009.5849 
+2 505.2956 505.2971 
P2-TflleFA 12.493 +1 1063.4622 1063.5576 
+2 532.2814 532.2845 
P1'-LeuFA 11 .773 +1 1009.5463 1009.5863 
+2 505.2956 505.7982 
P1'-HfLeuFA 11 .917 +1 1117.4622 1117.5272 
+2 559.2573 559.2684 
P1'-lleFA 11 .370 +1 1009.5463 1009.5858 
+2 505.2956 505.2975 
P1 '-TflleFA 11 .870 +1 1063.4622 1063.5556 
+2 532.2814 532.2816 
P2'-LeuFA 11 .847 +1 1009.5463 1009.5866 
+2 505.2956 505.2981 
P2'-HfLeuFA 12.197 +1 1117.4622 1117.5305 
+2 559.2573 559.2693 
P2'-lleFA 11 .557 +1 1009.5463 1009.5864 
+2 505.2956 505.2980 
P2'-TflleFA 12.283 +1 1063.4622 1063.5576 
+2 532.2814 532.2835 
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Figure S1: Analytical HPLC chromatograms of purified peptides; column: Luna™cs (5 µM, 250 x 4.6 mm, 
Phenomenex®}; Solvent A was H20 , solvent B was acetonitrile, both containing 0.1 % (v/v) TFA. The flow rate was 
1 mUmin; linear gradient from 5% B to 70% B over 18 min (see Table S1) . 
Enzymatic digestion studies 
Characterization of the enzymatic digestion reactions was carried out via analytical 
HPLC on a LaChrom-ELITE-HPLC-System from \N,/R International Hitachi 
(Darmstadt, Germany). The system contains an organizer, two HPLC-pumps (L-
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2130) with solvent degasser, an autosampler (L-2200) with a 100 µL sample loop, a 
diode array flow detector (L-2455) , a fluorescence detector (L-2485) and a high 
pressure gradient mixer. As eluents water and ACN, both containing 0.1 % (v/v) TFA 
were used , and a flow rate of 3 mUmin was applied. The used linear gradients are 
shown in Table S3. For the non-fluorinated peptides method A was used to follow the 
digestion process, and for the fluorinated peptides method B was applied. For 
chromatograms where an insufficient baseline separation was observed, 
measurements were repealed using methods C [FA (pepsin), P2-LeuFA 
(proteinase K) , P2-lleFA (pepsin), P2-lleFA (proteinase K) , P1 '-LeuFA (elastase), 
P1 '-Leu FA (proteinase K), P1 '-lie FA (proteinase K)] or D [P2-HfleuFA (proteinase K), 
P2-TflleFA (pepsin) , P2-TflleFA (proteinase K), P1'-TflleFA (elastase) , P2'-TflleFA 
(proteinase K)] . The obtained data were analyzed with EZChrom Elite software 
(version 3.3.2 , Agilent Technologies, Santa Clara , CA, USA) . 
Table S3: Used linear gradients to follow the digestion process by FL-RP-HPLC 
Method Time[min] Water+ 0.1% (v/v) TFA [%] ACN + 0.1% (v/v) TFA [%] 
A 0 95 5 
5 70 30 
5.5 70 30 
6 95 5 
9 95 5 
B 0 95 5 
5 60 40 
5.5 60 40 
6 95 5 
9 95 5 
C 0 95 5 
15 70 30 
15.5 70 30 
16 95 5 
17 95 5 
D 0 95 5 
15 55 45 
15,5 55 45 
16 95 5 
17 95 5 
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Figure S2: Chronological sequence of the substrate amount [%] over an incubation t ime of 180 min with (a) 
a-chymotrypsin, (b) pepsin , (c) elastase, and (d) prote1nase K. The depicted values represent the mean of three 
independent measurements. 
Identification of the proteolytic cleavage products (Table S4-S7) occurred according 
to the mass-to-charge ratios determined with an Agilent 6220 ESI-ToF-MS 
instrument (Agilent Technologies, Santa Clara, CA, USA). For this, the quenched 
peptide-enzyme-solutions after 120 min and 24 h incubation were analyzed. The 
solutions were injected directly into the spray chamber using a syringe pump with a 
flow rate of 1 O µ L min -1. Spray voltage was set to 3. 5 kV, a drying gas fl ow rate of 5 L 
min-1 was used, the nebulizer was set to 30 psi, and the gas temperature to 300 °C. 
The fragmentor voltage was 200 V. Not all corresponding fragments could be 
detected. 
Table S4: Identification of the cleavage products of the different peptides by ESI-ToF mass spectrometry after 
digestion with a- chymotrypsin. 
Peptide Fragment [M + HJ1' calculated [M + HJ" observed 
FA Abz-KAAFAAAAK 967.5364 967_5376 
Abz-KAAF 555.2559 555-2938 
AAAAK 431.2617 431 _2627 
P2-LeuFA Abz-KALeuFAAAAK 1009.5463 1009.5883 
Abz-KALeuF 597.3029 597.2609 
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AAAAK 431.2617 431 .2617 
P2-HfleuFA Abz-KAHILeuF AMM 1117.4622 111 7.5298 
P2-lleFA Abz-KAlleFAAAAK 1009.5463 1009.5851 
Abz-KAlleF 597.3029 597.3435 
AAAAK 431.2617 431.2647 
P2-TflleFA Abz-KATII leFAAAAK 1063.4622 1063.5577 
P1 '-LeuFA Abz-KAAFLeuAAM 1009.5463 1009.5866 
Abz-KAAFLeu 668.3400 668.3760 
Abz-KAAF 555.2559 555.2907 
LeuAAAK 473.3087 473.3087 
AAAK 360.2246 360.2239 
P1'-HfLeuFA Abz-KAAFHfLeuAAM 111 7.4622 111 7.5280 
Abz-KAAFHfLeu 776.2559 776.3214 
HfLeuAAAK 581.2246 581.2246 
Abz-KAAF 555.2559 555.2934 
AAAK 360.2246 360.3630 
P1'-lleFA Abz-KAAFlleAAAK 1009.5463 1009.5825 
Abz-KAAF 555.2559 555.2951 
lleAAAK 473.3087 473.3104 
P1 '-TflleFA Abz-KAAFTflleAAAK 1063.4622 1063.5604 
Abz-KAAF 555.2559 555.2954 
TflleAAAK 527.2246 527.2827 
P2'-LeuFA Abz-KAAF ALeuAM 1009.5463 1009.5872 
Abz-KAAF 555.2559 555.2922 
ALeuAAK 473.3087 473.3087 
P2'-HfLeuFA Abz-KAAFAHfLeuAM 111 7.4622 111 7.5331 
AHfLeuAAK 581.2246 581.2550 
Abz-KAAF 555.2559 555.2965 
P2'-lleFA Abz-KAAF AlleAAK 1009.5463 1009.5875 
Abz-KAAF 555.2559 555.2943 
AlleAAK 473.3087 473.311 2 
P2'-TflleFA Abz-KAAFATflleAAK 1063.4622 1063.5575 
Abz-KAAF 555.2559 555.2945 
ATflleAAK 527.2246 527.2822 
Table S5: Identification of the cleavage products of the different peptides by ESI-ToF mass spectrometry after 
digestion with pepsin. 
Peptide Fragment [M+H] calculated [M+H] observed 
FA Abz-KAAFAAAAK 96.5364 967.5434 
Abz-KAAF 555.2559 555.2967 
AAAAK 431 .2617 431 .2617 
P2-LeuFA Abz-KALeuFAAAAK 1009.5463 1009.5895 
Abz-KALeuF 597.3029 597.3438 
AAAAK 431 .2617 431 .2642 
P2-HfleuFA Abz-KAHfLeuFAAAAK 111 7.4622 1117.5302 
Abz-KAHfLeuF 705.2188 705.2870 
FAAAAK 578.3301 578.3327 
AAAAK 431.2617 431 .2636 
P2-lleFA Abz-KAlleFAAAAK 1009.5463 1009.5916 
Abz-KAlleF 597.3029 597.3442 
AAAAK 431.2617 431 .2647 
P2-TflleFA Abz-KA TflleFAAAAK 1063.4622 1063.5639 
P1'-LeuFA Abz-KAAFLeuAAAK 1009.5463 1009.5926 
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Abz-KAAFLeu 668.3400 668.3820 
Abz-KAAF 555.2559 555.2971 
LeuAAAK 473.3087 473.3126 
MAK 360.2246 360.2271 
P1'-HfLeuFA Abz-KAAFHfleuAMK 111 7.4622 1117.5325 
Abz-KAAFHfleu 776.2559 776.3236 
HfleuAAAK 581 .2246 581 .2553 
Abz-KAAF 555.2559 555.2956 
MAK 360.2246 360.2273 
P1'-lleFA Abz-KAAFlleMAK 1009.5463 1009.5908 
Abz-KAAF 555.2559 555.2969 
lleAAAK 473.3087 437.3087 
P1'-TflleFA Abz-KAAFTflleAAAK 1063.4622 1063.5634 
Abz-KAAF 555.2559 555.2969 
TflleMAK 527.2246 527.2843 
P2'-LeuFA Abz-KAAFALeuAAK 1009.5463 1009.5905 
Abz-KAAF 555.2559 555.2963 
AleuAAK 473.3087 473.3117 
P2'-HfLeuFA Abz-KAAFAHfleuMK 1117.4622 111 7.5307 
Abz-KAAFA 626.2930 626.3344 
HfleuAAK 510.1875 510.21 70 
P2'-lleFA Abz-KAAFAlleAAK 1009.5463 1009.5889 
Abz-KAAF 555.2559 555.2970 
AlleAAK 473.3087 473.31 21 
P2'-TflleFA Abz-KAAFATfl leMK 1063.4622 1063.5627 
FATflleAAK 674.2930 674.3530 
Abz-KAAFA 626.2930 626.3333 
Abz-KAAF 555.2559 555.2969 
ATflleMK 527.2246 527.2845 
TflleAAK 456.1875 456.2462 
Table S6: Identification of the cleavage products of the different peptides by ESI-ToF mass spectrometry after 
digestion \Mlh elastase. 
Peptide Fragment [M + HJ'" calculated [M + HJ'" observed 
FA Abz-KAAF AAAAK 967.5364 967.5352 
Abz-KAAFAAA 768.3672 768.4080 
Abz-KAAFAA 697.3301 697.3690 
AFAAMK 649.3673 648.2935 
Abz-KAAFA 626.2930 626.3308 
AMK 360.2246 360.2238 
AAK 289.1875 289.1872 
P2-LeuFA Abz-KALeuF AAMK 1009.5463 1009.5871 
Abz-KALeuF AAAA 881 .4513 881 .4831 
Abz-KALeuF AAA 810.4142 810.4831 
Abz-KAleuFAA 739.4116 739.4116 
LeuFAAAAK 691 .4142 691.4116 
Abz-KALeuFA 668.3404 668.3745 
AAAAK 431 .2617 430.0496 
AAAK 360.2246 360.2205 
AAK 289.1875 289.1858 
P2-HfLeuFA Abz-KAHfleuFAAAAK 1117.4622 111 7.5325 
Abz-KAHfleuFAAA 918.3301 918.3980 
Abz-KAHfleuFAA 847.2930 847.3610 
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Abz-KAHfleuFA 776.2559 776.2559 
FAAAAK 578.3301 578.2440 
P2-lleFA Abz-KAlleFAAAAK 1009.5463 1009.5884 
Abz-KAlleFAAAA 881.4513 881.4960 
Abz-KAlleFAAA 810.4142 810.4960 
Abz-KAlleFAA 739.3771 739.4176 
Abz-KAlleFA 668.3400 668.3787 
FAAAAK 578.3301 578.3322 
AAAK 360.2246 360.2256 
AAK 289.1875 289.1880 
AK 218.1504 218.1505 
P2-TflleFA Abz-KATflleFAAAAK 1063.4622 1063.5576 
Abz-KATflleFAAA 864.3301 864.4210 
Abz-KATflleFAA 793.2930 793.3844 
Abz-KATflleFA 722.2559 722.3470 
FAAAAK 578.3301 578.3271 
AAAK 360.2246 360.224 
P1'-LeuFA Abz-KAAFLeuAAAK 1009.5463 1009.5887 
Abz-KAAFLeuAAA 881.4513 881.4815 
Abz-KAAFLeuAA 810.4142 810.4472 
AAFLeuAAAK 762.4513 762.4458 
Abz-KAAFLeuA 739.3771 7394120 
AFLeuAAAK 691.4142 691.4142 
FLeuAAAK 620.3771 620.3783 
Abz-KAA 408.1875 408.1875 
Abz-KA 337.1504 337.1504 
AAK 289.1504 289.1858 
P1'-HfLeuFA Abz-KAAFHfleuAAAK 1117.4622 1117.5330 
Abz-KAAFHfleuAA 918.3301 918.3982 
AAFHfleuAAAK 870.3673 870.3975 
AFHfleuAAAK 799.3301 799.3600 
Abz-KA 337.1504 337.1864 
P1'-lleFA Abz-KAAFI leAAAK 1009.5463 1009.5853 
Abz-KAAFI leAA 810.4142 810.4500 
Abz-KAAFlleA 739.3771 739.4144 
FlleAAAK 620.3771 620.3747 
P1 '-TflleFA Abz-KAAFTflleAAAK 1063.4622 1063.5578 
Abz-KAAFTflleAA 864.3301 864.4205 
Abz-KAAFTflleA 793.2930 793.3844 
AFTflleAAAK 745.3301 745.3814 
AAK 289.1875 289.1857 
AK 218.1504 218.1483 
P2'-LeuFA Abz-KAAFALeuAAK 1009.5463 1009.5894 
Abz-KAAFALeuAA 881.4513 881.4938 
Abz-KAAFALeuA 810.4142 810.4938 
AFALeuAAK 691.4142 691.4168 
Abz-KAAFA 626.2930 626.3324 
LeuAAK 402.2716 402.2730 
Abz-KA 337.1504 337.1872 
P2'-HfLeuFA Abz-KAAFAHfleuAAK 1117.6622 1117.5330 
Abz-KAAFAHfleuA 918.3301 918.4349 
AAF AHfleuAAK 870.3673 870.4001 
AFAHfleuAAK 799.3301 799.3612 
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FAHfleuAAK 728.2930 728.3229 
Abz-KAAFA 626.2930 626.3230 
Abz-KAAFA 408.1875 408.2262 
P2'-lleFA Abz-KAAFAlleAAK 1009.5463 1009.5866 
Abz-KAAFAlleAA 881.4513 881.4910 
Abz-KAAFAlleA 810.4142 810.4539 
Abz-KAAFAlle 739.3771 739.4171 
FAlleAAK 620.3771 620.3687 
Abz-KAA 408.1875 408.2252 
P2'-TflleFA Abz-KAAFATfl leAAK 1063.4622 1063.5530 
Abz-KAAFATflle 793.2930 793.3851 
FATflleAAK 674.2930 674.3441 
Abz-KAA 408.1875 408.2233 
AAK 289.1875 289.1855 
Table S7: Identification of the cleavage products of the different peptides by ESI-ToF mass spectrometry after 
digestion w ith proteinase K. 
Peptide Fragment [M+H] calculated [M+H] observed 
FA Abz-KAAFAAAAK 967.5364 967.5376 
AFAAAAK 649.3673 649.2762 
P2-LeuFA Abz-KALeuFAAAAK 1009.5463 1009.5863 
Abz-KALeuFAAA 810.4142 810.4536 
Abz-KALeuFAA 739.4116 739.4179 
Abz-KALeuFA 668.3404 668.3816 
Abz-KALeu 450.2345 450.2719 
AAK 289.1504 289.1880 
P2-HfLeuFA Abz-KAHfleuFAAAAK 1117.4622 1117.5298 
Abz-KAHfleuFAAA 918.3301 918.3970 
Abz-KAHfleuFAA 847.2930 847.3608 
Abz-KAHfleuFA 776.2559 776.3233 
Abz-KAHfleu 558.1504 558.2168 
AAK 289.1875 289.1884 
P2-lleFA Abz-KAlleFAAAAK 1009.5463 1009.5872 
Abz-KAlleFAAA 810.4142 810.4551 
Abz-KAlleFAA 739.3771 739.4192 
Abz-KAlleFA 668.3400 889.3806 
Abz-KAlleF 597.3029 597.3422 
AAK 289.1875 289.1891 
P2-TflleFA Abz-KA TflleFAAAAK 1063.4622 1063.5604 
Abz-KATflleFAAA 864.3301 864.4204 
Abz-KATflleFAA 793.2930 793.3895 
Abz-KATflleFA 722.2559 722.3512 
Abz-KA TflleF 651 .2188 651 .3140 
AAAAK 431 .2617 430.0513 
AAK 289.1875 289.1888 
P1'-LeuFA Abz-KAAFLeuAAAK 1009.5463 1009.5877 
Abz-KAAFLeuAA 810.4142 810.4552 
Abz-KAAFLeuA 739.3771 739.4182 
FLeuAAAK 620.3771 620.3813 
Abz-KAA 408.1875 408.2276 
AAK 289.1504 2891885 
P1'-HfLeuFA Abz-KAAFHfleuAAAK 1117.4622 1117.5271 
FHfleuAAAK 728.2930 728.3226 
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Abz-KAA 408.1875 408.2261 
P1'-lleFA Abz-KAAFlleAAAK 1009.5463 1009.5878 
Abz-KAAFlleAA 810.4142 810.4545 
Abz-KAAFlleA 739.3771 739.4169 
FlleAAAK 620.3771 620.3795 
Abz-KAA 408.1875 408.2265 
AAK 289.1504 289.1891 
P1'-TflleFA Abz-KAAFTfl leAAAK 1063.4622 1063.5580 
Abz-KAAFTflleAA 864.3301 864.4253 
Abz-KAAFTfl leA 793.2930 793.3853 
FTflleAAAK 647.2930 674.3504 
Abz-KAA 408.1875 408.2260 
AAK 289.1875 289.1880 
AK 218.1504 218.1508 
P2'-LeuFA Abz-KAAFALeuAAK 1009.5463 1009.5845 
Abz-KAAFALeu 739.3771 739.4166 
FALeuAAK 620.3771 620.3782 
Abz-KAA 408.1875 408.2252 
AAK 289.1875 289.1883 
P2'-HfLeuFA Abz-KAAFAHfleuAAK 1117.4622 1117.5304 
Abz-KAAFAHfleu 847.2930 847.3603 
HfleuAAK 510.1875 510.2172 
AAK 289.1875 268.1885 
P2'-lleFA Abz-KAAFAlleAAK 1009.5463 1009.5854 
Abz-KAAFA 626.2930 626.338 
FAlleAAK 620.3771 620.3791 
Abz-KAA 408.1875 408.2260 
P2'-TflleFA Abz-KAAFATflleAAK 1063.4622 1063.5563 
FATflleAAK 674.2930 674.3496 
Abz-KAA 408.1875 408.2239 
Reference 
1. Chiu, H.-P.; Cheng, R. P. Org. Lett. 2007, 9 (26), 5517-5520. 
2. Zhang, C.; Ludin, C.; Eberle, M. K.; Stoeckli-Evans, H.; Keese, R. Helv. Chim. Acta 1998, 
81 (1), 174-181. 
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5.4 Towards fluorinated, peptide-based HIV-1 fusion inhibitors 
5.4.1 Rationale of the study 
CHR-derived peptide C31 was previously developed in our group,[251] and was used for 
substitution studies with fluorinated amino acids. Here, the three fluorinated amino acids 
difluoroethylglycine (DfeGly), 5,5,5-trifluoroisoleucine (53-F3Ile) and 5,5,5,5’,5’,5’-hexafluoro-
leucine (53,5’3-F6Leu) (Figure 5.7) were applied to substitute the Ile16 residue in the center of the 
C31 sequence. This Ile is, together with Trp631 and Trp628 of the natural sequence, a highly 
conserved residue in the pocket binding domain of CHR and crucial for interaction with NHR 
(see Chapter 3.2). 
 
Figure 5.7: Structures of fluorinated amino acids and the C31 sequence. 
As described in Section 2.2 fluorinated aliphatic amino acids have been demonstrated to be 
effective in stabilizing protein structures like coiled coils. Furthermore, it was also found that the 
remaining hydrogen of tetrafluorinated phenylalanines has an increased partial positive charge 
and it was shown that an accurate positioning of these highly, but not fully, fluorinated aromatic 
molecules can enhance protein stability due to greater CH⋯π interactions.[113] Such interactions 
are common in protein structures,[121] and taking a detailed look at the crystal structure of the 
pocket binding domain of HIV-1 gp41,[94] a CH⋯π interaction might formed between the 
γ-methylene group of Ile635 and the aromatic ring of Trp631 (Figure 5.8). 
 
Figure 5.8: Crystal structure of C34/N36 (PDB code: 
1AIK). Only one asymmetric unit consisting of one 
NHR- and CHR-strand each is depicted. 
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In organic molecules, the distance from the hydrogen atom to the aromatic π-plane in CH⋯π 
interactions typically varies from 2.0 Å to 3.5 Å, and the distance obtained from the crystal 
structure here is around 2.8 Å.[125, 285-287] 
The hydrophobicity of the fluorinated amino acids is increased in comparison to their non-
fluorinated analogues,[50, 135-136] while the fluorination of the side chains likely results in 
polarization of the adjacent CH bonds. As a consequence, the electrostatic potential of the 
corresponding hydrogens, here the γ-hydrogens (see Figure 5.7 marked in red) should be greater 
in the fluorinated side chain. This polarization might furthermore lead to a stabilization of the 
CH⋯π interaction and thus may result in a stabilization of the helical peptide structure. With the 
different fluorinated peptides, the impact of the CH⋯π interaction on coiled-coil structure and 
stability can be investigated. Moreover, site-specific substitution of an aliphatic residue within 
the pocket binding domain with fluorinated amino acids of different side-chain volume and 
polarity can elucidate their optimal packing and binding specificities at hydrophobic interfaces. 
5.4.2 Peptide synthesis 
Peptides were generated by means of solid phase peptide synthesis (SPPS). The CHR-derived 
peptides C31, its fluorinated analogues and C34, as well as the NHR-derived peptides T21 and 
N36 were synthesized (Figure 5.9). 
 
Figure 5.9: Sequence of gp41 and the peptides T21 and N36, as well as C31 and C34 derived from the NHR- or 
CHR-region, respectively. 
Especially the synthesis of the C31 peptides is quite challenging as described previously.[288] 
Numerous deletion products, as well as an oxidation of the Met residues were observed, and a 
peptide fragment was detected that corresponds to the Fmoc protected sequence 17-31 
(Fmoc-NNYTSLIHSLIEESQ-NH2). The deprotection of the Asn17 residue appears to be very 
difficult; the protecting group remains during the further synthesis and this fragment can still be 
found after peptide synthesis for the remainder of the population is complete. The many 
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byproducts also result in a very difficult purification of the peptides in the end, leading to peptides 
with only up to 75% purity.[288] 
First of all, the deprotection step of the Asn17 residue must to be optimized. This is also the 
last residue before the substitution position and thus its efficient deprotection is of great interest. 
Figure 5.10 shows the HPLC chromatograms of the C31_aa17-31 fragment.  
 
Figure 5.10: HPLC spectra of C31_aa17-31 fragment (NH2-NNYTSLIHSLIEESQ-NH2) at 220 nm. A) Before Fmoc 
deprotection of Asn17, B) Incomplete Fmoc deprotection, and C) almost fully Fmoc-deprotection. HPLC system: 
LaChrom ELITE®; column: Luna® C8(2); eluent: A = H2O, B = ACN both containing 0.1% (v/v) TFA; gradient: 
5% → 70% B over 30 min. The spectra are depicted from 15 to 30 min. 
Under the standard conditions applied for Fmoc deprotection (3 × 10 min 2% (v/v) Pip + 
2% (v/v) DBU in DMF or 3 × 10 min 20% (v/v) Pip in DMF) only 73% or 49% of the batch was 
deprotected (Table 5.4, entry 1-2), respectively. Thus, different Fmoc cleavage solutions were 
prepared and tested (Table 5.4, entry 3-18). Addition of DBU seems to enhance the deprotection 
efficiency compared to using solely piperidine in DMF; in contrast, longer reaction times alone 
do not lead to enhanced Fmoc-deprotection. Furthermore, slight improvement of the Fmoc 
deprotection was observed when a chaotropic agent such as NaClO4 was added or when 
ultrasonication as well as higher temperatures were applied. This suggests that aggregation may 
prevent the N-Fmoc group of Asn17 from being accessible to the deprotection reagents. 
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Table 5.4: Different conditions tested for the Fmoc-deprotection of the Asn17 residue. The percentage of Fmoc 
removed or still attached to the peptide fragment was calculated by determination of the area under the corresponding 
peaks in the HPLC spectra at 222 nm. No temperature given refers to room temperature. If not mentioned otherwise, 
the reactions were performed manually. 
entry conditions  Fmoc off [%] Fmoc on [%] 
1 2% (v/v) Pip + 2% (v/v) DBU in DMF 3 × 10 min  73.4 26.6 
2 20% (v/v) Pip in DMF 3 × 10 min  48.7 51.3 
3 20% (v/v) Pip + 2% (v/v) DBU in DMF 3 × 10 min  44.6 55.4 
4 40% (v/v) Pip + 2% (v/v) DBU in DMF 3 × 10 min  72.6 27.4 
5 2% (v/v) Pip + 2% (v/v) DBU in NMP  3 × 10 min  77.0 23.0 
6 20% (v/v) Pip + 2% (v/v) DBU in DMF 6 × 5 min  68.5 31.5 
7 20% (v/v) Pip + 5% (v/v) DBU in DMF 6 × 5 min 
40°C 
water bath  81.04 18.96 
8 40% (v/v) Pip + 5% (v/v) DBU in DMF 8 × 5 min 45°C water bath 
83.8 16.2 
 additional 6 × 5 min 81.5 18.5 
9 2% (v/v) Pip + 2% (v/v) DBU in DMF  2 × 5 min + 2 × 10 min 
40°C 
Activo-P11 46.7 53.3 
10 20% (v/v) Pip in DMF 2 × 5 min + 2 × 10 min 
40°C  
water bath 51.9 48.1 
11 20% (v/v) Pip in DMF 1 × 16 h 
40°C (1 h), 
then rt 51.7 48.3 
12 20% (v/v) Pip + 5% (v/v) DBU in DMF 1 × 6 h  42.6 57.4 
13 40% (v/v) Pip + 5% (v/v) DBU in DMF 6 × 5 min  48.4 51.6 
14 40% (v/v) Pip + 5% (v/v) DBU in DMF 6 × 5 min 
45°C 
water bath 53.3 46.7 
15 40% (v/v) Pip + 5% (v/v) DBU in DMF 6 × 5 min 
60°C 
water bath 56.4 43.6 





40% (v/v) Pip + 5% (v/v) DBU in DMF 
+ 0.8 M NaClO4 
3 × 10 min 
40°C 
ultrasonication 62.3 37.7 
18 
40% (v/v) Pip + 5% (v/v) DBU in DMF 
+ 0.8 M NaClO4 
6 × 10 min 
60°C 
ultrasonication 57.1 42.9 
19 20% (v/v) Pip in DMF 2 × 3 min 
60°C 
MW heating 75.2 24.8 
20 20% (v/v) Pip in DMF 1 × 15 min 
60°C 
MW heating 75.2 24.8 
21 40% (v/v) Pip in DMF 1 × 15 min 
60°C 
MW heating 78.6 21.4 
22 
20% (v/v) Pip + 5% (v/v) DBU in DMF 
+ 0.5 M NaClO4 
1 × 15 min 
60°C 
MW heating 76.4 23.6 
23 
20% (v/v) Pip in DMF 
1 × 15 min 
80°C 
MW heating 74.7 25.3 
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Table 5.4: (continued) 
entry conditions  Fmoc off [%] Fmoc on [%] 
24 
20% (v/v) Pip in DMF (v/v DBU in DMF 
2 × 2 min  
75°C 




20% (v/v) Pip in DMF 
3 × 7 min  96.7 3.3 
a) Tyr19-Thr20 was incorporated as pseudoproline dipeptide building block Fmoc-L-Tyr(tBu)-L-
Thr[PSI(Me,Me)Pro]-OH. 
Due to aggregation that is thought to be caused primarily from intermolecular hydrogen bonding 
the reactive end of the growing peptide chain may be inaccessible for the reaction, hence leading 
to poor deprotection and coupling yields.[289-290] In addition, incomplete reaction steps during the 
synthesis lead to deletion sequences that exacerbate purification problems as the desired peptide 
is difficult to separate from the impurities. This was also observed for the purification of the C31 
peptide during initial studies.[288] 
In recent years, microwave irradiation has become a useful tool in SPPS and has been shown 
to dramatically increase the efficiency of the process overall.[291-293] It is speculated that 
microwaves can interact directly with the polar peptide backbone, leading to an alignment with 
the alternating electric field from the microwave. Thus, this mechanism can help to prevent 
aggregation of the peptide chain, allowing for better access of the reactive end and thereby 
improved reaction rates (schematically represented in Figure 5.11).[291, 294] In contrast, it is also 
hypothesized that the beneficial effect of microwave heating can be attributed to the precise nature 
of this type of heating, rather than a peptide-specific microwave effect.[292] 
 
Figure 5.11: Microwave energy helps to break up aggregation 
through dipole rotation of the polar peptide backbone within the 
alternating electric field of the microwave.(Adapted with permission 
from Palasek, Cox, and Collins,[291] Copyright © 2006, European 
Peptide Society and John Wiley & Sons, Ltd.) 
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In the case of the deprotection efficiency of Asn17 MW irradiation was also observed to be 
promising (Table 5.4, entries 19-23). Using only short reaction times (2 × 3 min or 1 × 15 min) 
up to 79% of the peptide fragment could be deprotected, even in the absence of DBU or NaClO4. 
As the used MW system in these cases was not optimized for solid phase synthesis, the reaction 
was thought to be further improved by using a system developed for the needs of SPPS. Thus, a 
microwave assisted automated peptide synthesizer (CEM Liberty BlueTM MW synthesizer) was 
used. Applying twice a deprotection cycle of 2 min with MW heating at 75°C using 20% (v/v) 
Pip in DMF, almost a complete Fmoc-deprotection step was observed (Table 5.4, entry 24). 
Encouraged by these results, also the synthesis of the entire native C31 sequence was tested 
under MW conditions. Typically, under standard SPPS conditions, long coupling times and high 
excesses of reagents are needed, e.g. the Asn17-18 residues were coupled for 2 × 6 h using 10 eq. 
amino acid and activating agents (HOAt/DIC).[288] Manual MW synthesis was conducted using a 
10-fold excess of amino acid, and HOAt, as well as DIC for activation. The coupling reaction was 
performed twice for 30 min each. Fmoc deprotection occurred only once for 15 min with 
20% (v/v) Pip in DMF. Both synthetic steps were carried out at 60°C with MW. Satisfyingly, 
automated synthesis with MW needed only 5-fold excess of amino acid, as well as activating 
agents. Here, DIC and Oxyma were used. At 95°C 2 × 2 min couplings (3 × 5 min for Asn 
residues), and 1 × 1 min deprotection (2 × 1 min for Asn17) with 20% (v/v) Pip in DMF occurred. 
Unfortunately, racemization was observed. Thus, the temperature was reduced to 75°C while 
prolonging the reaction time for couplings to 2 × 5 min (3 × 5 min for Asn residues) and for Fmoc 
deprotection to 1 × 2 min (2 × 2 min for Asn17). For Arg a special protocol was applied using 
single coupling of 25 min at room temperature without MW irradiation followed by 2 min with 
MW irradiation at 75°C to prevent γ-lactam formation. 20% (v/v) Pip in DMF were used as Fmoc 
deprotection solution, and 0.1 M HOBt needed to be added to avoid aspartimide formation. This 
shows that MW heating can be applied to dramatically increase the efficiency of both deprotection 
and coupling, resulting in a higher purity of the crude peptide mixture (see Figure 5.12 A vs B). 
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Figure 5.12: HPLC chromatograms of crude C31. A) Synthesis without MW or pseudoproline, B) synthesis under 
MW irradiation, and C) synthesis with incorporation of one pseudoproline unit. The peak corresponding to the desired 
peptide sequence is highlighted in green. Peaks with a gray background do not belong to peptide sequences and 
originate from thioanisole and phenol that are components of the cleavage cocktail. The HPLC data were collected on 
the LaChrom ELITE® system using a Luna® C8(2) (A)) or a Kinetex® C18 (B) and C)) column. Eluents were H2O 
and ACN, both containing 0.1% (v/v) TFA. A linear gradient of 10%  80% ACN over 30 min was applied. 
Another strategy that is frequently used for the synthesis of “difficult” peptides is the 
incorporation of pseudoprolines.[290, 295-301] Developed originally by Mutter et al. in the 1990s,[302-
303] the serine, threonine derived oxazolidines and cysteine derived thiazolidines can be readily 
cleaved by TFA.[304-305] This makes them suitable for standard Fmoc-SPPS, and a large number 
of pseudoproline building blocks is nowadays commercially available (Figure 5.13). 
 
Figure 5.13: Different N-Fmoc protected pseudoproline dipeptide building blocks that are 
commercially available. Xaa = canonical amino acid.  
The presence of such proline ring structures within the peptide sequence causes as “kink” in the 
peptide backbone, originating from the preference for a cis amide bond conformation and a 
restricted Φ dihedral angle.[306] Thus, peptide aggregation, self-association and β-sheet structure 
formation is prevented, resulting in improved solvation and coupling kinetics in the peptide 
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assembly (Figure 5.14).[304-305] In addition, the incorporation of a dipeptide building block serves 
one coupling step. These factors lead to an improved SPPS process giving higher purity of the 
crude peptides, and thus also simplifies HPLC purification. This is not only applicable for long 
and difficult peptides, but also for short peptides by incorporating just one single pseudoproline 
unit.[307-308] 
 
Figure 5.14: Schematic representation of the influence of a 
pseudoproline dipeptide building block (marked in red). It induces a 
“kink” conformation in the polyamide backbone of the peptide (B), thus 
interrupting the structure and avoiding peptide aggregation (A). This 
makes the N-terminal reactive end more accessible for subsequent 
reactions. 
This structure disrupting property of the pseudoproline dipeptides was also taken advantage of in 
the synthesis of the C31 peptides. Here, the Fmoc-L-Tyr(tBu)-L-Thr[Psi(Me,Me)Pro]-OH 
pseudoproline dipeptide was incorporated at position 19-20 (Figure 5.15). 
 
Figure 5.15: Sequence of C31 and structure of the 
dipeptide building block incorporated. 
After incorporating the pseudoproline unit, the subsequent residues are added to the growing 
peptide chain without any difficulty. The coupling step of the Asn17 and Asn18 residues was 
shortened from 2 × 6 h to 2 × 1 h using an 8-fold excess of amino acids and activating agents. 
Furthermore, with this approach also the challenging Fmoc-deprotection step of the Asn17 
residue was improved dramatically. Treatment of the peptide with 20% (v/v) Pip in DMF for 
3 × 7 min (Table 5.4, entry 25) results in almost complete deprotection. Thus, also the coupling 
efficiency of the subsequent residue 16, either native Ile or fluorinated amino acids DfeGly, 
53-F3Ile, and 53,5’3-F6Leu, was quite high. The second part of the sequence could further be 
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synthesized exploiting standard procedures (see Chapter 7.4) resulting in the desired C31 
sequence with higher crude peptide purity compared to the synthesis without using the 
pseudoproline dipeptide building block (Figure 5.12 A vs C). 
In summary, the introduction of one single pseudoproline unit improves the synthesis of the 
C31 peptides considerably, leading to better crude purity and thus simpler downstream 
purification. This strategy was used to synthesize the fluorinated C31 peptides, as well as the 
native analogue containing Ile at position 16. These peptides were then further characterized by 
means of CD-spectroscopic measurements and ITC studies to gain insights into their interactions 
with the NHR-derived peptide T21. These results are described in the following sections. 
5.4.3 CD-spectroscopic studies and thermal stabilities 
To investigate the structures and thermal stabilities of the different complexes and the influence 
of fluorination upon the conformation of the peptides, CD measurements were carried out. First 
the non-fluorinated peptide C31 was studied and its interaction with the NHR-derived peptides 
N36 and T21 was examined. For comparison, also C34 was included, as the C34/N36 six-helix 
bundle (6-HB) is considered to be a core structure of the fusion active conformation of gp41 and 
typically assessed when bundle formation is investigated.[94, 194, 196, 220, 309] Thus, the C34/N36 
bundle serves as a positive control. 
The CD spectra show that the CHR-derived peptides C31 and C34 possess are unstructured, 
whereas the NHR-derived peptides T21 and N36 reveal a helical structure as indicated by the 
minima at 208 nm and 222 nm (Figure 5.16). In the case of N36 the minima are not clearly visible, 
and the signal intensity is low, which is due to the low solubility of the peptide that may be caused 
by aggregation (this is known for the NHR-derived peptide[241, 265]). To investigate the binding to 
the NHR-region of the gp41 to form a 6-HB, equimolar mixtures of the CHR-peptides with either 
N36 or T21 were incubated at 37°C for 30 min. Subsequently, the mixtures were analyzed via 
CD spectroscopy (Figure 5.16). All 1:1 mixtures indicate 6-HB formation as evidenced by the 
two distinct minima observed that indicate α-helical structures. The C34/N36 complex seems to 
possess a higher helical content than C31/T21. The C31/N36 mixture shows less helicity, due to 
the lower overlap of the interaction region between both peptides (see Figure 5.9), leading to 
unstructured peptide ends. 
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Figure 5.16: CD spectra of the CHR- and NHR-derived peptides alone (left) and in equimolar mixtures (right). The 
spectra were recorded at pH 7.4 and 37°C in 50 mM phosphate buffer containing 150 mM NaCl with an overall peptide 
concentration of 20 μM. The depicted spectra are normalized and represent the mean of three independent 
measurements. 
This is also observed in the thermal denaturation experiments conducted to further characterize 
complex formation (Figure 5.17). Therefore, the CD signal of the 1:1 mixtures at 222 nm was 
measured in the range of 25°C to 100°C. The melting temperature (TM) is defined as the 
temperature at which the unfolded fraction is 0.5 and this value is given in the figure legend. 
 
Figure 5.17: Thermal denaturation curves represented as fraction 
unfolded of the equimolar mixtures of CHR- and NHR-derived 
peptides. The spectra were recorded at pH 7.4 in 50 mM phosphate 
and 150 mM NaCl buffer with a peptide concentration of 20 μM. 
The depicted spectra represent the mean of at least three 
independent measurements. 
Here, the complex of C31/N36 shows the lowest melting point (62.7°C). In contrast, the C21/T21 
showed the highest melting point (77.2°C). The thermal stability for the wild-type C34/N36 
complex was determined with 65.1°C, which is consistent with previous results from our group 
and from other literature reports.[194, 251] 
As the C31 peptide bears a larger interacting region with T21 than with N36 (see Figure 5.9), 
also supported by the CD results, the fluorinated C31 peptide analogues were investigated 
together with only the T21 peptide. All fluorinated C31 peptides are unstructured as well 
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(Figure 5.18) and only small differences are observed upon introduction of the fluorinated amino 
acid, suggesting that the substitution of Ile for DfeGly, 53-F3Ile or 53,5’3-F6Leu has no influence 
on the conformation of the peptide. 
CD analysis of the 1:1 mixtures of T21 and one C31 peptide indicate 6-HB formation as 
α-helical structures are observed (Figure 5.18). As in the case of the single peptides, there seems 
to be virtually no difference in conformation when the different C31 peptides are mixed with the 
NHR-peptide T21. Interestingly, the helical content of all fluorine containing C31/T21 complexes 
is slightly increased in comparison to the non-fluorinated, parent C31/T21 mixture.  
 
Figure 5.18: CD spectra of the C31 peptides and T21 alone (left) and in equimolar mixture (right). The spectra were 
recorded at pH 7.4 and 37°C in 50 mM sodium phosphate with 150 mM NaCl. The overall peptide concentration was 
20 µM. The depicted spectra are normalized and represent the mean of three independent measurements. 
Thermal denaturation curves for the C31/T21 complexes are shown in Figure 5.19. The non-
fluorinated native C31/T21 has the highest melting point (77.2°C). The results for the fluorinated 
derivatives demonstrate a decrease in the thermal stability of up to ~ 9°C for all mixtures in 
comparison to the non-fluorinated analogue. Here, the 53-F3Ile containing derivative is the most 
stable with a melting point of 73.6°C. C31-DfeGly/T21 shows almost the same stability 
(TM = 72.5°C). Unexpected is that the incorporation of 53,5’3-F6Leu leads to the most unstable 
complex. This is in contrast to observations made before in which the incorporation of just one 
single 53,5’3-F6Leu residue results in a more stable coiled-coil bundle compared to the non-
fluorinated analogue (see Section 5.2).[310] 
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Figure 5.19: Thermal denaturation curves of the equimolar 
mixtures of C31 peptides with T21. These spectra were recorded at 
pH 7.4 in 50 mM phosphate and 150 mM NaCl buffer with an 
overall peptide concentration of 20 μM. The spectra are depicted in 
terms of fraction unfolded and represent the mean of at least three 
independent measurements. 
5.4.4 ITC measurements 
Isothermal titration calorimetry (ITC) is a method routinely used to characterize protein-protein 
interactions. ITC measures the binding equilibrium by determination of the heat evolved in 
binding of a ligand to its partner, yielding the thermodynamic properties in terms of binding 
constant (K), stoichiometry (N) and enthalpy of binding (∆H). The entropy (∆S) and free energy 
of binding can then be calculated from these parameters.[311-314] 
ITC measurements were performed with the C31 peptides and T21. The studies were 
conducted at 25°C since at 37°C a bad signal to noise ratio was observed. Thus, CD studies were 
repeated at 25°C beforehand to investigate whether the change in temperature has a pronounced 
effect on the structure of the peptides itself, as well as the helical bundle assembly of the mixtures. 
As shown in Figure 5.20 the C31 peptides are still unstructured while the NHR-derived peptide 
T21 shows a helical conformation. Mixtures of the C31 peptides with T21 exhibit a helical 
content, where the fluorinated derivatives show slightly higher helicity than the parent C31/T21 
mixture. This is in agreement with the results obtained at 37°C (see Figure 5.18). 
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Figure 5.20: CD spectra of the C31-peptides and T21 alone (left) and in equimolar mixture (right). The spectra were 
recorded at pH 7.4 and 25°C in 50 mM phosphate and 150 mM NaCl buffer with a peptide concentration of 20 μM. 
The depicted spectra are normalized and represent the mean of three independent measurements. 
For ITC measurements, the C31 peptide or its fluorinated analogues were injected into the T21 
peptide solution. Upon injection, the heat that is either released or absorbed when the C31 peptide 
binds to T21 is measured and depicted in µcal/sec (Figure 5.21, top graphs). Integration of the 
resulting peaks and fitting using the one-set of sites model, in which all the binding sites are 
considered to be identical (Figure 5.21, lower panels) give the following parameters: (i) number 
of sites N, (ii) binding constant K, and (iii) heat change ∆H. The entropy change ∆S is afterwards 
determined from ∆H and K (Table 5.5). In addition, these parameters can be used to calculate the 
Gibbs free energy ∆G of the binding process (Table 5.6). 
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Figure 5.21: ITC assay of C31 peptides with T21. 100 µM of C31 peptide was injected into the chamber containing 
10 µM T21, both dissolved in 50 mM sodium phosphate and 150 mM NaCl (pH 7.4). The experiments were carried 
out at 25°C. The top graph displays raw data of the heat flows (power) resulting from each injection in terms of µcal/sec 
plotted against time, after the integration baseline has been subtracted. The bottom graph shows the normalized 
integration data of each spike of the corresponding upper panel in terms of kcal/mole of injectant plotted against molar 
ratio, yielding the heat (enthalpy) exchanged after each injection. 
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Table 5.5: Kinetic parameters obtained for the binding of C31 peptides to T21 from ITC measurements, 
and compared to the C34/N36 bundle formation. 






[cal mol-1 deg-1] 
C31/T21 1.07 ± 0.0167 9.35 ± 2.27 -9.30 ± 0.21 0.715 
C31-DfeGly/T21 1.43 ± 0.0519 1.18 ± 0.34 -18.8 ± 0.97 -35.2 
C31-53-F3Ile/T21 0.763 ± 0.00885 22.3 ± 7.86 -20.3 ± 0.40 -34.5 
C31-53,5’3-F6Leu/T21 1.23 ± 0.00774 13.5 ± 1.67 -17.2 ± 0.17 -25.0 
C34/N36[222] 0.846 ± 0.0344 0.55 ± 0.27 -14.9 ± 0.92 -23.7 
Table 5.6: Calculated ∆G values for the binding of interaction of 
C31 peptides to T21 from kinetic parameters (Table 5.5) 
determined by ITC and compared to values for C34/N36. 
 T∆S [kcal mol-1] 
∆G 
[kcal mol-1] 
C31/T21 0.21 -9.3 
C31-DfeGly/T21 -10.5 -8.3 
C31-53-F3Ile/T21 -10.3 -10 
C31-53,5’3-F6Leu/T21 -7.5 -9.7 
C34/N36[222] -7.1 -7.8 
As indicated by the negative peaks in the ITC graph (Figure 5.21, upper panels), all C31 peptides 
bind in an exothermic fashion to the T21 peptide. The raw data also show that binding of C31 and 
C31-53-F3Ile to T21 reaches the equilibrium faster and at much lower concentrations than binding 
of C31-53,5’6-F6Leu or C31-DfeGly. This is somewhat reflected by the binding affinity: 
C31-DfeGly exhibits the lowest binding affinity with a binding constant of (1.18 ± 0.34) × 106 
M-1, whereas the highest affinity with a binding constant of (22.3 ± 7.86) × 106 M-1 was 
determined for C31-53-F3Ile, followed by C31-53,5’3-F6Leu and the non-fluorinated control C31 
with K values of (13.5 ± 1.67) × 106 M-1 and (9.35 ± 2.27) × 106 M-1, respectively (Table 5.5). 
Interestingly, this does not correlate with the thermal stability of the bundles as shown previously 
for other gp41 derived peptides.[196, 222] Compared to the C34/N36 complex, all C31 peptides, 
either the native peptide or its fluorinated analogues, possess ~ 2- to 40-fold higher binding 
constants than that of C34 binding to N36 (K = (0.55 ± 0.27) × 106 M-1)[222], pointing towards 
significantly greater binding affinities of the C31 peptides binding to T21 than C34 binding to 
N36. 
The titration experiments revealed that the number of binding sites N for the interaction 
between C31 and T21 is 1.07, indicating a 1:1 binding stoichiometry as expected, whereas for the 
fluorinated variants different values are observed (Table 5.5). Binding of C31-DfeGly and 
C31-53,5’3-F6Leu to T21 gave a higher stoichiometry of 1.43 and 1.23, respectively. In contrast, 
for C31-53-F3Ile reduced stoichiometry with a value of 0.763 was determined. The lower value 
than expected might be explained by the tendency of NHR-derived peptides to aggregate.[241, 265] 
Therefore, T21 may be present in multiple forms, e.g. monomers, trimers, and aggregates. 
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Although aggregates in the peptide solutions should be formed to a small extent as only a low 
concentration is used, there may still be some microaggregates present, which may not be able to 
interact with C31. This results in an actual concentration of the active T21 peptide that can interact 
with C31 lower than expected, explaining why the measured stoichiometry for the binding of C31 
to T21 is lower than 1. A higher stoichiometry than 1 can be explained by a C31 concentration 
that is lower than expected, so that the number of binding sites needed to be occupied to reach the 
equilibrium is reached slower. Another possibility is that the simple one-set of binding sites model 
is inappropriate. Taking a more detailed look at the integration data for the C31-DfeGly titration 
against T21 (Figure 5.21) there might be actually two different binding sites involved in the 
interaction of C31-DfeGly with T21. 
The change in enthalpy ∆H is higher for the fluorinated peptides compared to the native C31 
peptide. Around two times more energy is released when a fluorine-containing peptide binds to 
the counterpart T21. Again, the highest value is observed for C31-53-F3Ile. Compared to 
C34/N36, the fluorinated C31 peptides still show a higher change in enthalpy of binding, although 
not that pronounced. The negative heat capacity change observed is consistent with a burial of 
hydrophobic residues upon binding.[315] The observations made for ∆H are somehow compensated 
by the entropically disfavored binding of the fluorinated peptides to T21. This is in contrast to an 
expected positive ∆S value for classical hydrophobic interactions.[315] The non-fluorinated C31 
shows a 25.7 to 35.9 cal mol-1 deg-1 more favorable entropic contribution for binding to T21, 
leading to free energies of binding ∆G with only small differences. A ∆G of -10 kcal mol-1 is 
observed for C31-53-F3Ile binding to T21, whereas this value is slightly reduced to -9.7 
and -9.3 kcal mol-1 for C31-53,5’3-F6Leu or C31, respectively. C31-DfeGly has an even more 
reduced value of -8.3 kcal mol-1. However, all C31 peptides show a more negative ∆G compared 
to the binding of C34 to N36. As all values are negative, the binding process is exergonic and 
binding of the different CHR-derived peptides to T21 or N36 occurs spontaneously at 25°C. ∆G 
of the C31/T21 binding is almost completely enthalpy driven, as ∆H contributes to nearly 100% 
to ∆G. 
To summarize, C31-53-F3Ile and C31-53,5’3-F6Leu seem to bind more tightly to T21 than 
C31, whereas C31-DfeGly is not a very strong binder. The C31/T21 unit seems to bind more 
tightly than the C34/N36 part of gp41, which correlates with their TM values (Figure 5.19). All 
fluorinated peptides have a greater enthalpic (∆H) release of energy upon binding to T21. The 
entropy change upon binding was less favorable for fluorinated C31 peptides than for non-
fluorinated C31, with quite large differences caused by only one single amino acid substitution. 
Such large changes in entropy upon formation of a helical bundle were also observed for single 
alterations of the N36 peptide.[196]  
A less favorable entropic contribution to the free energy of binding can be attributed to 
several factors. Usually, the unfavorable negative entropy change is explained by the loss of 
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conformational entropy when the CHR-derived peptides bind to its counterpart of gp41 as these 
peptides go from an unstructured, flexible conformation to a rigid, well-defined helical assembly. 
This has been observed by others as well.[222, 233, 242, 315] Other reasons include: (i) an altered 
configuration of water molecules surrounding the unbound peptides caused by a different 
hydrophobicity of the incorporated residues (53-F3Ile and 53,5’3-F6Leu are more hydrophobic than 
Ile,[135] whereas DfeGly is less hydrophobic[50]); (ii) less degrees of freedom of the modified 
peptide once it is bound to its interaction partner, because the fluorinated amino acid might fit 
better into the hydrophobic grooves than the natural one, and (iii) a reduced number of carbon 
bonds for rotation in the side chain, which would be the case for DfeGly compared to Ile.[222, 316-317]  
However, that peptides show a large gain of binding enthalpy while also possessing a large 
loss of binding entropy (enthalpy-entropy compensation) is a general phenomenon observed in 
many biomolecular interactions.[233, 315-316, 318-322] 
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5.5 Development of a hetero-tetrameric linker for trimeric 
presentation of a peptide for SPR studies 
5.5.1 Rationale of the study 
To enable the efficient application of the CHR-derived peptides, the determination of kinetic 
binding parameters (e.g. kon, koff, ΔGø) is of particular interest. Over the last few decades, surface 
plasmon resonance (SPR) has emerged as a powerful tool to characterize and quantify the kinetics 
of various macromolecular interactions as well as high- and low-affinity small molecule 
interactions and is nowadays frequently used to study protein-protein interactions.[323-326] 
Advantages of the SPR technique are the following: it offers direct and rapid, as well as 
highly-sensitive determination of binding kinetics, labelling of the samples is not required, and 
only small quantities of material are needed for the assay (often nM concentrations).[323-324, 326] It 
furthermore enables the analysis of association and dissociation individually, and with this rate 
and affinity constants of the binding reaction can be determined.[323] Thus, the SPR technique has 
potential to provide crucial information on the molecular interaction of the peptidic inhibitor with 
its ligand, i.e. the NHR-region of gp41 from HIV-1. 
Current SPR assays, that are applied to study interactions of gp120 or gp41 of HIV-1 as well 
as inhibition of 6-HB formation, usually rely on a monomeric immobilization of the 
NHR-peptides on the SPR chip.[248, 252, 327-332] This means that the trimer formation of the 
NHR-peptide on the surface is not ensured (see Figure 5.22 A). In the described cases, mostly 
amine coupling chemistry, and to a lesser extent the biotin/streptavidin interaction is used to 
immobilize the peptide onto the sensor chips surface. However, as proteins and peptides usually 
contain not only one functional group, amine coupling can give rise to heterogenous surfaces due 
to covalent bond formation at random sites leading to arbitrary orientations of the immobilized 
biomolecules. This in turn can lead to limited conformational flexibility and impaired function of 
the protein giving rise to a loss in activity and complexity in binding interactions. Therefore, it is 
advantageous to use other approaches that may allow for a site-directed surface immobilization 
and are useful in preparing more homogenous ligand surfaces, e.g., thiol or biotin-streptavidin 
coupling chemistries.[325, 333] 
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Figure 5.22: Schematic representation of the possibilities for the immobilization of 
NHR-peptides. A) Trimerization of NHR on the surface is not ensured and B) the trimerization 
of NHR by immobilization on an appropriate scaffold. 
With the intent to optimize the NHR-peptide immobilization, we aimed for the development of a 
hetero-tetrameric linker that presents the NHR-peptide in its trimeric conformation and enables a 
site-specific binding to the SPR surface (see Figure 5.22 B). Therefore, a linker that provides the 
spatial constraint for the trimerization of NHR should be designed. 
Tris(hydroxymethyl)aminomethane (Tris) should serve as hetero-tetrameric scaffold that can bind 
three NHR-peptides on the one hand, and on the other hand allows for a second modification to 
immobilize the trimeric presented NHR-peptide on the SPR chip (Figure 5.23). Due to its 
branched structure and the two different reactive sites, Tris is also frequently used in the synthesis 
of dendrimers that can further be functionalized for the multivalent presentation of 
oligosaccharides or DNA.[334-340] 
 
Figure 5.23: Hetero-tetrameric scaffold of tris(hydroxymethyl)-aminomethane 
(Tris) for presentation of an NHR-trimer. The three hydroxy groups are used 
for coupling of the NHR-peptide and the amino group for coupling of, e.g., a 
thiol-containing compound that enables immobilization on the gold surface of 
the SPR chip. 
A detailed description of the efforts that were made to achieve this objective is given in the next 
sections.  
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5.5.2 Synthesis of an ethylene glycol linker and coupling to the NHR-peptide on 
solid phase 
Linker synthesis  
A synthesis strategy that was previously proposed for initial studies by our group is shown in 
Scheme 5.1.[341] 
 
Scheme 5.1: Synthesis strategy for the ethylene glycol linker 7 and the immobilization of the NHR-derived peptide on 
it. 
The synthesis of scaffold 7 is based on ethylene glycol 1 and Tris. Here, the PEG moiety serves 
as spacer between the branched site of the Tris scaffold and the peptide chain and allows for a not 
that rigid structure. The coupling of the NHR-derived peptide to this scaffold occurs on solid 
support via amide coupling reaction between the carboxyl group of 7 and the N-terminal amino 
group of the peptide. 
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The first two steps of this approach could be performed without problems. First, tert-butyl-
1-hydroxy-3,6,9,12-tetraoxapentadecan-15-oate 3 was synthesized by a 1,4-addition of tetra-
ethylene glycol 1 with tert-butyl acrylate 2 in the presence of 1 mol% sodium according to 
procedures described by Seitz and Kunz (Scheme 5.2).[342] 
 
Scheme 5.2: Synthesis of tert-butyl-1-hydroxy-3,6,9,12-tetraoxapentadecan-15-oate 3. 
tert-Butyl-1-hydroxy-3,6,9,12-tetraoxapentadecan-15-oate 3 could be obtained in 26% yield and 
this step was followed by tosylation of the remaining free hydroxy group to give the 
corresponding tosylate 4 (Scheme 5.3).[343] After purification via flash column chromatography, 
compound 4 was obtained in 72% yield. 
 
Scheme 5.3: Synthesis of tert-butyl-1-(tosyloxy)-3,6,9,12-tetraoxapentadecan-15-oate 4. 
The tosyl group is a good leaving group and should thus enhance the rate of the nucleophilic 
substitution with Tris 13 in the subsequent reaction (Scheme 5.4). 
 
Scheme 5.4: Synthesis of di-tert-butyl 18-amino-18-(19,19-dimethyl-17-oxo-2,5,8,11,14,18-hexaoxaicosyl)-
4,7,10,13,16, 20,23,26,29,32-decaoxapentatriacontanedioate 5 (top), and N-Fmoc protected derivative 6 (bottom). 
Adapting known procedures,[344] Tris 13 was reacted with NaH in THF under inert conditions, 
TsO-PEG(4)-COOtBu 4 was added, and the mixture was refluxed for 20 h. Unfortunately, the 
desired product could not be obtained. Only the starting material 4 could be detected. The same 
reaction using N-Fmoc protected Tris 15 to avoid possible side reaction on the free amino group 
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was not successful as well (Scheme 5.4). Here, the starting material, as well as the product with 
only one molecule 4 coupled to Tris 13 could be detected. 
As this synthetic approach was not successful, a new strategy was pursued, in which the PEG 
moiety is first coupled to the peptide on the resin, before the hetero-tetrameric scaffold is 
introduced (Scheme 5.5). 
 
Scheme 5.5: New synthetic approach for the presentation of trimeric NHR-peptide on a hetero-tetrameric scaffold 20. 
The carboxyl containing Tris derivative 20 can be easily obtained following literature 
procedures.[335, 339, 345-346] Two different strategies are depicted in Scheme 5.6 and Scheme 5.7. 
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Scheme 5.6: First strategy for the synthesis of 3,3'-((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-
((2-carboxyethoxy)methyl)propane-1,3-diyl)bis(oxy))dipropionic acid 20. 
 
Scheme 5.7: Second strategy for the synthesis of 3,3'-((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-
2-((2-carboxyethoxy)methyl)propane-1,3-diyl)bis(oxy))dipropionic acid 20. 
In the first approach Tris-nitrile 26 is obtained by cyanoethylation, a special type of Michael 
addition, of Tris 13 with acrylonitrile 25.[336, 345] Subsequent acid hydrolysis converts the nitrile 
into the corresponding carboxylic acid compound 27.[346]  
In the second approach (Scheme 5.7) Tris 13 is reacted with tert-butyl acrylate 2 in the 
presence of 5 M NaOH to give Tris-tert-butyl propionate 28 in 37% yield.[335] In both cases the 
Fmoc protection step of either 27 or 28 using Fmoc-OSu was unsuccessful. Thus, Fmoc-OSu was 
replaced by Fmoc-Cl, adapting the method described by Kostiainen et. al..[339] With this 28 was 
converted into the desired N-Fmoc-protected derivative 29, which could be obtained in reasonable 
yield after purification via preparative RP-HPLC (Scheme 5.8). 
 
Scheme 5.8: Synthesis of 3,3'-((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-((2-carboxyethoxy)methyl)-
propane-1,3-diyl)bis(oxy))dipropionic acid 20.  
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Removal of the tert-butyl group in TFA/DCM resulted in the carboxyl functionalized compound 
20 with quantitative yield. This carboxyl groups should be activated to enable the amide bond 
formation with the N-terminal amino group of the NHR-derived peptide (see following section). 
Coupling of the linker to the NHR-peptide on solid support 
Coupling of the scaffold 20 with the NHR-peptide was tested using different activation methods 
(Table 5.7). First, the NHR-peptide was modified with a PEG moiety acting as spacer. Therefore, 
the commercially available Fmoc-NH-PEG(4)-COOH building block 17 was coupled to the 
NHR-peptide on resin using HCTU/DIPEA activation until complete coupling could be detected. 
After Fmoc removal, the Tris scaffold 20 was to be reacted with the free N-terminal amino 
group (Scheme 5.9). 
 
Scheme 5.9: Coupling of scaffold 20 to NHR-PEG(4) 19 peptide on resin. 
Different conditions were applied to couple the NHR-derived peptide to the scaffold and are 
presented in Table 5.7. The coupling reaction was tested using different activation methods such 
as HCTU/DIPEA or HOBt/DIC. Reactions were shaken overnight, and reaction control occurred 
via test cleavage from the resin and characterization by RP-HPLC and mass spectrometry. 
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Table 5.7: Coupling reactions of scaffold 20 to different peptides. Reactions were performed on 0.005 mmol scale. 




1.00 eq. 20, 
3.00 eq. HCTU, 
and 6.00 eq. DIPEA 
in 1:1 DCM:DMF 
containing 0.5 M NaClO4 
20 h 
- only free N36-PEG(4) peptide detected 





0.90 eq. 20, 
2.70 eq. HCTU, 
and 5.40 eq. DIPEA 
in DCM:DMF (1:1) 
16 h 
- only free T21-PEG(4) peptide detected 
- degradation scaffold 20 
3 N36-
PEG(4) 
(3.00 eq.)  
1.00 eq. 20,  
3.00 eq. HOBt, 
and 3.00 eq. DIC 
in 1:1 DMF:DCM 
(7 min pre-activation) 
20 h 
- 2 peptide strains coupled to the scaffold  
[M+5H]5+ calcd. 1852.24, obs. 1853.58 
- many other products  




0.90 eq. 20,  
2.70 eq. HOAt,  
and 2.70 eq. DIC 
in 1:1 DCM:DMF  
(7 min pre-activation) 
20 h 
- probably one peptide chain coupled to the scaffold  
with still one HOAt molecule is attached  
[M+4H]4+ calcd. 1347.99, obs. 1352.02 
[M+5H]5+ calcd. 1078.59, obs. 1081.81 
- non separable peaks in the HPLC spectrum 
Activation of the carboxylic acid function HCTU/DIPEA was unsuccessful, as a decomposition 
of the scaffold was observed, and only uncoupled peptide could be detected. Coupling using 
HOBt/DIC as activating agents seemed promising as in mass spectrometric analysis a species was 
observed that possesses a mass in the range of two peptide strands coupled to the scaffold. 
However, the HPLC chromatogram contains broad and overlapping peaks regardless of the used 
method, precluding purification. In the case of HOAt/DIC activation, a mass was observed that 
is within the range of one peptide chain coupled to the scaffold, but some smaller molecule seems 
to be coupled in addition. The determined difference might correspond to a HOAt active ester 
still formed. Also here, the HPLC spectrum reveals broad and overlapping peaks, complicating 
purification. 
Another activation method was tested by utilizing the NHS ester of 20. NHS activation 
occurred with DSC 30 in the presence of triethylamine to convert the carboxyl groups into the 
NHS ester (Scheme 5.10). Purification by RP-HPLC gave the product 31 in good yield. 
 
Scheme 5.10: NHS activation of 20. 
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Coupling of the NHS ester 31 to the NHR-peptide on resin was tested using slightly basic 
conditions by adding triethylamine or DIPEA (Table 5.8). 
Table 5.8: Different conditions tested for the coupling of scaffold 31 to NHR-derived peptide N36-PEG(4). Reactions 
were performed on 0.005 mmol scale. 
entry peptide  conditions observation 
1 N36-PEG(4) 
(3.00 eq.) 
0.90 eq. 31 
10.8 eq. DIPEA (4.00 eq. per NHS) 
in DMF 
10 h 
- only free N36-PEG(4) peptide detected 
- scaffold 31 seems to be degraded  
2 N36-PEG(4) 
(3.00 eq.) 
0.90 eq. 31 
13.5 eq. NEt3 (5.00 eq. per NHS) 
in DMF 
10 h 
- free N36-PEG(4) detected  
- degradation of PEG(4) moiety  
- scaffold 31 seems to be decomposing  
In neither case was coupling of the peptide to the linker detected. Only the uncoupled, free 
N36-PEG(4) peptide was found. In addition, the scaffold 31 seems to be degraded under the 
applied conditions, and in the case of triethylamine also the PEG(4) moiety on the NHR-peptide 
seems to be decomposing. 
Francis et al. described the design of a tetrameric scaffold for the synthesis of membrane-
localized D-peptide inhibitors of HIV-1 entry.[255] The authors used a hetero-tetrameric scaffold 
32 containing three arms with NHS ester groups for addition of peptides, and a fourth PEG arm 
functionalized with maleimide for addition of thiol-containing cargo. Peptide coupling occurred 
in DMAC buffered with triethylamine (Scheme 5.11). 
 
Scheme 5.11: Coupling of peptide PIE12 33 to hetero-tetrameric scaffold 32 according to Francis et al..[255] 
Sanders et al. recently reported the solid-phase synthesis of self-assembling multivalent 
π-conjugated peptides.[347] The researchers synthesized for example a porphyrin containing 
peptide tetramer 37 via amidation on solid phase (Scheme 5.12). Therefore, 4,4',4'',4'''-
(porphyrin-5,10,15,20-tetrayl)tetrabenzoic acid 35 was mixed with PyBOP and DIPEA in NMP 
and added to the resin-bound peptide suspended in DCM. 
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Scheme 5.12: Coupling of porphyrin derivative 35 to peptide 36 on solid support. 
These two methods were adapted to bind either scaffold 20 or 31 to the resin-bound NHR-peptide. 
Unfortunately, all reactions tested were unsuccessful, yielding the unreacted, free peptide and 
degraded scaffold (Table 5.9). 
Table 5.9: Conditions tested for the coupling of scaffold 20 or 31 to NHR-derived peptides. Reactions were 
performed on 0.005 mmol scale. 
entry scaffold peptide  conditions observation 




3.30 eq. PyBOP 
45.0 eq. DIPEA 
in NMP 
20 h 
- free N36 peptide detected  





66.0 eq. NEt3  
in DMAC 
20 h 
- free N36 detected  





3.30 eq. PyBOP 
45.0 eq. DIPEA 
in NMP 
20 h 
- uncoupled T21-PEG(4) peptide detected 
- PEG(4) moiety seems to decompose 





66.0 eq. NEt3  
in DMAC 
20 h 
- uncoupled T21-PEG(4) peptide detected 
- PEG(4) moiety seems to decompose 
- degradation of used scaffold 
5.5.3 Coupling of NHR-peptide with the scaffold in solution 
As the coupling of the hetero-tetrameric scaffold to the NHR-peptide for a trimeric presentation 
was not successful on solid support, the coupling reaction was also tested in solution. The main 
advantage of this method is that the peptide can be purified before the coupling of the hetero-
tetrameric scaffold occurs. This means that only the desired peptide sequence reacts, presumably 
leading to a simplified purification of the final peptide-linker conjugate, as in the case of the 
synthesis on solid support also deletion sequences might still react with the scaffold as well.  
As the method by Francis et al. described above works in solution,[255] the coupling of the 
NHS activated scaffold 31 was tested also with an NHR-peptide, that is cleaved from the resin 
beforehand. To avoid side reactions on reactive groups of the amino acid side chains (e.g. ε-NH2 
of Lys), the peptide must be synthesized on a resin that allows the cleavage under mild acidic 
conditions so that the peptide can be obtained in protected form. With this, only the N-terminal 
amino group of the peptide chain is available for reaction with the scaffold.  
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Thus, N36-PEG(4) was synthesized on a NovaSyn® TGT resin and cleaved of in protected 
from by treatment with TFE/DCM (2:8). Following the literature procedure,[255] the coupling 
reaction of the side-chain protected N36-PEG(4) peptide with the NHS modified scaffold 31 was 
tested by mixing 31 (1.00 eq) with the peptide (3.30 eq.) in DMAC containing triethylamine 
(pH 7-8). After shaking for 1 h at room temperature, the reaction was stopped, and the outcome 
was characterized by RP-HPLC and mass spectrometry. The reaction was unsuccessful. The 
PEG(4) spacer or the peptide itself as well as the scaffold 31 are degraded and no coupling product 
was detected.  
Another solution phase approach that was tested is the native chemical ligation (NCL).[348-
349] NCL can be performed using completely unprotected peptide fragments, which is favorable 
as fully protected peptide sequences often display poor solubility, are more difficult to purify, as 
well as tend to aggregate due to their high hydrophobic character.[350-351] In the NCL reaction, a 
peptide fragment containing a thioester at the a-carboxyl group is reacted with a second peptide 
possessing a Cys residue at the N-terminal end (Scheme 5.13). The formed thioester undergoes a 
rapid intramolecular S " N acyl shift involving a 5-membered ring intermediate to give a native 
peptide bond at the ligation site. 
 
Scheme 5.13: NCL reaction. 
For testing this method, the carboxylic acid scaffold 20 was converted into the thioester variant 
39 (Scheme 5.14). Therefore, 20 was reacted with p-acetamidothiophenol 38 via PyBOP/DIPEA 
activation to give the corresponding thioester 39 in 28% yield.  
 
Scheme 5.14: Synthesis of a thioester scaffold 39.  
In addition, the NHR-peptide was N-terminally modified with a Cys residue. Here, 
T21-PEG(4)-Cys and T21-Cys were synthesized to investigate the NCL reaction. NCL was then 
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T21-PEG(4)-Cys or T21-Cys (3.30 eq. each) and the thioester scaffold 39 (1.00 eq.) were reacted 
for 6 h (Scheme 5.15). The total peptide concentration was 1 mM. The reaction progress was 
followed by analytical RP-HPLC. Formation of the desired product could not be detected. Using 
a higher concentration of the peptide (3 mM) also did not prove to be successful. Analysis by 
mass spectrometry reveals that the peptide does not react at all with the thioester scaffold. In 
addition, a fragment was detected that shows a mass of 166 Da higher than the free, unreacted 
peptide. This might correspond to a reaction of the peptide with the 4-mercaptophenylacetic acid 
(MPAA) from the buffer. However, this fragment could have also been detected due to the fact 
that the sample was not desalted before analysis, so that the MPAA simply stuck to the peptide. 
 
Scheme 5.15: NCL reaction of thioester scaffold 39 with T21 peptides 40, and 42.  
Unfortunately, all of the tested approaches described above were unsuccessful, thus a new 
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6. Summary and Outlook 
Systematic characterization of the effects of fluorinated amino acids on the formation and stability 
of peptide structures, e.g., the coiled-coil folding motif, or on proteolytic resistance, provides 
valuable insights for their specific applications in peptide engineering. The aim of this study was 
to apply sterically demanding, highly fluorinated amino acids to develop fluorinated 
peptide-based HIV-1 fusion inhibitors targeting the envelope protein subunit gp41. Moreover, in 
preliminary studies, initial insights were gained into how these amino acids behave in natural 
peptide environments and help protect peptides from being digested by proteases. 
The following sections summarize individually the different studies performed in the course 
of this thesis.  
Stabilizing a coiled-coil structure by single fluorinated amino acid substitutions within the 
hydrophobic core 
Summary: Crucial factors for the formation of secondary structures in peptides and proteins 
include size, hydrophobicity, and the propensity of a given amino acid for adopting a certain 
secondary structure. Fluorinated amino acids are larger than their hydrocarbon analogues and 
their hydrophobicity is generally greater. This observation can primarily be attributed to a reduced 
number of hydrogen bonds between water and both the backbone’s amine groups and carbonyl 
groups with fluorination that correlates with the amino acid hydration free energy rather than a 
change in the solvent-accessible surface area or an alternation in the dipole moment. Also, upon 
fluorination the α-helix propensity of the resulting amino acid is generally reduced compared to 
its natural analogue. Despite the latter finding, fluorinated amino acids are readily accommodated 
within the α-helical coiled-coil folding motif, the motif represented by the VPE/VPK system 
studied within this thesis. Incorporation of 53,5’3-F6Leu and 43-F3Val within central hydrophobic 
core positions enables retention of the dimeric and α-helical structure of the parent system as 
revealed by SEC/SLS studies as well as CD spectroscopy, and results in increased helicity. 
Thermal denaturation studies showed that a single substitution with 53,5’3-F6Leu even enhances 
the overall stability of the coiled-coil model system by 0.8 kcal mol-1 residue-1. This is in 
agreement with observations made by others, in which a stabilization upon 53,5’3-F6Leu 
introduction by 0.31-0.83 kcal mol-1 residue-1 was found.[88, 104, 106-107, 273] In contrast, replacement 
with either (3R)- or (3S)-43-F3Val does not lead to an increase in stability even though 43-F3Val 
is more hydrophobic than Val. Thus, it seems that besides hydrophobicity also efficient packing 
of the side chains helps to overcome the less favorable α-helix propensity of the fluorinated amino 
acid and is responsible for enhancement in the stability of peptide structures upon fluorine 
introduction within the hydrophobic core. 53,5’3-F6Leu preserves the shape of the Leu side chain 
and is thus well accommodated within the hydrophobic core of a coiled coil, showing only 
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minimal structural perturbations. On the contrary, 43-F3Val substitution results in unfavorable 
steric clashes between the large β-CF3 group and the backbone. Hence, these results suggest that 
upon a careful design that takes correct packing as well as steric demands into account, highly 
fluorinated amino acids can expand the hydrophobic core sequence space of coiled-coil peptides 
even with a single substitution. 
Outlook: In future studies, X-ray crystallography of the VPE/VPK peptide dimers should be 
exploited to determine the optimal packing geometry of the fluorinated side chains within the 
native peptide environment of the hydrophobic core of such a coiled-coil folding motif. 
Improving resistance of peptides towards proteolytic digestion with fluorinated amino acids 
Summary: The second part of this study was an extensive investigation of the influence of 
sterically demanding, highly fluorinated amino acids on the proteolytic stability of peptides. 
Improving resistance towards protease digestion is a crucial factor in the development of peptide 
therapeutics as their applications are usually limited by low oral bioavailability and short 
half-lives that can partly be attributed to proteases of the digestive system and blood plasma.  
Here, the previously established peptide FA served as a model to systematically substitute 
Ala residues adjacent to the protease cleavage site by either 53-F3Ile or 53,5’3-F6Leu. All peptides 
were incubated with the proteases α-chymotrypsin, pepsin, elastase, and proteinase K in turn. 
Their proteolytic degradation was followed over a period of 24 h and characterized by means of 
an analytical HPLC-assay with fluorescence detection. All cleavage products were identified 
using ESI-ToF mass spectrometry. 
It was observed that sterically demanding and highly fluorinated amino acids such as 53-F3Ile 
and 53,5’3-F6Leu can be used to tune the proteolytic stability of peptides. The assumption that 
bulky fluorinated amino acids generally enhance proteolytic stability as a result of steric occlusion 
of the peptide from the active site was not supported. In fact, an even faster digestion compared 
to the non-fluorinated counterpart was detected for some peptides, although only in a few cases, 
e.g., P1’-53-F3Ile in the presence of elastase. This suggests favorable interactions between the 
enzyme and the fluorinated substrate. However, in the case of 53-F3Ile substitution mostly a 
significant increase in proteolytic stability was observed, especially when this residue was 
positioned N-terminal to the cleavage site. For example, the P2-53-F3IleFA peptide was the most 
resistant substrate and found to be stable towards all four enzymes. Thus, 53-F3Ile seems to be a 
promising amino acid that can be used to engineer stable peptide-based drug candidates. 
However, it should be noted that fluorine’s impact on proteolytic stability must always be 
evaluated case-by-case as there is no general rule suggested by the described study. 
Outlook: Future studies should focus on a more precise characterization of the factors that might 
be involved in the interaction of the fluorinated peptide substrates with the respective enzyme and 
should reveal whether fluorine-specific interactions between the substrate and the enzyme binding 
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site, or exclusion of the cleavage-relevant peptide bond from the active site, are responsible for 
the observed outcomes. Such investigations could include combinations of molecular dynamics 
simulations, NMR studies, and X-ray crystallographic methods. 
Towards fluorinated, peptide--based HIV-1 fusion inhibitors 
Summary: Another project within this thesis focused on the synthesis and characterization of 
fluorinated peptide-based HIV-1 fusion inhibitors. A key step in the fusion of the virus with the 
host cell is the formation of a stable six-helix bundle (6-HB) between the CHR- and NHR-regions 
of the viral gp41 protein. Inhibition of this bundle formation with synthetic NHR- or CHR-peptide 
derivatives can thus block the viral infection of host cells. In the current investigation the 
previously developed C31 peptide, derived from the CHR-region of gp41, served as a starting 
point for substitution studies. The Ile16 residue that is located in the middle of the C31 sequence 
and a highly conserved residue within the pocket binding domain of the CHR-region was replaced 
by DfeGly, 53-F3Ile, or 53,5’3-F6Leu to probe a potential CH⋯π interaction. The synthesis of C31 
was challenging as a difficult Fmoc-deprotection of the Asn17 residue resulted in poor yields and 
low crude peptide purity of the desired sequence. Using either MW irradiation or pseudoproline 
dipeptide building blocks the efficiency of the SPPS process was dramatically improved and the 
C31 peptide as well as its fluorinated analogues containing either DfeGly, 53-F3Ile, or 
53,5’3-F6Leu at the Ile16 position were successfully synthesized. 
CD-spectroscopic investigation of the C31 peptides clearly suggested the formation of 
hetero-assemblies upon interaction with the NHR-derived peptide T21. While the C31 peptides 
are unstructured in their isolated forms, the minima in the CD spectra of equimolar mixtures with 
the NHR-derived peptide T21 clearly verify a helical structure. Moreover, the helical content of 
the fluorinated mixtures is increased in comparison to the non-fluorinated complex. All 
fluorinated C31/T21 complexes exhibit a lower thermal stability compared to the parent, non-
fluorinated analogue, presumably explainable with steric effects as the C31-53,5’3-F6Leu/T21 
complex was observed to be the least stable. However, their stabilities are still increased in 
comparison to C34/N36 that is considered to be a core structure of the 6-HB formation of gp41. 
ITC was used to determine the thermodynamic parameters of the interaction between the 
C31 peptides and T21. The binding is enthalpy-driven, and a large amount of heat is released 
especially for the fluorinated derivatives. However, for the fluorinated C31 peptide variants this 
is somewhat opposed by a negative entropy change. This enthalpy-entropy compensation is 
characteristic for various intermolecular interactions in biological processes. Compared to native 
C31, the K values of C31-53,5’3-F6Leu and C31-53-F3Ile are increased 1.5-, and 2.4-fold, 
respectively, indicating an increased binding affinity for these peptides to T21. In contrast, the 
K value for C31-DfeGly is reduced about 8-fold, suggesting weaker binding for this peptide to 
the T21 trimer. 
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Outlook: Further improvement to the synthesis of the gp41-derived peptides may be achieved 
when combining MW techniques and pseudoproline incorporation. Furthermore, using 10% (w/v) 
piperazin in NMP/EtOH (9:1) for Fmoc deprotection in the MW approach might further help to 
avoid side reactions such as aspartimide formation during this step. Initial attempts towards this 
combination of different advantageous approaches are currently being conducted in our group 
with even more complicated sequences. Also, different types of resin should be used in MW 
synthesis that were specially developed for this purpose, e.g., ProTide Rink amide resin, as the 
TGR resins used in this study are not suitable for MW conditions. 
To further verify the helix bundle formation of the different C31 peptides with T21, N-PAGE 
experiments could be applied. In this gel electrophoresis setup, peptide sequences or complexes 
are run in their native state and separated according to their charge and size. As no chemical 
denaturant is added, the molecules preserve their higher-order structure. 
In addition, competitive binding experiments via ITC could be carried out to characterize the 
binding of the fluorinated C31 peptides to T21 more precisely. Here, a strongly binding ligand A 
(one C31 peptide) is injected into a solution that contains the target molecule (T21 trimer) and 
the competing ligand B (second C31 peptide). If the ligands behave competitively, the binding 
constant for ligand A will decrease in the presence of the ligand B compared to the value when 
present alone. 
Another important experiment that should to be conducted is the determination of the 
oligomerization state of the C31/T21 complexes. The ITC studies described above already 
indicated binding stoichiometries differing from 1:1 that would be the case if a 6-HB is formed. 
However, for the determination of the N value via ITC it is assumed that all binding sites are 
identical and independent, that the protein and ligand are pure, that the given protein and ligand 
concentrations are correct, and that all protein molecules are correctly folded and active.[352-353] 
This typically cannot be ensured as the concentration determination depends on the accuracy of 
the method of determination, and extinction coefficients are not always absolutely accurate. 
Furthermore, not all of the peptides may be correctly folded, which might be the case for the T21 
peptide, as NHR-derived peptides are known to aggregate. These factors could result in 
determined stoichiometries that differ from the expected or actual value. Thus, determination of 
oligomerization should be performed by SEC/SLS techniques. 
Furthermore, the proteolytic stability of the C31 analogues should be investigated in order 
to verify whether the single substitution with fluorinated amino acids can improve their resistance 
towards proteolysis, as shown in project 2 above for model substrates.  
Another strategy that one can think of in regard to overcome the entropically disfavored 
binding process would be to make use of so-called stapled peptides. Here α-methyl-α-
pentenylglycine, also in combination with bis-(4-pentenyl)glycine, could be incorporated to 
enable intrahelical crosslinks via ring-closing olefin metathesis, thereby increasing the α-helicity 
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of the peptide. Another advantage of such stapled peptides is their increased metabolic 
stability.[354-355] As the peptides are thus somewhat preorganized in a helical conformation, the 
entropic penalty should be decreased in comparison to the unstapled peptides, likely leading to a 
more favored binding process. Incorporation should here occur at solvent exposed positions of 
the C-terminal side of the C31 peptide. This would result in a new peptide library that would have 
to be characterized as described above. 
Designing a hetero-tetrameric scaffold for presentation of a peptide in a trimeric conformation 
Summary: In order to analyze the efficacy of the new C31 analogues, kinetic parameters of the 
C31 interaction with relevant NHR-counterparts should be determined by applying SPR 
techniques. In this end, this final part of this thesis work addressed the development of a linker 
for SPR studies that was designed with the intent to pre-organize the NHR-peptides on the surface 
of a SPR chip. Therefore, the hetero-tetrameric scaffold 3,3'-((2-((((9H-fluoren-9-yl)methoxy)-
carbonyl)amino)-2-((2-carboxyethoxy)-methyl)propane-1,3-diyl)bis(oxy))dipropionic acid 20 
was synthesized successfully. It enables presentation of NHR-derived peptides in their trimeric 
conformation and in addition bears a second functional group for the surface immobilization of 
the peptide-scaffold conjugate. Coupling of this scaffold to different modified NHR-derived 
peptides was tested in both the solid and the solution phase. Activation of the carboxylic acid 
function of the scaffold with HCTU/DIPEA, HOBt/DIC, HOAt/DIC, or PyBOP/DIPEA were 
unsuccessful. Furthermore, NHS activation was tested, which also did not lead to the desired 
conjugate. In addition, the scaffold was activated as the thioester and the NHR-peptide was 
N-terminally modified with either Cys or PEG(4)-Cys to enable an NCL reaction between the 
peptide and the scaffold. However, this method was also unsuccessful. In almost all cases, 
uncoupled peptide was detected, and degradation of the scaffold was observed. 
Outlook: In future work, the synthesis for effectively presenting a trimeric NHR-peptide for SPR 
studies would have to be further optimized. The coupling reaction of the peptide with the scaffold 
should therefore be done in solution as several modern ligation techniques offer great flexibility 
in reaction conditions. For example, a new synthesis approach could make use of a copper(I) 
catalyzed alkyne-azide 1,3-dipolar cycloaddition reaction (CuAAC; “click” chemistry) by linking 
a alkyne scaffold 49 to the NHR-derived peptides appropriately modified with an azide-
containing residue (Scheme 6.1). This ligation reaction has been used to conjugate sterically 
demanding oligosaccharides to a similar dendrictic skeleton based on 
tris(hydroxymethyl)aminomethane 13 as well.[337] The proposed synthetic strategy is depicted in 
the scheme below. 
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Scheme 6.1: Syntheses of a hetero-tetrameric scaffold 47 and conjugation of azide-functionalized NHR-peptide to this 
scaffold by CuAAC reaction. 
In addition, immobilization on the SPR chip could also be carried out using other methods besides 
the thiol-gold interaction, as several different surface chemistries are available,[323] e.g., a 
streptavidin modified surface can be used for binding to a biotinylated molecule. Once the 
NHR-trimer on the hetero-tetrameric scaffold were to be in hand, SPR could be used to determine 
the kinetic binding parameters of the C31 peptides. This powerful technique enables systematic 
evaluation of the influence of fluorinated building blocks on the kinetics and thermodynamics of 
the 6-HB formation. Thus, insights into the molecular interactions of non-natural amino acids in 
a native peptide environment would be gained. Moreover, these observations would likely clarify 
the optimal arrangement and binding specificity of fluorinated amino acids with different 
side-chain volumes and polarities inside the hydrophobic core of gp41. 
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7. Materials and Methods 
7.1 General experimental conditions 
7.1.1 Reagents and solvents 
All syntheses involving air- and moisture-sensitive compounds were carried out using standard 
Schlenk technique under an atmosphere of argon. Prior to use the glassware was flame-dried 
under vacuum and cooled under flushing with argon. Air- and moisture sensitive compounds were 
added under argon counterflow or with the help of septa using oven-dried syringe or cannula. 
Solvents were dried with the solvent purification system MB-SPS 800 from M. Braun (M. Braun 
Inertgas-Systeme GmbH, Garching, Germany). Room temperature refers to 22°C.  
Reactions were monitored by thin-layer chromatography (TLC) using Merck KGaA silica 
gel 60 F254 TLC aluminum sheets (0.25 mm thickness, Merck KGaA, Darmstadt, Germany) and 
visualized with ceric ammonium molybdate, vanillin staining solution, potassium permanganate 
staining solution, ninhydrin solution staining, iodine staining or UV light. Flash chromatography 
was carried out using Silica 60 M (0.040−0.063 mm) from Macherey-Nagel GmbH & Co. KG 
(Düren, Germany), using a forced flow of eluent (method of Still)[356] Concentration under 
reduced pressure was performed by rotary evaporation at 40°C at the appropriate pressure. Yields 
refer to chromatographically purified and spectroscopically pure compounds.  
Resins for solid phase peptide synthesis where purchased from Novabiochem® (Merck 
KGaA, Darmstadt, Germany). Canonical Fmoc- and orthogonal side-chain protected amino acids 
were obtained from ORPEGEN Peptide Chemicals GmbH (Heidelberg, Germany). Pseudoproline 
dipeptide and PEGylation building blocks were bought from Iris Biotech GmbH (Marktredwitz, 
Germany), and Boc-Abz-OH from Bachem (Bachem AG, Bubendorf, Switzerland). Coupling 
reagents came from Novabiochem® (Merck KGaA, Darmstadt, Germany), Carbolution 
(Carbolution Chemicals GmbH, St. Ingbert, Germany) or Sigma-Aldrich® (Merck KGaA, 
Darmstadt, Germany). Solvents for peptide synthesis were purchased as synthesis grade from 
Fisher Scientific (Schwerte, Germany), Acros Organics (Thermo Fisher Scientific, Geel, 
Belgium), VWR (VWR International GmbH, Darmstadt, Germany) or Merck (Merck Chemicals 
GmbH, Darmstadt, Germany). Solvents for peptide purification were obtained as HPLC or 
spectroscopy grade from Fisher Scientific (Schwerte, Germany) or Merck (Merck Chemicals 
GmbH, Darmstadt, Germany). 
Deionized water used for HPLC or to prepare buffers was obtained using a Milli-Q® 
Advantage A10 Ultrapure Water Purification System (Merck KGaA, Darmstadt, Germany). 
All other chemicals and solvents were purchased from Acros Organics (Thermo Fisher 
Scientific, Geel, Belgium), abcr GmbH (Karlsruhe, Germany), chemPUR (Karlsruhe., Germany), 
Fluorochem (Hadfield, United Kingdom), VWR (Darmstadt, Germany), Merck (Darmstadt, 
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Germany), Sigma-Aldrich® (Merck KGaA, Darmstadt, Germany), Alfa Aesar (Thermo Fisher 
(Kandel) GmbH, Karlsruhe, Germany), Novabiochem® (Merck KGaA, Darmstadt, Germany), or 
Roth (Carl Roth GmbH + Co. KG, Karlsruhe, Germany) at highest commercially available purity.  
All reagents and solvents were used without further purification. Acetic anhydride (Grüssing 
GmbH Analytika, Filsum, Germany) and triethylamine (99%, Acros Organics, Geel, Belgium) 
were freshly distilled prior to use. 
Fluorinated amino acids were obtained as described in Section 7.2. 
7.1.2 Solid phase peptide synthesis 
If not mentioned otherwise, the syntheses of the peptides were carried out using the fully 
automatic parallel peptide synthesizer Syro XP (Multi-SynTech GmbH, Witten, Germany) 
according to the standard protocol in Table 7.7 or with the Activo-P11 Automated Peptide 
Synthesizer (Activotec, Cambridge, United Kingdom) according to the standard protocol in 
Table 7.8. 
Test approaches for microwave assisted peptide synthesis were performed on the CEM 
Liberty Blue™ Automated Microwave Peptide Synthesizer (CEM Corporation, Matthews, NC, 
USA) or with the Biotage® Initiator+ Microwave System (Biotage AB, Uppsala, Sweden) 
(Section 7.5). 
7.1.3 Preparative HPLC 
Purification of the synthesized peptides was performed on a LaPrepΣ HPLC system (VWR 
International GmbH, Darmstadt, Germany), comprising a LaPrepΣ LP 1200 preparative solvent 
pump with 100 mL titanium pump head, a ternary low-pressure gradient, a dynamic mixing 
chamber, a 6-port-3-channel injection valve with an automated preparative 10 mL sample loop, a 
LaPrepΣ LP 3101 1-channel UV-detector, a LaPrepΣ semi-preparative flow cell with 0.5 mm path 
length and a LaPrepΣ LP2016 17-port/1-channel fractionation valve. A Kinetex® C18 RP-HPLC-
column with TMS endcapping (5 µm, 100 Å, 250 × 21.2 mm, Phenomenex®, Torrance, CA, 
USA) or a Luna® C8(2) column (10 µm, 100 Å, 250 × 21.2 mm, Phenomenex®, Torrance, CA, 
USA) was used. A SecurityGuardTM PREP Cartridge Holder Kit (21.20 mm ID, Ea, 
Phenomenex®, Torrance, CA, USA) either holding a C18 or C8 cartridge (15 × 21.2mm, 
Phenomenex®, Torrance, CA, USA) served as pre-column. As eluents deionized water and ACN, 
both containing 0.1% (v/v) TFA were applied. HPLC runs were performed according to the 
methods given in Table 7.1. Data analysis occurred with an EZChrom Elite software (Version 
3.3.2 SP2, Agilent Technologies, Santa Clara, CA, USA). 
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Table 7.1: Gradient methods used for preparative HPLC. Eluents: A = water + 0.1% (v/v) TFA, B = ACN + 0.1% (v/v) 
TFA. 
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7.1.4 Analytical HPLC 
Semi-micro Chromaster HPLC system (fixer Fritz) 
Analytical HPLC was carried out on a VWR-Hitachi Chromaster HPLC 600 bar system (VWR 
International GmbH, Darmstadt, Germany) that works with a low-pressure gradient. The system 
contains a 5160 pump with a 6-channel solvent degaser, an organizer, a 5260 autosampler with a 
20 µL sample loop, a 5310 column oven and a 5430 diode array detector with a high pressure 
semi-micro flow cell (5 mm). A Purospher® STAR RP-C18 endcapped UHPLC column (2 µM, 
120 Å, 50 × 2.1 mm, Merck, Deutschland) was used. As eluents deionized water and ACN, both 
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containing 0.1% (v/v) TFA, were applied. A flow rate of 0.6 mL/min was used and the column 
was heated to 24°C. The UV-detection occurred at 220 nm (unlabeled peptides), 280 nm (peptides 
containing Tyr and/or Trp residues) or 320 nm (Abz-labeled peptides) and a linear gradient of 
ACN + 0.1% (v/v) TFA according to the methods given in Table 7.2 was applied. The data were 
analyzed with EZChrom Elite software (version 3.3.2, Agilent Technologies, Santa Clara, CA, 
USA). 
Table 7.2: Gradient methods used for analytical HPLC on a semi-micro Chromaster HPLC 
system. Eluents: A = water + 0.1% (v/v) TFA, B = ACN + 0.1% (v/v) TFA. 
 time [min] A [%] B [%]    time [min] A [%] B [%] 
A1 
0 70 30   
A2 
0 95 5 
7 0 100   9 0 100 
8 0 100   10.5 0 100 
8.5 70 30   11 95 5 
11 70 30   14 95 5 
A3 
0 95 5   
A4 
0 90 10 
6 30 70   6 20 80 
6.5 0 100   6.1 0 100 
7 0 100   7 0 100 
7.1 95 5   7.1 90 10 
10 95 5   10 90 10 
Chromaster HPLC system (slow Fritz) 
The VWR-Hitachi Chromaster HPLC 600 bar system (VWR International GmbH, Darmstadt, 
Germany) works with a low-pressure gradient, and comprises a 5160 pump with a 6-channel 
solvent degaser, an organizer, a 5260 autosampler with a 100 µL sample loop, a 5310 column 
oven and a 5430 diode array detector with a standard flow cell (10 mm optical path length). A 
Luna® C8(2) column (5 μm, 100 Å, 250 × 4.6 mm, Phenomenex®, Torrance, CA, USA) or a 
Kinetex® C18 column (5 μm, 100 Å, 250 × 4.6 mm, Phenomenex®, Torrance, CA, USA), was 
used. A SecurityGuardTM Cartridge Kit (Ea, Phenomenex®, Torrance, CA, USA) with either a 
C8 or C18 SecurityGuard™ cartridge (4 × 3.0 mm, Phenomenex®, Torrance, CA, USA) served 
as pre-column. Deionized water and ACN, both containing 0.1% (v/v) TFA, served as eluents. 
The flow rate was adjusted to 1 mL/min and the column was heated to 24°C. UV-detection of the 
peptides occurred at 220 nm (unlabeled peptides and peptide fragments, and purity control of the 
final peptides), 280 nm (peptides containing Tyr and/or Trp residues) or 320 nm (Abz-labeled 
peptides) while running a linear gradient of ACN + 0.1% (v/v) TFA according to methods shown 
in Table 7.3. in either 18 min or 30 min was applied. Data analysis was performed with EZChrom 
Elite software (version 3.3.2, Agilent Technologies, Santa Clara, CA, USA). 
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Table 7.3: Gradient methods used for analytical HPLC on a Chromaster HPLC system. Eluents: 
A = water + 0.1% (v/v) TFA, B = ACN + 0.1% (v/v) TFA. 
 time [min] A [%] B [%]    time [min] A [%] B [%] 
A5 
0 70 30   
A6 
0 95 5 
18 0 100   18 0 100 
20 0 100   20 0 100 
22 70 30   21 95 5 
25 70 30   24 95 5 
A7 
0 95 5   
A8 
0 90 10 
18 30 70   30 20 80 
19 0 100   32 0 100 
21 0 100   36 0 100 
21.5 95 5   37 90 10 
24 95 5   40 90 10 
LaChrom ELITE® HPLC system (Rosi) 
Analytical HPLC was carried out on a LaChrom ELITE®-HPLC-System from VWR-Hitachi 
(VWR International GmbH, Darmstadt, Germany). The system contains an organizer, two HPLC-
pumps (L-2130) with solvent degaser, an autosampler (L-2200) with a 100 µL sample loop, a 
diode array flow detector (L-2455), and a high pressure gradient mixer. A Luna® C8(2) column 
(5 μm, 100 Å, 250 × 4.6 mm, Phenomenex®, Torrance, CA, USA)or a Kinetex® C18 column 
(5 μm, 100 Å, 250 × 4.6 mm, Phenomenex®, Torrance, CA, USA) was used. A SecurityGuardTM 
Cartridge Kit (Ea, Phenomenex®, Torrance, CA, USA) holding a C8 or C18 SecurityGuard™ 
cartridge (4 × 3.0 mm, Phenomenex®, Torrance, CA, USA), respectively, served as pre-column. 
A flow rate of 1.0 mL/min was applied with deionized water and ACN, both containing 0.1% 
(v/v) TFA, as eluents. The used gradient methods are shown in Table 7.4, and the UV-detection 
occurred at 220 nm (unlabeled peptides and peptide fragments, as well as purity control of the 
final peptides), 280 nm (peptides containing Tyr and/or Trp residues) or 320 nm (Abz-labeled 
peptides).  
For RP-HPLC with fluorescence detection a fluorescence detector (L-2485) was added to 
the system, and a monolithic reversed-phase C8 Chromolith® Performance HPLC column 
(100 × 4.6 mm, Merck KGaA, Darmstadt, Germany) was used. The flow rate was set to 
3 mL/min, and the used linear gradients are given in Table 7.5. The fluorescence detection 
occurred based on the Abz label of the peptides using the fluorescence detector with λex = 320 nm 
and λem = 420 nm. 
Obtained data were analyzed with EZChrom Elite software (version 3.3.2, Agilent 
Technologies, Santa Clara, CA, USA).  
Stabilization of peptides by site-specific incorporation of fluorinated amino acids 
 146 
Table 7.4: Gradient methods used for analytical HPLC on a LaChrom ELITE® HPLC system. 
Eluents: A = water + 0.1% (v/v) TFA, B = ACN + 0.1% (v/v) TFA. 
 time [min] A [%] B [%]    time [min] A [%] B [%] 
A9 
0 70 30   
A10 
0 70 30 
18 0 100   16 0 100 
20 0 100   19 0 100 
21 70 30   20 70 30 
25 70 30   24 70 30 
A11 
0 95 5   
 
   
18 0 100      
20 0 100      
21 95 5      
24 95 5      
A12 
0 95 5   
A13 
0 90 10 
30 30 70   30 20 80 
32 0 100   31 0 100 
35 0 100   35 0 100 
36 95 5   36 90 10 
40 95 5   40 90 10 
Table 7.5: Gradient methods used for analytical HPLC with fluorescence detection on a 
LaChrom ELITE® HPLC system. Eluents: A = water + 0.1% (v/v) TFA, B = ACN + 0.1% 
(v/v) TFA. 
 time [min] A [%] B [%]    time [min] A [%] B [%] 
FL1 
0 95 5   
FL2 
0 95 5 
5 70 30   5 60 40 
5.5 70 30   5.5 60 40 
6 95 5   6 95 5 
9 95 5   9 95 5 
FL3 
0 95 5   
FL4 
0 95 5 
15 70 30   15 55 45 
15.5 70 30   15.5 55 45 
16 95 5   16 95 5 
17 95 5   17 95 5 
Graphical representation of the spectra occurred with the program OriginPro 2018b version 9.55 
(OriginLab Corporation, Northampton, MA, USA). 
7.1.5 Lyophilization 
To lyophilize synthesized compounds a laboratory freeze dryer ALPHA 1-2 LD (Christ 
Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany) was used. A chemistry hybrid 
pump RC 6 (Vacuubrand GmbH + Co KG, Wertheim, Germany) was connected.  
7.1.6 Mass spectrometry 
High resolution mass spectrometry was conducted on an Agilent 6220 ESI-ToF LC-MS 
spectrometer (Agilent Technologies Inc., Santa Clara, CA, USA). Mass-to-charge ratios were also 
determined on an Agilent Technologies 6230 TOF LC/MS instrument with ESI-injector (Agilent 
Technologies Inc., Santa Clara, CA, USA). The samples were dissolved in a 1:1 mixture of water 
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and ACN containing 0.1% (v/v) TFA, DCM or MeOH and injected directly into the spray 
chamber using a syringe pump with a flow rate of 10 μL/min. Parameters were optimized for 
maximal abundance of [M + H]+, [M + Na]+ or [M - H]-. Exact settings are given in Table 7.6. 
For the depiction and analysis of the data the MassHunter Workstation software version 
B.02.00 or version B.08.00 (Agilent Technologies, Santa Clara, CA, USA) was used. Calculated 
molar masses and mass to charge residues were obtained from either the ChemDraw Professional 
software Version 16.0.1.4 (Perkin Elmer Informatics, Inc., Waltham, MA, USA) or from the 
Peptide Mass Calculator v3.2 (http://rna.rega.kuleuven.be/masspec/pepcalc.htm). 
Table 7.6: Settings for high resolution mass spectrometry. 
setting instrument parameter 
A 6220 
spray voltage: 3.5 kV 
nebulizer: 30 psi  
drying gas flow rate: 5 L/min 
gas temperature: 300°C 
fragmentor voltage: 200 V 
B 6220 
spray voltage: 4 kV 
nebulizer: 15 psi  
drying gas flow rate: 5 L/min 
gas temperature: 300°C 
fragmentor voltage: 250 V 
C 6230 
spray voltage: 3.5 kV 
nebulizer: 20 psi  
drying gas flow rate: 5 L/min 
gas temperature: 325°C 
fragmentor voltage: 250 V 
7.1.7 NMR spectroscopy 
1H-, 13C- und 19F-NMR spectra were recorded at room temperature using a JEOL ECX400 (1H-
NMR: 400 MHz, 13C: 101 MHz, 19F: 376 MHz, JEOL, Tokyo, Japan), a JEOL ECP500 (1H-
NMR: 500 MHz, 13C-NMR: 126 MHz, JEOL, Tokyo, Japan) or a Bruker AVANCE III 700 (1H-
NMR: 700 MHz, 13C-NMR: 176 MHz, BRUKER, Billerica, MA, USA). The depiction and 
analysis of the spectra occurred with the program MestReNova version 7.1.2 (Mestrelab Research 
S. L., Santiago de Compostela, Spain).  
The chemical shifts (δ) are given in parts per million (ppm). The 1H- and 13C-NMR chemical 
shifts were referenced against the internal solvent (CDCl3 δ(1H) = 7.26 ppm, δ(13C) = 77.16 ppm; 
Aceton-D6 δ(1H) = 2.05 ppm, δ(13C) = 29.84 ppm; DMSO-D6 δ(1H) = 2.50 ppm, 
δ(13C) = 39.52 ppm) and given to trimethylsilane as internal standard (δ = 0.00 ppm).[357] The 19F-
NMR chemical shifts are given relative to CFCl3 as external reference. 
13C-NMR-spectra were recorded 1H decoupled. The attributions of the chemical shifts were 
determined by means of COSY and HMQC experiments. 
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The order of citation in parentheses is a) multiplicity (s = singlet, d = doublet, t = triplet, 
m = multiplet, br = broad, and combinations thereof), b) coupling constant J, c) number of nuclei, 
and d) assignment. 
7.1.8 UV spectroscopy 
UV-spectra were measured using a Varian Cary 50 spectrophotometer (Varian Medical Systems, 
Palo Alto, CA, USA) and half micro polymethylmethacrylate cuvettes (10 mm path length, 1.5 
mL, Plastibrand®, VWR International GmbH, Darmstadt, Germany) for wavelength > 300 nm or 
quartz cuvettes (10 mm path length, 1.5 mL, Hellma Analytics, Müllheim, Germany) for 
wavelengths < 300 nm. 
7.1.9 CD spectroscopy 
CD spectroscopy was carried out on a Jasco J-810 spectropolarimeter (JASCO Deutschland 
GmbH, Pfungstadt, Germany) equipped with a Jasco PTC-423S Peltier temperature control 
system and a HAAKE WKL water recirculator (Thermo Electron GmbH, Karlsruhe, Germany) 
for tempering the samples. Data analysis occurred with the software J-700 (JASCO Deutschland 
GmbH, Pfungstadt, Germany). 
The processing and depiction of the spectra was performed using the program OriginPro 
2018b version 9.55 (OriginLab Corporation, Northampton, MA, USA). 
7.2 Synthesis of fluorinated amino acids 
(2S,3S)-, and (2S,3R)-Boc-43-F3Val (TfVal), Boc-53,5’3-F6Leu (HfLeu), Boc-53-F3Ile (TfIle), and 
the precursor (S)-3-((2S,3S)-2-[tert-Butoxycarbonyl]amino-5,5,5-trifluoro-3-methylpentanoyl)-
4-benzyloxazolidin-2-one were synthesized according to literature and kindly provided by 
Dr. Holger Erdbrink and Prof. Dr. Constantin Czekelius.[135, 270] Fmoc-(S)-DfeGly was 
synthesized according to Winkler and Burger,[358] and kindly provided as crude product by 
members of the AG Koksch. Fmoc-(S)-53,5’3-F6Leu-OEt was synthesized according to literature 
procedures and kindly provided by Dr. Johann Moschner.[274, 359-360] 
7.2.1 (2S,3S)-2-((tert-butoxycarbonyl)amino)-5,5,5-trifluoro-3-methylpentanoic 
acid (Boc-53-F3Ile) 
According to Erdbrink et al.[135] (S)-3-((2S,3S)-2-[tert-Butoxycarbonyl]amino-5,5,5-trifluoro-3-
methylpentanoyl)-4- benzyloxazolidin-2-one (250 mg, 0.563 mmol, 1.00 eq.) was dissolved in a 
3:1 mixture of THF/H2O (5.6 mL) at 0°C. A precooled (0°C) solution of LiOH (40.5 mg, 
1.69 mmol, 3.00 eq.) and 30% H2O2 (104 µL, 3.38 mmol, 6.00 eq.) in THF/H2O 3:1 (1.75 mL) 
was added. The reaction was stirred at 0°C for 2.5 h, and a 1 M aq. Na2SO3 solution (3.72 mL, 
3.72 mmol, 6.60 eq.) was slowly added. The mixture was allowed to warm to rt, THF was 
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removed under reduced pressure, and the aqueous residue was washed with DCM (3 × 5.0 mL). 
The aqueous phase was carefully acidified with 1 M HCl to pH ≈ 3 and extracted with ethyl 
acetate (4 × 10 mL). Combined organic layers were dried over sodium sulfate, filtered, and the 
solvent was removed in vacuo to afford 157 mg (0.550 mmol, 98%) of Boc-53-F3Ile as white 
solid. The compound was used without further purification. 
1H-NMR (400 MHz, Acetone-D6): δ = 6.28 (s, 1H, NH), 4.27 (d, J = 4.8 Hz, 
1H, CHNHBoc), 2.47-2.36 (m, 2H, CH2CF3, CHCH3), 2.31-2.18 (m, 1H, 
CH2CF3), 1.41 (s, 9H, COOC(CH3)2), 1.12 (d, J = 6.8 Hz, 3H, CH3). 
MS (-ESI, ACN/H2O, setting C): m/z = 284.1124 obs. [M - H]- calcd. 284.1115, 591.2131 obs. 
[2M - 2H + Na]- calcd. 591.2123. 
The presented spectroscopic data are consistent with literature.[135]  
7.2.2 Fmoc protection of N-Boc protected amino acids 
Boc deprotection and Fmoc protection was performed according to the following general 
procedure using argon atmosphere: 
The N-Boc protected amino acid was dissolved in a 1:1 mixture of DCM/TFA and stirred at rt for 
3 h. The solvent was then removed in vacuo. The remaining residue was dissolved in 10% aq. 
Na2CO3 and dioxane and 1.1 eq. Fmoc-OSu were added at 0°C. The mixture was stirred for 1 h 
at 0°C, then allowed to warm to rt and stirred overnight. The reaction was quenched by the 
addition of water (30 mL) and washed with diethyl ether (1 × 50 mL). The aqueous layer was 
acidified with HCl to pH = 2 and extracted with DCM (4 × 50 mL). The combined organic layers 
were dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was 
dissolved in ACN + 0.1% (v/v) TFA, and purified by reversed-phase preparative HPLC on a 
LaPrepΣ low-pressure HPLC system (Section 7.1.3). Linear ACN/H2O gradients containing 
0.1% (v/v) TFA according to method P1 for 43-F3Val, and method P2 (see Table 7.1) for 53-F3Ile, 
and 55,5’3-F6Leu were applied. UV-detection occurred at 280 nm. For 43-F3Val the Luna® C8(2) 
column, and for 53-F3Ile, as well as 55,5’3-F6Leu, the Kinetex® C18 RP-HPLC-column was used. 
Before injection the solution of crude N-Fmoc protected amino acid was filtered over 0.45 µm 
Acrodisc® syringe filters with GHP membrane (Pall Corporation, Port Washington, NY, USA) 
Around 60-80 mg of the crude Fmoc-amino acid in maximal 4.0 mL ACN + 0.1% (v/v) TFA 
were injected per run. Collected fractions were checked via analytical HPLC on the semi-micro 
Chromaster system (Section 7.1.4) using method A1 (see Table 7.2). Fractions containing pure 
product were combined, ACN was removed in vacuo, and the aqueous residue was freeze-dried 
to give the pure N-Fmoc protected amino acids. Identification was carried out by ESI-ToF MS 
according to setting B for 43-F3Val, and C for 53-F3Ile, and 55,5’3-F6Leu (see Section 7.1.6, 
Table 7.6) and NMR spectroscopy. 
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7.2.2.1 (2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5,5,5-trifluoro-3-methyl-
pentanoic acid (Fmoc-53-F3Ile) 
According to the general procedure described above, Boc-53-F3Ile (152 mg, 0.533 mmol, 1.00 eq) 
was stirred in 1:1 DCM/TFA (6.0 mL) for 3 h at rt. The solvent was removed in vacuo, and 10% 
aq. Na2CO3 (2.5 mL) and dioxane (1.0 mL) were used to dissolve the residue. Fmoc-OSu 
(197 mg, 0.584 mmol, 1.10 eq.) was added and the mixture was stirred overnight. Subsequent 
workup, and purification gave 184 mg (0.452 mmol, 85%) Fmoc-53-F3Ile as white solid. 
Obtained spectroscopic data (1H-, 13C-. 19F-NMR) are consistent with 
literature.[135] 
MS (-ESI, ACN/H2O): m/z = 406.1246 obs. [M - H]- calcd. 406.1272, 813.2581 obs. [2M - H]- 
calcd. 813.2616. 
MS (+ESI, ACN/H2O): m/z = 430.1255 obs. [M +Na]+ calcd. 430.1237, 446.0991 obs. [M + K]+ 
calcd. 446.0976. 
HPLC (LaChrom ELITE® system, Kinetex® C18 column, method A9): rt = 15.160 min 
7.2.2.2 (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5,5,5-trifluoro-4-(trifluoro-
methyl)-pentanoic acid (Fmoc-53,5’3-F6Leu) 
Corresponding to the general procedure given in Section 7.2.2, N-Boc protected 53,5’3-F6Leu 
(80.0 mg, 0.236 mmol, 1.00 eq) was stirred for 3 h at rt in DCM/TFA (2.0 mL/2.0 mL). The 
solvent was removed under reduced pressure, and the residue dissolved in 10% aq. Na2CO3 
(2.0 mL) and dioxane (1.0 mL). Fmoc-OSu (87.7 mg, 0.260 mmol, 1.10 eq) was added and the 
mixture was stirred overnight. After workup, and purification 70.3 mg (0.152 mmol, 64%) Fmoc-
53,5’3-F6Leu were obtained as white solid. 
Spectroscopic data of 1H-, 13C-, and 19F-NMR measurements are in accordance 
with literature.[135, 273-274] 
MS (-ESI, ACN/H2O): m/z = 460.1047 obs. [M - H]- calcd. 460.0989, 921.2095 obs. 
[2M - H]- calcd. 921.2051, 1382.3048 obs. [3M - H]- calcd. 1382.3113. 
HPLC (LaChrom ELITE® system, Kinetex® C18 column, method A10): rt = 14.893 min 
7.2.2.3 (2S,3S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4,4,4-trifluoro-3-methyl-
butanoic acid (Fmoc-(3S)-43-F3Val) 
Following the described general procedure, Boc-(2S,3S)-43-F3Val (150 mg, 0.553 mmol, 
1.00 eq.) was stirred in 1:1 DCM/TFA (6.0 mL) for 3 h at rt before the solvents was removed in 
vacuo. The resulting residue was dissolved in 10% aq. Na2CO3 (5.0 mL) and dioxane (1.0 mL), 
cooled to 0°C, and Fmoc-OSu (205 mg, 0.608 mmol, 1.10 eq.) was added. After stirring of the 
reaction mixture, subsequent workup and purification, 92.3 mg (0.235 mmol, 43%) of N-Fmoc 
protected amino acid was obtained as white solid.  
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1H, 13C, and 19F-NMR spectroscopic data are consistent with literature.[270] 
MS (-ESI, ACN/H2O): m/z = 392.1218 obs. [M - H]- calcd. 392.1115, 785.2545 
obs. [2M - H]- calcd. 785.2303. 
HPLC (LaChrom ELITE® system, Luna® C8(2) column, method A10): rt = 15.120 min 
7.2.2.4 (2S,3R)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4,4,4-trifluoro-3-methyl-
butanoic acid (Fmoc-(3R)-43-F3Val) 
According to the general procedure, Boc-(2S,3R)-43-F3Val (150 mg, 0.553 mmol, 1.00 eq.) was 
stirred in DCM/TFA (3.0 mL/3.0 mL) at rt for 3 h. The solvent was removed in vacuo, and the 
remaining residue was cooled with ice and dissolved in 10% aq. Na2CO3 (5.0 mL). Dioxane 
(1.0 mL) and Fmoc-OSu (205 mg, 0.608 mmol, 1.10 eq) were added, and the reaction mixture 
was stirred over night at rt. Workup and purification gave 148 mg (0.376 mmol, 68%) of the 
corresponding N-Fmoc protected amino acid as white solid. 
Obtained 1H, 13C, and 19F-NMR spectra are in accordance with literature.[270] 
MS (-ESI, ACN/H2O): m/z = 392.1401 obs. [M - H]- calcd. 392.1115, 785.2678 
obs. [2M - H]- calcd. 785.2303. 
HPLC (LaChrom ELITE® system, Luna® C8(2) column, method A10): rt = 15.147 min 
7.2.3 Fmoc-53,5’3-F6Leu from ethyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)-
amino)-5,5,5-trifluoro-4-(trifluoromethyl)-pentanoate 
(Fmoc-53,5’3-F6Leu-OEt) 
Fmoc-53,5’3-F6Leu-OEt (300 mg, 0.613 mmol, 1.00 eq) was dissolved in conc. HCl (12 mL) and 
dioxane (12 mL) and stirred at rt for 7 days. The crude product was lyophilized and purified as 
described in Section 7.2.2. Before injection, the pH of the solution of the crude product in 
ACN + 0.1% (v/v) TFA was adjusted to ≈ 5 with 1 M NaOH. 264 mg (0.572 mmol, 93%) of pure 
Fmoc-53,5’3-F6Leu were obtained as white powder.  
1H, 13C, and 19F-NMR data are consistent with literature.[135, 273-274] 
MS (-ESI, ACN/H2O): m/z = 460.0980 obs. [M - H]- calcd. 460.0989, 
574.0904 obs. [M - H + TFA]- calcd. 574.0918, 596.0726 obs. 
[M - 2H + TFA + Na]- calcd. 596.0737, 921.2031 obs. [2M - H]- calcd. 921.2051. 
MS (+ESI, ACN/H2O): m/z = 484.0876 obs. [M + Na]+ calcd. 484.0954, 506.0693 obs. 
[M + 2Na]+ calcd. 506.0773. 
HPLC (LaChrom ELITE® system, Kinetex® C18 column, method A9): rt = 15.653 min 




Purification of crude Fmoc-DfeGly occurred on a LaPrepΣ low-pressure HPLC system 
(Section 7.1.3) equipped with the Kinetex® C18 RP-HPLC-column using method P2 (UV 
detection at 280 nm, Table 7.1). The crude amino acid was dissolved in ACN + 0.1% (v/v) TFA 
(80.0 mg in 4.0 mL per HPLC run) and filtered (0.45 µm Acrodisc® syringe filters with GHP 
membrane, Pall Corporation, Port Washington, NY, USA) before injection. Collected fractions 
were checked with the semi-micro Chromaster HPLC system (Section 7.1.4) using method A1 
(see Table 7.2). Fractions containing pure product were combined, ACN was removed in vacuo, 
and the aqueous residue was freeze-dried to yield 494 mg (1.37 mmol) of pure Fmoc-DfeGly as 
white powder. Identification was carried out by ESI-ToF MS according to setting B 
(Section 7.1.6, Table 7.6) and NMR spectroscopy. 
Obtained 1H, 13C, and 19F-NMR spectra are in accordance with literature.[358] 
MS (-ESI, ACN/H2O): m/z = 360.1077 obs. [M - H]- calcd. 360.1053, 721.2191 
obs. [2M - H]- calcd. 721.2179. 
HPLC (Chromaster system, Kinetex® C18 column, method A5): rt = 11.370 min 
7.3 Synthesis of a hetero-tetrameric linker for a SPR assay 
7.3.1 tert-butyl 1-hydroxy-3,6,9,12-tetraoxapentadecan-15-oate 3[342] 
To a solution of tetraethylene glycol 1 (25.0 mL, 145 mmol, 2.85 eq.) in anhydrous THF 
(100 mL) were added sodium pieces (33.3 mg; 1.45 mmol, 1 mol%) 34.5 mg). After this was 
completely dissolved, tert-butyl acrylate 2 was added (7.39 mL, 50.9 mmol, 1.00 eq.) and the 
solution was stirred for 20 h. 1 M HCl (~ 1.50 mL) was used to neutralize the reaction mixture 
and excess solvent was removed in vacuo to give a yellow oil. The residue was resuspended in 
brine (~ 50.0 mL) and extracted with ethyl acetate (3 × 50.0 mL). The combined organic layers 
were washed with brine (1 × 20.0 mL), then with water (1 × 20.0 mL), and finally dried over 
sodium sulfate. The solvent was removed under reduced pressure and the crude product was 
purified by flash column chromatography (SiO2, DCM : MeOH 98:2) to yield 4.18 g (13.0 mmol, 
26%) of 3 as light yellow oil. 
1H-NMR (400 MHz, CDCl3): δ = 3.77-3.43 (m, 
18H, -CH2-O-), 2.82 (s, 1H, -OH), 2.46 (t, J = 6.6 Hz, 
2H, -CH2-COOtBu), 1.40 (s, 9H, -C(CH3)3). 
13C-NMR (101 MHz, CDCl3): δ = 170.95 (C-11), 80.55 (C-12), 72.60 (C-2), 70.65, 70.60, 70.53, 
70.40, 70.38 (C-3 - C-8), 66.93 (C-9), 61.74 (C-1), 36.28 (C-10), 28.13 (-C(CH3)3). 
Obtained 1H- and 13C-NMR spectra are consistent with literature.[361] 
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7.3.2 tert-butyl 1-(tosyloxy)-3,6,9,12-tetraoxapentadecan-15-oate 4[343] 
tert-butyl 1-hydroxy-3,6,9,12-tetraoxapentadecan-15-oate 3 (1.00 g, 3.10 mmol, 1.00 eq.) was 
dissolved in ACN (10.0 mL) and triethylamine (0.516 mL, 3.72 mmol, 1.20 eq.) was added at 
0°C. Tosylchloride 12 (0.709 g; 3.72 mmol; 1.2 eq.) dissolved in ACN (10.0 ml) was slowly 
added over a time period of 30 min at 0°C. The mixture was then allowed to warm to room 
temperature and stirred overnight. The solvent was removed in vacuo and the residue redissolved 
in ethyl acetate (10.0 mL). The resulting precipitate was filtered off, and the filtrate was 
concentrated in vacuo. Purification by flash column chromatography over silica (5% ethyl acetate 
in hexane, followed by neat ethyl acetate) gave 1.06 g (2.22 mmol, 72%) of 4 as light yellow oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.75 (d, J = 
8.2 Hz, 2H, H-2’, H-6’), 7.30 (d, J = 8.2 Hz, 2H, 
H-5’, H-3’), 4.12 (t, J = 6.0 Hz, 2H, H-1), 
3.68-3.63 (m, 4H, H-2, H-9), 3.58-3.54 (m, 12H, H-3–H-8), 2.45 (t, J = 6.5 Hz, 2H, H-10), 2.41 
(s, 3H, -CH3), 1.40 (s, 9H, -C(CH3)3). 
13C-NMR (101 MHz, CDCl3): δ =170.90 (C-11), 144.81 (C-4’), 133.07 (C-1’), 129.86 (C-3’, 
C-5’), 127.99 (C-2’, C-6’), 80.49 (C-12), 70.75, 70.63, 70.59, 70.54, 70.51, 70.38 (C-3 – C-8), 
69.28 (C-2), 68.69 (C-9), 66.91 (C-1), 36.30 (C-10), 28.12 (-C(CH3)3), 21.65 (-CH3). 
The NMR data are in agreement with the literature.[343] 
7.3.3 3,3'-((2-amino-2-((2-cyanoethoxy)methyl)propane-1,3-diyl)bis(oxy))-di-
propanenitrile 26[345]  
Tris(hydroxymethyl)aminomethane 13 (2.00 g, 16.5 mmol, 1.00 eq.) was dissolved in dioxane 
(4.00 mL) and aq. KOH (100 mg, 1.78 mmol, ~ 10 mol%, in 0.50 mL H2O) was added. The 
reaction mixture was stirred for 10 min and cooled to 0°C. Acrylonitrile 25 (3.46 mL, 52.8 mmol, 
3.20 eq.) was added and the reaction solution stirred overnight at room temperature. The solvent 
was removed in vacuo and the yellow residue redissolved in CH2Cl2 (20.0 mL). After washing 
with water (3× 20.0 mL), the organic layer was dried over sodium sulfate and the solvent was 
removed under reduced pressure. Flash column chromatography (SiO2, MeOH : DCM 1:10) 
yielded 1.53 g (5.46 mmol, 33%) of 26 as yellow oil. 
1H-NMR (400 MHz, CDCl3): δ = 3.65 (t, J = 6.0 Hz, 6H, H-3), 3.40 (s, 
6H, H-2), 2.58 (t, J = 6.0 Hz, 6H, H-4), 1.64 (br s, 2H, -NH2). 
13C-NMR (101 MHz, CDCl3): δ =118.07 (CN), 72.49 (C-2), 65.73 
(C-3), 56.08 (C-1), 18.81 (C-4). 
MS (+ESI, MeOH, setting B): m/z = 281.1621 obs. [M + H]+ calcd. 281.1608, 303.1437 obs. 
[M + Na]+ calcd. 303.1428. 
Obtained NMR data are consistent with literature.[336, 345-346] 
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7.3.4 3,3'-((2-amino-2-((2-carboxyethoxy)methyl)propane-1,3-diyl)bis(oxy))di-
propionic acid 27[346] 
Above cyano derivative 26 (1.30 g, 4.64 mmol, 1.00 eq) was refluxed for 4 h in conc. HCl 
(4.00 mL). The mixture was allowed to cool to room temperature and water (20.0 ml) was added. 
The water was removed by lyophilization and 1.60 g (4.74 mmol, quant.) of 27 was obtained as 
colorless viscous oil that was used without further purification. 
1H-NMR (400 MHz, DMSO-D6): δ = 8.09 (br s, 2H, -NH2), 3.58 
(t, J = 6.3 Hz, 6H, H-3), 3.42 (s, 6H, H-2), 2.44 (t, J = 6.3 Hz, 6H, 
H-4). 
13C-NMR (101 MHz, DMSO-D6): δ =173.13 (COOH), 75.38 
(C-2), 67.51 (C-3), 59.39 (C-1), 34.82 (C-4).  
MS (-ESI, MeOH, setting B): m/z = 366.1363 obs. [M - H]- calcd. 336.1300. 
1H-, and 13C-NMR data are in accordance with literature.[346] 
7.3.5 Di-tert-butyl 3,3'-((2-amino-2-((3-(tert-butoxy)-3-oxopropoxy)methyl)-
propane-1,3-diyl)bis(oxy))dipropionate 28[335] 
Tris(hydroxymethyl)aminomethane 13 (1.21 g, 10.0 mmol, 1.00 eq.) was dissolved in DMSO 
(2.00 mL) and cooled to 15°C. 5 M NaOH (200 µL) was added and afterwards tert-butylacrylate 
2 (4.94 mL; 34.0 mmol, 3.40 eq.) was added dropwise under stirring. The reaction mixture was 
allowed to warm to room temperature and left stirring overnight. The solvent was removed under 
high vacuum applying gentle heat (40°C). Purification via flash column chromatography (SiO2, 
ethyl acetate : hexane 2:1 to 100% ethyl acetate) gave 1.89 g (3.74 mmol, 37%) of 28 as yellow 
oil. 
1H-NMR (400 MHz, CDCl3): δ = 3.62 (t, J = 6.4 Hz, 6H, H-3), 
3.29 (s, 6H, H-2), 2.43 (t, J = 6.4 Hz, 6H, H-4), 1.42 (s, 27H, 
-C(CH3)3). 
13C-NMR (101 MHz, CDCl3): δ = 171.04 (C-5), 80.53 (C-6), 
72.91 (C-2), 67.22 (C-3), 56.08 (C-1), 36.41 (C-4), 28.20 
(C-7). 
MS (+ESI, MeOH, setting B): m/z = 506.3371 obs. [M + H]+ calcd. 506.3324, 1011.6608 obs. 
[2M + H]+ calcd. 1011.6574. 
Obtained spectroscopic data are comparable to literature.[335, 362] 





28 (100 mg, 0.198 mmol, 1.00 eq.) was dissolved in DCM and 20% Na2CO3 (2.5:1, 3.00 mL). 
Fmoc-Cl (154 mg, 0.594 mmol, 3.00 eq.), dissolved in DCM (0.5 mL), was added dropwise under 
stirring, and the mixture was kept stirred overnight. DCM was removed in vacuo and the aqueous 
layer was dried via lyophilization. Purification occurred on a LaPrepΣ low-pressure HPLC system 
(Section 7.1.3) equipped with the Kinetex® C18 RP-HPLC-column using method P3 (UV 
detection at 280 nm, Table 7.1). The crude compound was dissolved in 1:1 H2O: ACN, both 
containing 0.1% (v/v) TFA, (100 mg in 5.0 mL per HPLC run) and filtered over a 0.45 µm 
Acrodisc® syringe filter (GHP membrane, Pall Corporation, Port Washington, NY, USA) before 
injection. Collected fractions were checked with the semi-micro Chromaster HPLC system 
(Chapter 7.1.4) using method A2 (Table 7.2). Fractions containing pure product were combined, 
ACN was removed in vacuo, and the aqueous residue was freeze-dried to yield 88.0 mg 
(0.121 mmol, 61%) of 29 as colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.76 (d, J = 7.5 Hz, 2H, 
H-8’), 7.62 (d, J = 7.4 Hz, 2H, H-5’), 7.39 (t, J = 7.4 Hz, 2H, 
H-7’), 7.31 (t, J = 7.4 Hz, 2H, H-6’), 5.38 (br s, 1H, NH), 
4.37-4.22 (br m, 2H, H-2’), 4.20 (t, J = 6.8 Hz, 1H, H-3’), 
3.82-3.54 (br m, 12H, H-3, H-2), 2.60-2.35 (br m, 6H, H-4), 
1.44 (s, 27H, -C(CH3)3). 
13C-NMR (101 MHz, CDCl3): δ = 170.97 (C-5), 144.22 
(C-4’), 141.37 (C-9’), 127.71 (C-6’), 127.17 (C-7’), 125.30 
(C-5‘), 120.01 (C-8’), 80.57 (C-6), 70.83 (C-2’), 69.43 (C-2), 67.17 (C-3), 58.90 (C-1), 47.33 
(C-3’), 36.33 (C-4), 28.21 (C-7)). 
MS (+ESI, DCM/MeOH, setting B): m/z = 728.4031 obs. [M + H]+ calcd. 728.4004, 750.3863 
obs. [M + Na]+ calcd. 750.3824, 766.3599 obs. [M + K]+ calcd. 766.3563. 
HPLC (LaChrom ELITE® system, Kinetex® C18 column, method A11): rt = 23.013 min 
Spectroscopic data comparable to literature.[339] 
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7.3.7 3,3'-((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-((2-carboxyethoxy)-
methyl)propane-1,3-diyl)bis(oxy))dipropionic acid 20 
FmocTrisCOOtBu 29 (88.0 mg, 0.121 mmol, 1.00 eq.) was stirred for 3 h in 1:1 DCM:TFA 
(6.00 mL) at room temperature. The solvent was removed in vacuo to obtain 70.7 mg of 20 
(0.126 mmol, quant.) as light yellow oil. The product was used without further purification.  
1H-NMR (500 MHz, CDCl3): δ = 7.75 (d, J = 7.5 Hz, 2H, H-8’), 
7.58 (d, J = 7.4 Hz, 2H, H-5’), 7.38 (t, J = 7.4 Hz, 2H, H-7’), 
7.31 (t, J = 7.4 Hz, 2H, H-6’), 4.39-4.26 (br m, 2H, H-2’), 4.21 
(t, J = 5.7 Hz, 1H, H-3’), 3.77-3.55 (br m, 10H, H-aliph.), 2.60-
2.41 (br m, 8H, H-aliph.). 
13C-NMR (126 MHz, CDCl3): δ = 144.14 (C-5), 141.63 
(C-arom.), 141.50 (C-arom.), 127.85 (C-arom.), 127.28 (C-
arom.), 120.46 (C-arom.), 120.14 (C-arom.), 69.59 (C-2), 66.57 (C-3), 58.86 (C-2’), 47.27 (C-3’), 
34.89 (C-4). 
MS (+ESI, ACN, setting B): m/z = 560.2151 obs. [M + H]+ calcd. 560.2126, 582.1971 obs. 
[M + Na]+ calcd. 582.1946, 598.1688 obs. [M + K]+ calcd. 598.1685, 1119.4211 [2M + H]+ 
calcd. 1119.4180, 1141.4043 obs. [2M + Na]+ calcd. 1141.3999, 1157.3746 obs. [2M + K]+ calcd. 
1157.3739. 
MS (-ESI, ACN, setting B): m/z = 558.2112 obs. [M - H]- calcd. 558.1981, 672.2057 obs. 
[M - H + TFA]- calcd. 672.1909, 1117.4249 obs. [2M - H]- calcd. 1117.4034. 
HPLC (LaChrom ELITE® system, Kinetex® C18 column, method A11): rt = 14.260 min 
7.3.8 NHS-activation of FmocTrisCOOH 20 (31) 
FmocTrisCOOH 20 (10.0 mg, 0.018 mmol, 1.00 eq.) and N,N′-Disuccinimidyl carbonate (DSC) 
30 (41.5 mg, 0.162 mmol, 9.00 eq.) were dissolved in a 1:1 mixture of THF:ACN (4.00 mL) and 
freshly distilled triethylamine (37.6 µL, 0.270 mmol, 15.00 eq.) was added. The mixture was 
stirred at room temperature, and the reaction progress was followed by RP-HPLC (LaChrom 
ELITE® system, Kinetex® C18 column, method A11). After 1 h the solvent was removed under 
reduced pressure. Purification occurred on a LaPrepΣ low-pressure HPLC system (Section 7.1.3) 
using the Kinetex® C18 RP-HPLC-column, and method P3 with UV detection at 280 nm 
(Table 7.1). The crude compound was dissolved in 3.0 mL 1:1 H2O:ACN, both containing 0.1% 
(v/v) TFA, and filtered over a 0.45 µm Acrodisc® syringe filter (GHP membrane, Pall 
Corporation, Port Washington, NY, USA) before injection. Collected fractions were checked with 
the semi-micro Chromaster HPLC system (Chapter 7.1.4) using method A2 (Table 7.2). Fractions 
containing pure product were combined, ACN was removed in vacuo, and the aqueous residue 
was freeze-dried to give 10.5 mg (0.012 mmol, 67%) of 31 as white solid. 
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1H-NMR (500 MHz, CDCl3): δ = 7.76 (d, J = 7.4 Hz, 2H, 
H-8’), 7.64 (d, J = 7.5 Hz, 2H, H-5’), 7.39 (t, J = 7.4 Hz, 
2H, H-7’), 7.31 (t, J = 7.5 Hz, 2H, H-6’), 4.38-4.22 (br m, 
2H, H-2’), 4.21 (t, J = 6.8 Hz, 1H, H-3’), 3.89-3.65 (br m, 
12H, H-3, H-2), 2.88-2.82 (m, 6H, H-4), 2.81-2.75 (m, 12H, 
H-7, H-8). 
13C-NMR (126 MHz, CDCl3): δ = 169.21 (C-6, C-9), 
167.02 (C-5), 144.37 (C-1’), 134.44 (C-arom.), 133.98 (C-
arom.), 127.79 (C-arom.), 127.75 (C-arom.), 120.77 (C-arom.), 120.06 (C-arom.), 69.25 (C-2), 
65.87 (C-3), 47.41 (C-2’), 32.25 (C-4), 25.73 (C-7, C-8). 
MS (+ESI, DCM/MeOH, setting B): m/z = 851.2660 obs. [M + H]+ calcd. 851.2618, 1701.5212 
obs. [2M + H]+ calcd. 1701.5163. 
HPLC (LaChrom ELITE® system, Kinetex® C18 column, method A11): rt = 17.387 min 
7.3.9 Thioester-activation of FmocTrisCOOH 20 (39) 
FmocTrisCOOH 20 (10.0 mg, 0.018 mmol, 1.00 eq.), p-acetamidothiophenol 38 (45.2 mg, 
0.270 mmol, 15.0 eq.) and PyBOP (140.5 mg, 0.270 mmol, 15.00 eq.) were dissolved in 1.00 mL 
DCM. DIPEA (44.6 µL, 0.270 mmol, 15.0 eq.) was added, and the mixture was stirred at room 
temperature for 6 h. After the solvent was removed in vacuo, the crude mixture was purified by 
RP-HPLC using the LaPrepΣ low-pressure system (Chapter 7.1.3). The Kinetex® C18 RP-
HPLC-column was used while applying method P3 (Table 7.1). UV detection occurred at 260 
nm. Therefore, the crude residue was dissolved in 3.0 mL 2:1 ACN:H2O, both containing 0.1% 
(v/v) TFA, and filtered over a 0.45 µm Acrodisc® syringe filter (GHP membrane, Pall 
Corporation, Port Washington, NY, USA) before injection. Collected fractions were checked with 
the semi-micro Chromaster HPLC system (Section 7.1.4) using method A2 (Table 7.2). Fractions 
containing pure product were combined, ACN was removed in vacuo, and the aqueous residue 
was freeze-dried to give 5.1 mg (0.005 mmol, 28%) of 39 as white solid. 
1H-NMR (500 MHz, CDCl3): δ = 7.84-7-70 (m, 6H, 
H-arom.), 7.58-7.48 (m, 2H, H-arom.(Fmoc)), 7.48-
7.40 (m, 4H, H-arom.(Fmoc)), 7.40-7.35 (m, 2H, 
H-arom.(Fmoc)), 7.35-7.23 (m, 6H, H-arom.) 4.32-
3.96 (br m, 7H, H-aliph.), 3.82-3.60 (br m, 9H, 
H-aliph.), 2.93-2.72 (m, 5H, H-aliph.), 2.15 (s, 
9H, -CH3). 
A 13C-NMR spectrum could not be analyzed, presumably due to the low concentration of the 
sample measured. Although the measurement was performed for 14 h (25000 scans) no 
reasonable intensity was obtained. 
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MS (+ESI, H2O/ACN, setting B): m/z = 1007.3023 obs. [M + H]+ calcd. 1007.3024, 1029.2809 
obs. [M + Na]+ calcd. 1029.2843, 1045.2571 obs. [M + K]+ calcd. 1045.2583. 
HPLC (Chromaster system, Kinetex® C18 column, method A6): rt = 16.953 min 
7.4 Solid phase peptide synthesis 
All peptides were synthesized from the C-terminal to the N-terminal end on solid phase according 
to standard Fmoc/tBu protecting group strategy.[363] If not stated otherwise, synthesis occurred in 
0.05 mmol scale. 
The following protected derivatives of the standard canonical amino acids were used: 
Fmoc-L-Ala-OH × H2O, Fmoc-L-Arg(Pbf)-OH, Fmoc-L-Asn(Trt)-OH, Fmoc-L-Asp(OtBu)-OH, 
Fmoc-L-Cys(Trt)-OH, Fmoc-L-Gln(Trt)-OH, Fmoc-L-Glu(OtBu)-OH × H2O, Fmoc-Gly-OH, 
Fmoc-L-His(Trt)-OH, Fmoc-L-Ile-OH, Fmoc-L-Leu-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-L-Met-
OH, Fmoc-L-Phe-OH, Fmoc-L-Ser(tBu)-OH, Fmoc-L-Thr(tBu)-OH, Fmoc-L-Trp(Boc)-OH, 
Fmoc-L-Tyr(tBu)-OH, Fmoc-L-Val-OH.  
The following pseudoproline dipeptides, PEGylation agents and non-natural building blocks 
were used for the synthesis: Fmoc-L-Tyr(tBu)-L-Thr[PSI(Me,Me)Pro]-OH, Fmoc-L-Leu-L-
Thr[PSI(Me,Me)Pro]-OH, Fmoc-NH-PEG(4)-COOH, and Boc-2-Abz-OH. 
The following fluorinated amino acids were used: Fmoc-(S)-DfeGly, Fmoc-(2S,3R)-43-
F3Val, Fmoc-(2S,3S)-43-F3Val, Fmoc-(S)-53-F3Ile, Fmoc-(S)-53,5’3-F6Leu (for synthesis see 
Chapter 7.2).  
7.4.1 Loading of the resin 
Gp41 peptides were synthesized on a NovaSyn®TGR-resin (loading capacity: 0.250 mmol/g), 
which had to be preloaded with the C-terminal amino acid Fmoc-L-Leu-OH in case of C34 and 
N36, and Fmoc-L-Gln(Trt)-OH for the C31 peptides and T21.  
First the resin was swelled in DMF for 2 × 30 min (5.0 mL for 500 mg resin). Five 
equivalents of the amino acid were pre-activated with HOBt and DIC, each five equivalents, in 
DMF (4.0 mL per 500 mg resin) for 7 min and then added to the resin. After three hours the resin 
was washed with DMF, DCM and MeOH (each 3 × 5.0 mL) and dried in vacuo.  
The loading of the resin was determined via UV-detection of the Fmoc protecting group 
according to the procedure of Gude et al..[364] Approximately 30.0 mg of each loaded resin were 
swelled in 20.0 mL DMF for 30 min. Then 400 μL DBU were added and it was shaken for another 
30 min. Subsequently, the reaction was quenched by adding ACN to a total volume of 100 mL. 
2.0 mL of this solution were then diluted with ACN to a volume of 25.0 mL. With this solution, 
the UV-detection was carried out. The absorption was measured at 294 nm and 304 nm in 1 cm 
quartz glass cuvettes and performed in triplicate. The spectra were recorded with baseline 
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correction through a blank sample containing only the reference that was prepared in the same 
manner but without addition of the resin. The resin loading was calculated according to the 
following equations:[364] 
loading �mmol g� �
294nm
= absorbance × 142.14
mresin[mg]
     (7.1) 
loading �mmol g� �
304nm
= absorbance × 163.96
mresin[mg]
    (7.2) 
For the Fmoc-L-Leu-OH loaded resin a loading of 0.250 mmol/g and for the Fmoc-L-Gln(Trt)-
OH loaded resin a loading of 0.230 mmol/g was determined. 
Potentially unreacted NH2-groups on the resin surface were capped afterwards by treatment 
with a solution containing 10% acetic anhydride and 10% DIPEA in DMF (5.0 mL per 500 mg 
resin) three times for 10 min. The resin was then washed with DMF, DCM and MeOH (each 
3 × 5.0 mL) and dried in vacuo.  
7.4.2 Automated peptide synthesis 
The peptides described in this thesis were almost completely synthesized via automated peptide 
synthesis.  
Synthesis on a MultiSynTech Syro XP fully automated, parallel peptide synthesizer 
(MultiSynTech GmbH, Witten, Germany) occurred according to the protocol shown in Table 7.7. 
The coupling of the amino acids was carried out using TBTU/HOBt/DIPEA activation. Therefore, 
four or five equivalents of the corresponding amino acid, TBTU and HOBt, as well as eight or 
ten equivalents DIPEA in DMF were added to the resin. Furthermore, the coupling mixture 
contained sodium perchlorate (0.23 M) to prevent on-resin aggregation during synthesis. After 
30 min to one hour, the resin was washed with 2.5 mL DMF and the coupling was repeated under 
the same conditions. Fmoc deprotection was achieved by treatment of the resin with 2% (v/v) 
piperidine and 2% (v/v) DBU in DMF, 20% (v/v) piperidine in DMF, or 20% (v/v) piperidine + 
0.1 M HOBt in DMF (4 × 5 min) after washing three times with 2.5 mL DMF. Then the resin was 
washed six times with 2.5 mL DMF. Prior to the synthesis the resin was swelled two times in 
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Table 7.7: Protocol for the automated solid phase peptide synthesis with 0.05 mmol scale on a MultiSynTech Syro XP 
peptide synthesizer. 
process step reagents reaction time 
Start 
Swelling 2.5 mL DMF 2 × 15 min 
Fmoc-deprotection 
2% piperidine, 2% DBU in DMF,  
20% piperidine in DMF or 
20% piperidine + 0.1 M HOBt in DMF 
4 × 5 min 





4 or 5 eq. Fmoc-X-OH and HOBt in DMF 
4 or 5 eq. TBTU in DMF 
8 or 10 eq. DIPEA in NMP 
30 or 60 min 
Washing 2.5 mL DMF 1 min 
Amino acid 
coupling 
4 or 5 eq. Fmoc-X-OH and HOBt in DMF 
4 or 5 eq. TBTU in DMF 
8 or 10 eq. DIPEA in NMP 
30 or 60 min 
Washing 2.5 mL DMF 3 × 1 min 
Fmoc-deprotection 
2% piperidine, 2% DBU in DMF,  
20% piperidine in DMF or 
20% piperidine + 0.1 M HOBt in DMF 
4 × 5 min 
Washing 2.5 mL DMF 6 × 1 min 
Synthesis was also performed on an Activo-P11 Automated Peptide Synthesizer (Activotec, 
Cambridge, United Kingdom) following the protocol given in Table 7.8. The coupling of the 
amino acids was carried out using HOAt/DIC activation. Therefore, 8 or 10 equivalents HOAt, 8 
or 10 equivalents DIC and 8 or 10 equivalents of the corresponding amino acid in 1.6 mL DMF 
were added to the resin. Furthermore, the coupling solution contained sodium perchlorate 
(0.25 M) to prevent aggregation on the resin during synthesis. After 1-2 hours the coupling was 
repeated under the same conditions. After washing five times with 2.0 mL DMF, Fmoc 
deprotection was achieved by treatment of the resin with 2.0 mL of either 2% (v/v) piperidine and 
2% (v/v) DBU in DMF, 20% (v/v) piperidine in DMF, or 20% (v/v) piperidine + 0.1 M HOBt in 
DMF for 2 × 5 min and 2 × 10 min, or 4 × 5 min. Then the resin was washed six times with 
2.0 mL DMF. Prior to the synthesis the resin was swelled two times in 2.0 mL DMF for 15 min. 
At the end of the synthesis the resin was washed three times for 2 min with 2.0 mL of DCM. 
Coupling steps were performed also via HATU/DIPEA activation (Table 7.9). Here, 5 eq. 
amino acid, 4.9 eq. HATU and 10 eq. DIPEA in 1.6 mL DMF were added to the resin. The 
coupling solution also contained 0.25 M NaClO4 to prevent on-resin aggregation. This reaction 
step was performed two times for 45 min. 
All coupling and deprotection steps were carried out at 40°C. Coupling of His-residues 
occurred at room temperature to avoid racemization, and for Met-residues the temperature was 
slightly reduced to 35°C. The washing steps were conducted at ambient temperature. 
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Table 7.8: Protocol for the automated solid phase peptide synthesis with 0.05 mmol scale on the Activo-P11 Automated 
Peptide Synthesizer using HOAt/DIC activation. 
process step reagents reaction time 
Start 
Swelling 2.0 mL DMF 2 × 15 min 
Fmoc-
deprotection 
2.0 mL  
2% piperidine, 2% DBU in DMF,  
20% piperidine in DMF or 
20% piperidine + 0.1 M HOBt in DMF 
2 × 5 min + 2 × 10 min 
or  
4 × 5min 





8 or 10 eq. Fmoc-X-OH, 8 or 10 eq. HOAt and 8 
or 10 eq. DIC in 1.6 mL DMF 2 × 1-2 h 
Washing 2.0 mL DMF 5 × 1 min 
Fmoc-
deprotection 
2.0 mL  
2% piperidine, 2% DBU in DMF,  
20% piperidine in DMF or 
20% piperidine + 0.1 M HOBt in DMF 
2 × 5 min + 2 × 10 min 
or  
4 × 5min 
Washing 2.0 mL DMF 6 × 1 min 
Table 7.9: Protocol for the automated solid phase peptide synthesis with 0.05 mmol scale on the Activo-P11 Automated 
Peptide Synthesizer using HATU/DIPEA activation. 
process step reagents reaction time 
Start 
Swelling 2.0 mL DMF 2 × 15 min 
Fmoc-deprotection 2.0 mL 20% piperidine in DMF 4 × 5min 





5 eq. Fmoc-X-OH, 4.9 eq. HATU and 
10 eq. DIPEA in 1.6 mL DMF 2 × 45 min 
Washing 2.0 mL DMF 5 × 1 min 
Fmoc-deprotection 2.0 mL 20% piperidine in DMF 4 × 5min 
Washing 2.0 mL DMF 6 × 1 min 
7.4.3 Manual peptide synthesis 
Peptide synthesis carried out manually followed the procedure described in Table 7.10 using 10 
mL polypropylene reactors. The reaction cycles started with the Fmoc deprotection. For this the 
resin was treated with a 2.0 mL mixture of 20% (v/v) piperidine in DMF three times for 7 min. 
After washing with DMF and DCM, each three times, the amino acid coupling was performed. 
Eight equivalents of the canonical N-Fmoc-protected amino acid were mixed with eight 
equivalents of DIC and HOAt in 2.0 mL DMF containing 0.4 M NaClO4 and pre-activated for 
7 min. Instead of HOAt, also HOBt can be used. The resulting mixture was added to the resin. 
After shaking for 60 min, the resin was washed once with 5 mL DMF and the coupling was 
repeated another time under the same conditions. Finally, the resin was washed with DCM and 
DMF. Prior to the synthesis the resin was swelled two times for 15 min in 5.0 mL DMF. 
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Table 7.10: Protocol for manual solid phase peptide synthesis (0.05 mmol scale). HOAt can also be replaced by HOBt 
process step reagents reaction time 
Swelling 5.0 mL DMF 2 × 15 min 
Fmoc-deprotection 2.0 mL 20% piperidine DMF 3 × 7 min 
Washing 
5.0 mL DMF 
5.0 mL DCM 
3 × 1 min 
3 × 1 min 
Amino acid coupling 8 eq. Fmoc-X-OH, 8 eq. HOAt and 8 eq. DIC in 2.0 mL DMF 2 × 1 h 
Washing 5.0 mL DMF 5.0 mL DCM 
3 × 1 min 
3 × 1 min 
Coupling of fluorinated amino acids and other non-natural building blocks also occurred 
manually under the conditions that are described in the next section. 
7.4.3.1 Coupling of non-natural building blocks, and N-terminal capping 
Coupling of the fluorinated amino acids 
Fluorinated amino acids as well as the first subsequent amino acid were activated by DIC/HOAt 
1:1. For fluorine-containing residues a single coupling step was carried out with a molar excess 
of the amino acid and coupling reagents of 1.2-fold relative to the resin loading in 2.0 mL DMF 
containing 0.4 M NaClO4. These couplings were performed for 12 h. If insufficient coupling was 
detected (test cleavage, see Section 7.6.1), another 0.5 eq. of amino acid and coupling reagents 
(DIC/HOAt) were added to the resin and shaken for 12 h. Prior to the Fmoc deprotection of the 
fluorinated amino acids possibly free N-termini were capped by adding a mixture of acetic 
anhydride (10% (v/v)) and DIPEA (10% (v/v)) in DMF (2.0 mL; 3 × 10 min). The resin was 
washed with DMF and DCM (3 × 5.0 mL each). The amino acid that is immediately following 
the fluorinated one was also coupled manually according to the protocol in Table 7.10 using 
8-fold excess of amino acid and coupling reagents (DIC/HOAt). 
Coupling of Pseudoproline Dipeptides 
Coupling of pseudoproline dipeptide building blocks occurred manually with HCTU/DIPEA 
activation. 1.5 eq pseudoproline and 1.5 eq HCTU were dissolved in 2.0 mL DMF + 0.4 M 
NaClO4, and 3.0 eq DIPEA were added. The mixture was added to the resin without pre-activation 
and then shaken for 12 h. Afterwards, the resin was washed with DMF and DCM (both 
3 × 5.0 mL). If an incomplete coupling was observed, another 0.8 eq. pseudoproline together with 
0.8 eq. HCTU and 1.6 eq. DIPEA in 2.0 mL DMF + 0.4 M NaClO4 were added to the resin and 
shaken over-night. Free α-amino groups that have not reacted during the coupling reaction were 
then capped by treatment of the resin with 2.0 mL of a mixture of 10% (v/v) acetic anhydride and 
10% (v/v) DIPEA in DMF three times for 10 min. After this, the resin was washed three times 
with each DMF and DCM. 
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Coupling of PEG(4) 
PEGylation of peptides was usually performed on a 0.005 mmol scale. Coupling occurred with a 
1.5-fold excess of FmocNH-PEG(4)-COOH and HCTU, as well as a three-fold excess of DIPEA 
in 0.5 mL of a 1:1 mixture of DMF:DCM for 2 × 12 h. Afterwards, the resin was washed with 
DMF and DCM (both 3 × 5.0 mL). To block free α-amino groups that have not reacted during the 
coupling reaction, the resin was treated with 1.0 mL of 10% (v/v) acetic anhydride and 10% (v/v) 
DIPEA in DMF three times for 10 min. After this, the resin was washed three times with each 
2.0 mL of DMF and DCM. 
Coupling of N-terminal Abz label  
N-terminal labeling with o-aminobenzoic acid (Abz) was carried out manually using Boc-Abz-
OH. Therefore, 5 eq. Boc-Abz-OH, 5eq. HOBt and 5 eq. DIC were dissolved in 2.0 mL DMF 
supplemented with 0.4 M NaClO4, and after 7 min preactivation the mixture was added to the 
resin. The reaction was shaken for 1 h and repeated a second time under the same conditions. 
HOBt can also be replaced with HOAt. Afterwards, the resin was washed with DMF, DCM, and 
MeOH (3 × 5.0 mL each). 
Capping 
N-terminal capping was carried out by treatment of the resin with 2.0 mL of a mixture of 
10% (v/v) acetic anhydride and 10% (v/v) DIPEA in DMF three times for 10 min. After this, the 
resin was washed three times with 5.0 mL of each DMF, DCM and MeOH. 
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The peptide sequences summarized in Table 7.11 were synthesized within the course of the 
present thesis. A detailed synthetic protocol for the peptides is given in the following sections. 








































*These peptides were kept on resin for further reactions and thus used without purification. 
†Synthesis on a NovaSyn®TGT resin gave fully protected peptides that were used without purification. 
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7.4.4 Synthesis of VPE/VPK 
VPE, and VPK peptides were synthesized on Fmoc-L-Glu-(OtBu)- and Fmoc-L-Lys-(Boc)-
NovaSyn®TGA resins (0.2 mmol/g or 0.23 mmol/g), respectively, using the Syro XP peptide 
synthesizer according to Table 7.7. Couplings occurred with a four-fold excess of amino acids 
and coupling reagents (TBTU/HOBt) as well as an eight-fold excess of DIPEA relative to the 
resin loading (2 × 30 min). Fluorinated amino acids as well as the first subsequent amino acid 
were coupled as described in Section 7.4.3. Fmoc deprotection was achieved by treatment with a 
mixture of piperidine (2% (v/v)) and DBU (2% (v/v)) in DMF. VPE and all VPK peptides were 
N-terminally labeled with o-aminobenzoic acid (Abz) to enable photometric concentration 
determination. Abz was coupled manually according to Section 7.4.3. 
7.4.5 Synthesis of FA peptides  
FA peptides were synthesized manually on a preloaded Fmoc-L-Lys(Boc)Wang resin (0.57 
mmol/g loading). Couplings of non-fluorinated amino acids were performed as described in 
Section 7.4.3 using HOBt and DIC as activating agents. The fluorinated amino acid 53-F3Ile was 
coupled according to the procedure described in Section 7.4.3. All peptides were N-terminally 
labeled with o-aminobenzoic acid (Abz) to enable photometric detection (see Section 7.4.3). 
7.4.6 Synthesis of gp41-peptides 
C31 
The synthesis of the C31-peptides was carried on a NovaSyn®TGR-resin that was loaded with 
Fmoc-L-Glu(OtBu)-OH beforehand (loading 0.23 mmol/g, see Section 7.4.1). 
The first part of the sequence (amino acid residues 21-31) was synthesized on the Syro XP 
instrument according to the standard protocol for the automated peptide synthesis in Table 7.7. 
5eq. amino acid, HOBt/TBTU and 10 eq. DIPEA were used, and the coupling lasted 2 × 60min. 
This part of the sequence could also be synthesized on the Activo-P11 peptide synthesizer using 
either HOAt/DIC activation (8 eq., 2 × 90 min, Table 7.8) or HATU/DIPEA activation 
(Table 7.9). As Fmoc deprotection solution 20% (v/v) piperidine in DMF was used (4 × 5 min). 
Residues 19-20 were coupled manually as pseudoproline dipeptide building block Fmoc-L-
Tyr(tBu)-L-Thr[PSI(Me,Me)Pro]-OH following the procedure described in Section 7.4.3. The rest 
of the sequence for native C31 (residues 1-18) was afterwards synthesized in the Activo-P11 
peptide synthesizer using the protocol given in Table 7.8. 10-fold excess of amino acids and 
coupling reagents (HOAt/DIC) were used for 2 2h. Fmoc-deprotection of these residues occurred 
with 20% (v/v) piperidine + 0.1 M HOBt in DMF for 4 × 5 min. 
For the fluorinated C31 derivatives, Asn17 and Asn18 were coupled manually according to 
the procedure described in Section 7.4.3 (Table 7.10). The fluorinated amino acids in position 16 
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and the subsequent amino acid Glu15 were coupled manually as described in Section 7.4.3. The 
rest of the sequence (residues 1-14) was again synthesized automatically with the Activo-P11 
synthesizer according to the protocol described in Table 7.8 using an 8-fold excess of amino acids, 
and activation agents (HOAt/DIC) for 2 × 2 h. As Fmoc-deprotection solution 20% (v/v) 
piperidine + 0.1 M HOBt in DMF was used. The deprotection step occurred four times for 5 min.  
The N-terminal amino group of the C31-peptides was acetylated using acetic anhydride as 
described in Section 7.4.3 (see capping). 
C34 
Synthesis of C34 was conducted on a NovaSyn®TGR-resin that was loaded with Fmoc-L-Leu-
OH beforehand (loading 0.25 mmol/g, Section 7.4.1). Amino acids residues 29-34 were coupled 
on the Syro XP peptide synthesizer according to Table 7.7 using 5 eq. of amino acid for 2 × 1 h. 
For Fmoc deprotection 20% (v/v) piperidine in DMF was used. Residues 13-28 were coupled 
with the Activo-P11 synthesizer, using 8 eq. amino acid/HOAt/DIC (2 × 1 h) and 20% (v/v) 
piperidine in DMF for Fmoc removal (2 × 5 min + 2 × 10 min). Amino acids 11+12 were coupled 
as the Fmoc-L-Tyr(tBu)-L-Thr[PSI(Me,Me)Pro]-OH pseudoproline building block as described 
in Section 7.4.3. Amino acid residue 10 was coupled manually following the protocol in 
Table 7.10. The final residues 1-9 were coupled again on Activo-P11 synthesizer using 8 eq. of 
amino acid with 8 eq HOAt and 8 eq DIC. Fmoc deprotection was conducted with a solution of 
20% (v/v) piperidine + 0.1 M HOBt in DMF (2 × 5 min + 2 × 10 min) to avoid aspartimide 
formation at the Asp-residue. The coupling time was prolonged to 2 × 90 min. N-terminal capping 
was performed as described in Section 7.4.3.  
T21 
T21 was synthesized on a NovaSyn®TGR resin preloaded with Fmoc-L-Glu(OtBu)-OH (loading 
0.23 mmol/g, see Section 7.4.1). The first five amino acid residues (33-38) were coupled on the 
Syro XP automated peptide synthesizer using five-fold excess of Fmoc-L-amino acid, HOBt, and 
TBTU, as well as a 10-fold excess of DIPEA according to the procedure described in 
Section 7.4.2 (see Table 7.7) for 2 × 60 min. Amino acid residues 23-32 were also coupled 
automatically, but this time using the Activo-P11 synthesizer. Couplings were conducted with 
eight equivalents of amino acid and coupling reagents (DIC/HOAt) for 2 × 60 min according to 
Section 7.4.2 (Table 7.8). Arg residues were coupled 2 × 90 min, and Fmoc-deprotection was 
conducted for 2 × 5 min and 2 × 10 min. Amino acid residues 18-22 were coupled in the same 
way on Activo-P11, but the reaction time was prolonged to 2 × 90 min. Coupling of the next two 
amino acids (16+17) occurred manually by incorporation of the pseudoproline building block 
Fmoc-L-Leu-L-Thr[PSI(Me,Me)Pro]-OH using HCTU/DIPEA activation following the method 
described in Section 7.4.3. The subsequent amino acid Gln15 was coupled manually as described 
in Table 7.10. The rest of the sequence was synthesized on the Activo-P11 automatic peptide 
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synthesizer using the general procedure given in Section 7.4.2 (Table 7.8). An eight-fold excess 
of amino acids and coupling reagents (HOAt/DIC) relative to the resin loading was used. 
Coupling reaction lasted 2 × 90 min for aa5-14 and 2 × 120 min for aa1-4, and Fmoc deprotection 
was performed 2 × 5 min and 2 × 10 min. For all deprotection steps during the synthesis of T21 
a solution of 20% (v/v) piperidine containing 0.1 M HOBt in DMF was used to avoid aspartimide 
formation. For N-terminal acetylation see Section 7.4.3. 
N36 
Synthesis of N36 occurred on a NovaSyn®TGR-resin that was preloaded with Fmoc-L-Leu-OH 
(loading 0.25 mmol/g, Section 7.4.1). The synthesis of the complete sequence occurred at the 
Activo-P11 automated peptide synthesizer applying the procedure described in Section 7.4.2 
(Table 7.8). Fmoc deprotection was performed with a solution of 2% (v/v) piperidine + 2% DBU 
(v/v) in DMF (2 × 5 min + 2 × 10 min). The first 15 amino acid residues (21-35) were coupled 
using an 8-fold excess of amino acid and coupling reagents (HOAt/DIC) for 2 × 1 h. For the 
second part of the peptide (residues 1-20) the excess of amino acid and coupling reagents was 
raised to 10-fold, and the coupling time was prolonged to 2 × 2 h. N-terminal capping was 
performed as described in Section 7.4.3. 
7.4.6.1 N36 and T21 derivatives 
N36 and T21 peptides were modified to test different approaches for coupling of a hetero-
tetrameric linker (see Section 5.5). 
Therefore, another 0.05 mmol of T21 without performing the N-terminal acetylation step† 
was synthesized as described before. A new batch of N36 was synthesized under slightly different 
conditions as described in the next paragraphs. 
N36 with a free N-terminus* 
Synthesis of an unacetylated N36 peptide that is used for SPR linker coupling tests occurred under 
optimized conditions. The synthesis was also performed on a NovaSyn®TGR-resin preloaded 
with Fmoc-L-Leu-OH (loading 0.25 mmol/g, Section 7.4.1) via the Activo-P11 automated peptide 
synthesizer using the procedure described in Section 7.4.2 (Table 7.8). Here, Fmoc deprotection 
was conducted with a solution of 20% (v/v) piperidine in DMF (2 × 5 min + 2 × 10 min). 
Residues 26-36 were coupled with an 8-fold excess of amino acid and coupling reagents 
(HOAt/DIC) for 2 × 90min. For coupling of residues 1-25 a 10-fold excess of amino acid and 
coupling reagents was used.  
 
†Synthesis on a NovaSyn®TGT resin gave fully protected peptides that were used without purification for 
further reactions. 
*This peptide was kept on resin for further reactions and thus used without purification. 
Stabilization of peptides by site-specific incorporation of fluorinated amino acids 
 168 
N36 on TGT resin† 
For cleavage as fully protected peptide fragment, N36 was furthermore synthesized on a 
NovaSyn®TGT-resin preloaded with Fmoc-L-Leu-OH (loading 0.22 mmol/g). Synthesis was 
performed on the Actico-P11 synthesizer according to Section 7.4.2 (Table 7.8). Fmoc 
deprotection occurred with a solution of 20% (v/v) piperidine in DMF (2 × 5 min + 2 × 10 min). 
Residues 6-35 were coupled for 2 × 90 min, using an 8-fold excess of amino acid and coupling 
reagents (HOAt/DIC) for amino acids 16-35, and a 10-fold excess for residues 6-15. For coupling 
of residues 1-5 also a 10-fold excess of amino acid and coupling reagents was used, and the time 
for coupling reaction was prolonged to 2 × 2 h.  
N36-PEG(4)* and N36-PEG(4)TGT† 
0.005 mmol of each N36 synthesized on either the TGT or TGR resin were PEGylated with 
FmocNH-PEG(4)-COOH according to the procedure given in Section 7.4.3. Final Fmoc cleavage 
was done manually by treatment of the resin with a solution of 20% (v/v) piperidine in DMF for 
3 × 10 min (1.0 mL each). Afterwards, the resin was washed with DMF (3 × 2.0 mL) and DCM 
(3 × 2.0 mL). 
T21-PEG(4)* 
0.005 mmol T21 were PEGylated as described in Section 7.4.3. Final Fmoc-deprotection occurred 
manually by treatment of the resin with 1.0 mL of a solution of 20% (v/v) piperidine + 0.1 M 
HOBt in DMF for 3 × 7 min. Afterwards, the resin was washed with DMF and DCM (each 
3 × 2.0 mL). 
T21-Cys and T21-PEG(4)-Cys 
For an NCL approach, 0.005 mmol of T21 peptide was modified N-terminally with a Cys residue. 
Another 0.005 mmol were first modified with PEG(4) as spacer before coupling of the Cys 
residue. PEGylation occurred as described before for T21-PEG(4). The Cys residue was coupled 
manually for 2 ×1 h using 8-fold excess of Fmoc-L-Cys(Trt)-OH, and activation agents 
(HOAt/DIC) in 1.0 mL DMF (7 min preactivation). Final Fmoc cleavage was performed three 
times for 10 min using each 1.0 mL 20% (v/v) piperidine + 0.1 M HOBt in DMF. Afterwards, the 





†Synthesis on a NovaSyn®TGT resin gave fully protected peptides that were used without purification for 
further reactions. 
*These peptides were kept on resin for further reactions and thus used without purification. 
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7.5 Microwave assisted solid phase peptide synthesis 
C31 peptide synthesis was tested with the help of MW irradiation as well. Synthesis occurred 
either manually or automated on a NovaSyn®TGR-resin preloaded with Fmoc-L-Glu(OtBu)-OH 
beforehand (loading 0.23 mmol/g, see Section 7.4.1) in 0.05 mmol scale. 
Manual peptide synthesis under MW conditions was conducted using the Biotage® 
Initiator+ Microwave System. Temperature was set to 60°C (max. 75 W power) for both Fmoc-
deprotection and amino acid coupling, and the stirring rate was 660. Fmoc deprotection occurred 
for 1 × 15 min with 3.0 mL 20% (v/v) Pip in DMF, and coupling reaction were performed for 
2 × 30 min using 10-fold excess of amino acid and activating agents (HOAt/DIC) relative to the 
resin loading in 3.0 mL DMF. Washing after Fmoc-deprotection and the second coupling step 
was done 6 ×1 min with each 5.0 mL DMF without MW irradiation. 
Automated peptide synthesis under MW conditions was performed with the CEM Liberty 
Blue™ Automated Microwave Peptide Synthesizer. Coupling occurred 2 × 5 min (3 × 5 min for 
Asn residues) using 5 eq. of amino acid and Oxyma/DIC as activating agents in 4.0 mL DMF. 
Fmoc deprotection was conducted 1 × 2 min (2 × 2 min for Asn17) in 4.0 mL 20% (v/v) Pip in 
DMF supplemented with 0.1 M HOBt to avoid aspartimide formation. Both coupling and 
deprotection steps were performed at 75°C. For the Arg residue a special protocol was used with 
a single coupling of 25 min without the use of MW, followed by 2 min at 75°C under MW 
irradiation to prevent γ-lactam formation. Furthermore, His was coupled at only 50°C for 
2 × 10 min. The power of the MW was adjusted as such that the desired temperature was reached 
within the first 15 sec of the reaction step, and then set to a lower value so that the temperature is 
kept constant for the remaining reaction time. Washing steps occurred without the use of MW. 
The resin was washed with 3 × 5.0 mL DMF after the deprotection and coupling step. The 
synthesis started with 5 min resin swelling without MW.  
N-terminal capping was done manually in both cases according to the procedure described 
in Section 7.4.3. 
7.6 Cleavage from the resin, and purification 
7.6.1 Test cleavage for validation of synthetic progress 
To monitor the progress of the synthesis, test cleavages with a small amount of resin (spatula tip, 
~ 0.5 - 1 mg) in 100 µL of cleavage cocktail were conducted. Therefore, the resin was placed in 
an Eppendorf tube, the cleavage cocktail was added, and it was shaken for 2 - 2.5 h. For peptide 
fragments containing Met-, Cys-, Trp- and/or Arg-residues a mixture of 85% (v/v) TFA, 5% (v/v) 
H2O, 5% (v/v) TA, 2.5% (v/v) EDT and 2.5% (w/v) Phenol was used to avoid side-reactions. All 
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other peptide fragments were treated with a mixture of 10% (v/v) TIS, 1% (v/v) H2O and 89% 
(v/v) TFA. 
The peptide was then precipitated with 1.0 mL of ice-cold diethyl ether. After centrifugation, 
the ether was decanted and the peptide residue was dissolved in 1:1 ACN:H2O + 0.1% TFA 
(~ 150 µL). The resin beads were separated via centrifugation, and the supernatant containing the 
peptide was injected into analytical HPLC to verify the success of the reaction step.  
7.6.2 Full cleavage 
After the synthesis, the resin was dried in vacuo and cleavage from the resin and side-chain 
deprotection of the peptides occurred by treatment with the cleavage cocktail solution given in 
Table 7.12 (2.0 mL per 150 mg of resin). The reaction mixture was shaken for 2-3 h at room 
temperature. Cleavage of the C31-peptides was performed under argon atmosphere. Afterwards, 
the reaction solution was filtered into a 100 mL flask and the resin was washed with TFA 
(2 × 2.0 mL) and DCM (4 × 2.0 mL). The washing solutions were combined with the cleavage 
solution and excess solvent was removed by evaporation. The crude peptide was precipitated by 
addition of ~ 80 mL ice-cold diethyl ether (Et2O), and separated by centrifugation (4°C, 4.4 rpm, 
4 min). The residue was washed with ice-cold Et2O (2 × 10 mL) and dried in vacuo prior to 
purification. 
Table 7.12: Used cleavage cocktails. 
peptide cleavage cocktail duration 
VPE 
VPK-peptides 
2.5% (v/v) TIS 
2.5% (v/v) H2O 




10% (v/v) TIS 
1% (v/v) H2O 
89% (v/v) TFA 
3 h (FA-peptides) 




85% (v/v) TFA 
5% (v/v) TA 
5% (v/v) H2O 
2.5% (v/v) EDT 
2.5% (w/v) Phenol 
2.5 h 
Cleavage of T21-Cys and T21-PEG(4)-Cys occurred with only 1 mL of 85% (v/v) TFA, 5% (v/v) 
TA, 5% (v/v) H2O, 2.5% (v/v) EDT and 2.5% (w/v) Phenol. After shaking for 2.5 h, the resin was 
filtered off and washed with TFA (2 × 1.0 mL) and DCM (2 × 1.0 mL). The solvent was 
evaporated, and the crude peptide was precipitated with 15 mL ice-cold Et2O. The peptide residue 
was separated by centrifugation (4°C, 4.4 rpm, 2 min) and dried in vacuo. 
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7.6.3 Cleavage of side-chain protected peptide fragments 
Side-chain protected peptides were obtained by cleaving from NovaSyn®TGT resin under mild 
conditions with TFE. 0.005 mmol of resin were treated with 1.0 mL TFE/DCM (2:8) for 4 × 1h. 
After the appropriate time, the resin was removed by filtration und washed 3 times with the 
cleavage mixture (1.0 mL each). The solvent was evaporated, and the protected peptide was 
precipitated with ice-cold Et2O (10 mL). The residue was separated by centrifugation (4°C, 
4.4 rpm, 4 min) and dried via lyophilization. The protected peptide was used as such in further 
experiments. 
7.6.4 Purification and Characterization 
The crude peptides were dissolved in ACN/H2O + 0.1% TFA (2.0 mL- 4.0 mL per 30-40 mg). 
For increasing the solubility of the C31-DfeGly peptide, a few drops of 0.1 M NaOH were added 
to the solution to yield a pH of ~ 8. C31-53,5’3-F6Leu was dissolved in MeOH. Purification 
occurred by reversed-phase preparative HPLC using linear ACN/H2O gradients containing 0.1% 
TFA (Section 7.1.3). Used methods and columns are given in Table 7.13. Prior to injection, the 
peptide solution was filtered over 0.45 µm Acrodisc® syringe filters with GHP membrane (Pall 
Corporation, Port Washington, NY, USA). Up to a maximum of 40 mg crude peptide in maximal 
4.0 mL were injected per run. 
Table 7.13: Used methods and columns for purification of peptides. For detailed method 
parameters see Table 7.1. 
peptide used method column detection wavelength 
VPE/VPK P4 Luna® C8(2) 320nm 






Kinetex® C18 220 nm 
2nd purification: 
P7 Kinetex® C18 220 nm 




Kinetex® C18 280 nm 
2nd purification: 
P10 Kinetex® C18 220 nm 




Kinetex® C18 220 nm 
2nd purification: 
P11 Luna® C8(2) 220 nm 
T21-Cys 
T21-PEG(4)-Cys P12 Kinetex® C18 220 nm 
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Collected fractions were analyzed via analytical HPLC on the semi-micro Chromaster system 
(see Chapter 7.1.4) and the molecular masses were identified by ESI-ToF MS (Section 7.1.6). For 
VPE, and VPK-peptides, as well as all FA-peptides method A3 (Table 7.2) was used. For all gp41 
derived peptides method A4 was applied. 
Fractions containing the desired and pure peptide were combined, ACN was reduced in 
vacuo, and the remaining aqueous solution was dried by lyophilization to yield the pure peptides 
as white powder. The purity of the resulting products was confirmed by analytical HPLC (Section 
7.1.4), and all peptides were identified by high resolution ESI-ToF-MS (Section 7.1.6). For 
fractions with insufficient purity, a second purification step was performed using optimized 
methods (see Table 7.13). 
The detailed characterization data of the synthesized peptides are given in the next section.  
7.7 Synthesized peptides 
The peptide sequences synthesized within the scope of the present thesis were identified by 
ESI-ToF mass spectrometry (Section 7.1.6, Table 7.6). The results are shown in Table 7.14 - 7.17. 
HPLC chromatograms of pure peptides are depicted in Figure 7.1 - 7.8. Used HPLC settings (see 
Section 7.1.4) are given in the figure caption. HPLC-purity of all synthesized peptides is > 95%.  
Table 7.14: Identification of synthesized VPE/VPK peptides by 






VPE [M+4H]4+ 948.2762 948.2743 
[M+5H]5+ 758.8222 758.8210 
VPK [M+4H]4+ 947.8034 947.8005 
[M+5H]5+ 758.4444 758.4420 
VPK-53,5’3-F6Leu19 [M+4H]4+ 974.7974 974.7864 
[M+5H]5+ 780.0405 780.0306 
VPK-(3R)-43-F3Val16 [M+4H]4+ 961.3033 961.2934 
[M+5H]5+ 769.2460 769.2363 
VPK-(3S)-43-F3Val16 [M+4H]4+ 961.3044 961.2934 
[M+5H]5+ 769.2469 769.2363 
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Figure 7.1: HPLC chromatograms of purified VPE/VPK-peptides. HPLC system: 
LaChrom ELITE®; column: Luna® C8(2); eluent: A = 0.1% TFA in water, B = 0.1% 
TFA in ACN; gradient: 5%  70% B in 30min (method A12, Table 7.4). 
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Table 7.15: Identification of synthesized FA peptides by ESI-ToF 






FA [M+H]+ 967.5396 967.5364 
[M+2H]2+ 484.2736 484.2721 
P2-IleFA [M+H]+ 1009.5849 1009.5834 
[M+2H]2+ 505.2971 505.2956 
P2-53-F3IleFA [M+H]+ 1063.5576 1063.5551 
[M+2H]2+ 532.2845 532.2814 
P1’-IleFA [M+H]+ 1009.5858 1009.5834 
[M+2H]2+ 505.2975 505.2956 
P1’-53-F3IleFA [M+H]+ 1063.5556 1063.5551 
[M+2H]2+ 532.2816 532.2814 
P2’-IleFA [M+H]+ 1009.5864 1009.5834 
[M+2H]2+ 505.2980 505.2956 
P2’-53-F3IleFA [M+H]+ 1063.5576 1063.5551 
[M+2H]2+ 532.2835 532.2814 
 
Figure 7.2: Analytical HPLC chromatogram of purified FA on a Chromaster 
600 bar DAD HPLC system. Column: Luna® C8(2); eluent: A = H2O + 0.1% (v/v) 
TFA, B = ACN + 0.1% (v/v) TFA; gradient: 5%  70% B over 18 min (method 
A7, Table 7.3). 
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Figure 7.3: HPLC chromatograms of pure P2-IleFA, and P2-53-F3IleFA. HPLC 
system: Chromaster 600 bar DAD; column: Luna® C8(2); eluent: A = 0.1% TFA 
in water, B = 0.1% TFA in ACN; gradient: 5%  70% B over 18 min (method 
A7, Table 7.3). 
 
Figure 7.4: Analytical HPLC chromatograms of P1’-IleFA, and P1’-53-F3IleFA on 
a Chromaster 600 bar DAD HPLC system. Column: Luna® C8(2); eluent: A = H2O 
+ 0.1% (v/v) TFA, B = ACN + 0.1% (v/v) TFA; gradient: 5%  70% B over 18 min 
(method A7, Table 7.3). 
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Figure 7.5: HPLC chromatograms of pure P2’-IleFA, and P2’-53-F3IleFA. Used 
HPLC system: Chromaster 600 bar DAD; column: Luna® C8(2); eluent: A = H2O 
+ 0.1% (v/v) TFA, B = ACN + 0.1% (v/v) TFA; gradient: 5%  70% B over 18 min 
(method A7, Table 7.3). 
Table 7.16: Identification of synthesized gp41-derived peptides by 






C31 [M+2H]2+ 1975.9083 1975.9097 
 [M+3H]3+ 1317.6106 1317.6091 
 [M+4H]4+ 988.4616 988.4588 
C31-DfeGly [M+2H]2+ 1979.8828 1979.8847 
 [M+3H]3+ 1320.2624 1320.2590 
 [M+4H]4+ 990.4486 990.4462 
C31-53-F3Ile [M+2H]2+ 2002.8959 2002.8956 
 [M+3H]3+ 1335.6049 1335.5997 
 [M+4H]4+ 1001.9576 1001.9517 
C31-53,5’3-F6Leu [M+2H]2+ 2029.8840 2029.8815 
 [M+3H]3+ 1353.5940 1353.5902 
 [M+4H]4+ 1015.4488 1015.4446 
C34 [M+3H]3+ 1430.0119 1430.0137 
 [M+4H]4+ 1072.7610 1072.7622 
T21 [M+3H]3+ 1508.8586 1508.8612 
 [M+4H]4+ 1131.8974 1131.8979 
 [M+5H]5+ 905.7196 905.7199 
 [M+6H]6+ 754.9346 754.9345 
N36 [M+3H]3+ 1388.1278 1388.1295 
 [M+4H]4+ 1041.3482 1041.3490 
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Figure 7.6: HPLC chromatograms of pure C31-peptides. Used HPLC system: LaChrom 
ELITE®; column: Kinetex® C18; eluent: A = H2O + 0.1% (v/v) TFA, B = ACN + 0.1% 
(v/v) TFA; gradient: 10%  80% B over 30 min (method A13, Table 7.4). 
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Figure 7.7: HPLC chromatograms of purified C34, T21 and N36. Used HPLC system: 
LaChrom ELITE®; column: Kinetex® C18; eluent: A = H2O, B = ACN, both containing 
0.1% (v/v) TFA; gradient: 10%  80% B over 30 min (method A13, Table 7.4). 
Table 7.17: Identification of T21-Cys and T21-PEG(4)-Cys peptides 






T21-Cys [M+4H]4+ 1147.1505 1147.1475 
 [M+5H]5+ 917.9207 917.9196 
T21-PEG(4)-Cys [M+4H]4+ 1208.9383 1208.9330 
 [M+5H]5+ 967.3525 967.3480 
 [M+6H]6+ 806.2952 806.2913 
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Figure 7.8: HPLC chromatograms of pure T21-Cys, and T21-PEG(4)-Cys. HPLC 
system: Chromaster 600 bar DAD; column: Kinetex® C18; eluent: A = 0.1% TFA in 
water, B = 0.1% TFA in ACN; gradient: 10%  80% B over 30 min (method A8, 
Table 7.3). 
7.8 Determination of peptide concentration 
The concentration of peptide stock solutions was determined by UV detection (Section 7.1.8) 
using quartz cuvettes. The spectra were baseline corrected by the spectra of a sample containing 
solely buffer. The measurement was carried out in triplicate and the concentration was calculated 
according to the Lambert-Beer law (equation 7.3). 
Eλ = ελ ∙ c ∙ d     (7.3) 
Here, 𝐸𝐸𝜆𝜆 is the measured absorption at the wavelength λ, 𝜀𝜀𝜆𝜆 is the extinction coefficient of 
the peptide at the wavelength λ in M-1m-1, c the peptide concentration in mol/L and the path 
length of the cell in m. 
VPE/VPK peptides 
Peptide concentrations were determined by measuring the absorbance of o-aminobenzoic acid 
(λmax = 320 nm at pH 7.4), which is attached at the N-terminus of each peptide, as described 
before.[79, 251, 365] Therefore, a calibration curve was recorded using different concentrations of 
H2N-Abz-Gly-COOH × HCl (Bachem AG, Bubendorf, Switzerland) in the buffer used for CD 
spectroscopy containing 6 M guanidine hydrochloride (Figure 7.9). 
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Figure 7.9: Calibration curve for the determination of peptide concentrations 
recorded at 20°C in 100 mM phosphate buffer containing 6 M GdnHCl (pH 7.4). 
Gp41-derived peptides 
Peptide stock solutions were prepared by dissolving the lyophilized peptide in HFIP. An aliquot 
of the stock solution (10 µL) was taken, and HFIP was removed carefully under a gentle stream 
of argon. The resulting film was dissolved in 1.0 mL 50 mM sodium phosphate and 150 mM 
NaCl buffer containing 6 M guanidinium chloride (pH 7.4), and the absorbance at 280 nm was 
measured. The extinction coefficient of the peptides was determined using equation 7.4 according 
to Pace et al.[366] and the concentration of the stock solution was then calculated via the Lambert-
Beer law (equation 7.3). 
ε280nm �M-1∙cm-1� = #Trp∙5500 + #Tyr∙1490 + #Cys∙125    (7.4) #𝑇𝑇𝑇𝑇𝑇𝑇, #𝑇𝑇𝑇𝑇𝑇𝑇 and #𝐶𝐶𝑇𝑇𝐶𝐶 are the numbers of tryptophan, tyrosine and cysteine residues in the 
peptide sequence. 
Table 7.18: Calculated extinction coefficients. 





Prior to the experiments, the desired amount of the peptide stock solution was aliquoted, HFIP 
was removed and the peptide was dissolved in freshly prepared 50 mM sodium phosphate and 
150 mM NaCl buffer (pH 7.4). If necessary, the pH of this solution was adjusted to 7.4 by addition 
of NaOH and HCl. Stock solutions of 500 µM were prepared and stored at -20°C until use. 
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7.9 Structural analysis 
7.9.1 CD spectroscopy 
VPE/VPK peptides 
CD spectra were recorded using Quartz Suprasil® cuvettes of 1.0 mm path length (Hellma 
Analytics, Müllheim, Germany) equipped with a stopper. Measurements were performed with an 
overall peptide concentration of 20 μM (for equimolar mixtures: 10 µM VPE and 10 µM VPK) 
in 100 mM phosphate buffer (pH 7.4) at 20°C. Each reported CD value represents the mean of at 
least 3 independent measurements. The spectra were recorded with the parameters listed in Table 
7.19, and background-corrected by subtraction of the corresponding buffer spectra. 
Table 7.19: Parameters of CD spectroscopy for 
VPE/VPK peptides. 
parameter value 
sensitivity Standard (100 mdeg) 
wavelength start 240 nm 
wavelength end 190 nm 
data pitch 0.2 nm 
scanning mode continuous 
scanning speed 100 nm/min 
response 2 s 
bandwith 2 nm 
accumulation 3 
N2 flow 3 L/min 
The measured CD data in mdeg were converted into molar ellipticity per residue [θ] 
[mdeg⋅cm2⋅dmol-1·residue-1] according to equation 7.5. [𝜃𝜃] = 𝜃𝜃𝑜𝑜𝑜𝑜𝑜𝑜
10000∙𝑙𝑙∙𝑐𝑐∙𝑛𝑛
       (7.5) 
Here, 𝜃𝜃𝑜𝑜𝑜𝑜𝑜𝑜 is the measured ellipticity in deg, 𝑐𝑐 the peptide concentration in mol/l, 𝑙𝑙 the path 
length of the cell in cm and 𝑛𝑛 the number of amino acid residues (here 35).  
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Table 7.20: Parameters for thermal denaturation studies 
of VPE/VPK peptides. 
parameter value 
sensitivity Standard (100 mdeg) 
wavelength 222 nm 
starting temperature 20°C 
ending temperature 100°C 
data pitch 0.1°C 
delay time 0 s 
temperature slope 3°C/min 
response 1 s 
bandwith 1 nm 
N2 flow 3.0 L/min 
The melting curves were first normalized according to equation 7.5, and then fitted assuming two-
state unfolding to determine the melting temperature and free energy of unfolding (ΔGØ) as 
described before.[79] Each reported value represents the mean of at least 3 independent 
measurements. 
The fractional helical content of peptide (fH) was calculated from the mean residue molar 
ellipticity at 222 nm and the number of backbone amides (n = 35) using equation 7.6. 
𝑓𝑓𝐻𝐻 = [𝜃𝜃]222𝑛𝑛𝑛𝑛−40000 ∙ �1 − 4.6
𝑛𝑛
�
      (7.6) 
Gp41-derived peptides 
For this study 20 μM solutions of the peptides were prepared in 50 mM sodium phosphate and 
150 mM NaCl buffer (pH 7.4). CD spectra of the CHR/NHR peptide mixtures were also measured 
at an overall peptide concentration of 20 µM (10 µM in each monomer). The samples were 
incubated at 37°C for 30 min using a thermoshaker (300 rpm) before measuring. CD spectra were 
recorded at 25°C and 37°C using 1.0 mm Quartz Suprasil® cuvettes (Hellma Analytics, 
Müllheim, Germany) equipped with a stopper applying the parameters shown in the following 
table.  
Table 7.21: Parameters for CD spectroscopy of gp41 
derived peptides. 
parameter value 
sensitivity Standard (100 mdeg) 
wavelength start 240 nm 
wavelength end 195 nm 
data pitch 0.2 nm 
scanning mode continuous 
scanning speed 100 nm/min 
response 2 s 
bandwith 2 nm 
accumulation 3 
N2 flow 3.0 L/min 
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The measurements were carried out in triplicate. Spectra were background corrected by 
subtraction of the corresponding buffer spectra and normalized according to equation 7.5.  
To ensure that an interaction between the CHR- and NHR-peptide has taken place, the 
measured CD data of the individual peptides were summed up and the result was then divided in 
half. The so obtained CD spectrums are different from the ones of the individual peptides and the 
1:1 mixtures (data not shown). Thus, an interaction can be assumed.  
Thermal denaturation curves were recorded under the following conditions: 
Table 7.22: Parameters for thermal denaturation 
measurements of gp41 derived peptides. 
parameter value 
sensitivity Standard (100 mdeg) 
wavelength 222 nm 
starting temperature 25°C 
ending temperature 100°C 
data pitch 0.1°C 
delay time 0 s 
temperature slope 3°C/min 
response 1 s 
bandwith 1 nm 
N2 flow 3.0 L/min 
Measurements occurred at a peptide concentration of 20 μM in 50 mM sodium phosphate with 
150 mM NaCl buffer (pH 7.4) as well, and were repeated three times, in order to assure 
reproducibility and give standard deviations. The data were first normalized according to equation 
7.5 and then fitted with the following formula to determine the melting points as described 
before.[79, 251, 365]  
𝑓𝑓𝑛𝑛(𝑇𝑇) =  θ𝑜𝑜𝑜𝑜𝑜𝑜−�𝑚𝑚𝑓𝑓∙𝑇𝑇+θ𝑓𝑓��𝑚𝑚𝑢𝑢𝑛𝑛𝑓𝑓∙𝑇𝑇+θ𝑢𝑢𝑛𝑛𝑓𝑓�− �𝑚𝑚𝑓𝑓∙𝑇𝑇+θ𝑓𝑓�      (7.7) 
Here, 𝑚𝑚𝑓𝑓 is slope of the folded state, θ𝑓𝑓 the CD signal of the folded state, 𝑚𝑚𝑢𝑢𝑛𝑛𝑓𝑓 the slope of 
the unfolded state θ𝑢𝑢𝑛𝑛𝑓𝑓 the CD signal of the unfolded state and 𝑇𝑇 the temperature in K. The values 
can be obtained by fitting straight lines to the complete folded and unfolded state of the 
normalized melting curve (see Figure 7.10). The fits were performed in Microsoft® Excel 
Version 16.13 (Microsoft, Redmond, WA). 
Stabilization of peptides by site-specific incorporation of fluorinated amino acids 
 184 
 
Figure 7.10: Representation of a peptides melting curve with the 
interpolated straight lines for the complete folded and unfolded 
state.[365] 
The turning point of the melting curve represents the melting point of the investigated peptide or 
peptide assembly. For the fitted curve the melting point is marked by the temperature value for 
𝑓𝑓𝑛𝑛 = 0.5.[367] 
7.9.2 Size exclusion/static light scattering 
VPE/VPK peptides 
The oligomerization state of the peptide assemblies was determined by applying size exclusion 
chromatography (SEC) in combination with static light scattering (SLS). SLC data were collected 
on a Dawn 8+ multi-angle static light scattering (MALS) detector and an Optilab T-rEX 
differential Refractive index (dRI) detector (both Wyatt Technology Europe GmbH, Dernbach, 
Germany) coupled with an analytical SEC system. The latter consists of a VWR-Hitachi LaChrom 
ELITE HPLC workstation containing an organizer, a pump L-2130, and an UV-detector L-2400 
(all VWR International GmbH, Darmstadt, Germany). A WTC-015S5 column (5 μm, 150 Å, 
7.8 × 300 mm, Wyatt Technology Europe GmbH, Dernbach, Germany) was used and UV 
detection of the peptides occurred at λ = 220 nm. All measurements were performed at room 
temperature with 10 mM PBS, pH 7.4 as eluent and a flow rate of 0.3 mL/min. The overall peptide 
concentration was 35 µM from a 1:1 mixture of the different VPK/VPE variants, and the injection 
volume was 100 µL in each case. All experiments were performed in triplicate to confirm 
reproducibility and give standard deviations. Data were analyzed using the ASTRA software 
version 5.3.4.20 (Wyatt Technology), and the program OriginPro 2018b version 9.55 (OriginLab 
Corporation, Northampton, MA, USA). 
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7.9.3 Isothermal Titration Calorimetry (ITC) 
ITC assay was performed using a MicroCal iTC200 isothermal titration calorimeter (Malvern 
Panalytical Ltd, Malvern, United Kingdom). The CHR-peptide (100 µM) was injected into the 
cell containing the NHR-peptide (10 µM), both in 50 mM sodium phosphate with 150 mM NaCl 
buffer (pH 7.4). Measurements occurred at 25°C with the settings shown in Table 7.23 and 7.24. 
The reference cell contained Milli-Q-H2O. 
Table 7.23: Experimental parameters for 
ITC assay. 
parameter value 
total # injections 20 
cell temperature [°C] 25 
reference power [µcal/sec] 5 
initial delay [sec] 180 
stirring speed [rpm] 750 
Table 7.24: Injection parameters for the ITC assay. 
injection # volume [µL] duration [sec] spacing [sec] filter period [sec] 
1 0.5 1.0 180 5 
2-20 2.0 4.0 180 5 
Before the measurement, the peptide samples were dialyzed against the buffer for 3 h using the 
Pur-A-Lyzer™ Midi Dialysis Kit (MWCO 1 kDa, Sigma-Aldrich®/Merck KGaA, Darmstadt, 
Germany). Data analysis occurred using the MicroCal LLC ITC200 AddOn for the Origin 
software (version 7.0, SP4, OriginLab, Northampton, MA, USA). 
7.10 Enzymatic digestion studies 
All FA peptides were used as the TFA salts obtained after lyophilization. Stock solutions of 
α-chymotrypsin (from bovine pancreas, EC 3.4.21.1, ≥40.0 units/mg of protein, Sigma Aldrich, 
St. Louis, MO, USA), and pepsin (from porcine stomach mucosa, EC 3.4.23.1, ≥250 units/mg of 
protein, Sigma Aldrich, St. Louis, MO, USA) were prepared in phosphate buffer (10 mM, pH 
7.4), or in acetate buffer (10 mM, pH 4.0), respectively. Proteinase K (from Tritirachium album, 
EC 3.4.21.64, ≥30 units/mg of protein, Sigma Aldrich, St. Louis, MO, USA) and elastase (from 
porcine pancreas, EC 3.4.21.36, 6.2 units/mg of protein, Sigma Aldrich, St. Louis, MO, USA) 
were dissolved in Tris/HCl (50 mM) + CaCl2 (10 mM) buffer (pH 7.5), or in Tris/HCl buffer (100 
mM, pH 8.4), respectively. All enzyme stocks were prepared at concentrations of 1 mg/mL. 
Stock solutions of the peptides (2.00 µmol each) were prepared in DMSO (100 µL). 
Incubation with the respective enzymes occurred at 30°C (for α-chymotrypsin and pepsin) or 
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37°C (for proteinase K and elastase) with shaking at 300 rpm in a thermomixer over a period of 
24 h. The reaction mixture consisted of DMSO (15 μL), corresponding buffer (25 μL), peptide 
solution (5 μL) and the corresponding enzyme solution (5 μL). The concentration of enzyme in 
the reaction mixture was optimized such that the hydrolysis of the control peptide FA was about 
40% after 120 min incubation. Aliquots of 5 μL were taken at fixed time points (0, 15, 30, 60, 90, 
120 min as well as 3 h and 24 h) and either quenched with ACN containing 0.1% (v/v) TFA 
(95 μL), in the case of α-chymotrypsin, proteinase K and elastase, or 2% aqueous ammonia 
(95 μL), in the case of pepsin.  
For characterization of the enzymatic digestion reactions all samples were subjected to 
analytical HPLC on a LaChrom-ELITE system with fluorescence detection (see Section 7.1.4). 
Linear gradients of eluents were applied according to the methods described in Table 7.5. For the 
non-fluorinated peptides method FL1 was used, and for the fluorinated peptides method FL2 was 
applied to follow the digestion process. For chromatograms where an insufficient baseline 
separation was observed, measurements were repeated using methods FL3 [FA (pepsin), 
P2-IleFA (pepsin), P2-IleFA (proteinase K), P1'-IleFA (proteinase K)] or FL4 [P2-53-F3IleFA 
(pepsin), P2-53-F3IleFA (proteinase K), P1'-53-F3IleFA (elastase), P2'-53-F3IleFA (proteinase K)]. 
In all cases, the peaks corresponding to the starting materials (full-length peptides) or the 
N-terminal fragments (digestion products) were integrated and used to determine the amount of 
substrate still present (in %), and the velocity of the reaction. The FA peptide was used as a 
reference. Identification of each fragment cleaved from the full-length peptide (Table 8.1 - 8.4, 
Supplementary data) occurred according to the mass-to-charge ratios determined on an Agilent 
6220 ESI-ToF-MS instrument using setting A (see Section 7.1.6, Table 7.6). For this, the 
quenched peptide-enzyme-solutions after 120 min and 24 h incubation were analyzed. Not all 
corresponding fragments could be detected. All experiments were performed in triplicate. 
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8. Supplementary Data 
Crystal structure depiction 
Graphics of the peptides crystal structures were created using the UCSF Chimera package. 
Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics at the 
University of California, San Francisco (supported by NIGMS P41-GM103311).[368] The 
structural data were taken from the PDB (https://www.rcsb.org). 
SEC/SLS to determine the oligomerization state of VPE/VPK bundles  
The dimeric oligomerization states of the parent VPE/VPK assembly as well as the fluorinated 
variants have been determined by SEC/SLS. Single peaks were found for all VPE/VPK variants 
with SEC corresponding species of molecular weights comparable to the theoretical dimer mass 
(Table 5.2, Figure 8.1). 
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Figure 8.1: SEC/SLS chromatograms of VPE/VPK bundles. Peptide concentration: 35 µM; eluent: 10 mM PBS, pH 
7.4; flow rate: 0.3 mL/min. Measurements were taken from equimolar mixtures of the different VPK/VPE variants and 
repeated two times to confirm reproducibility and give standard deviations. Single peaks were detected with UV at 220 






Identification of the proteolytic cleavage products of the enzymatic digestion assay of FA 
peptides by ESI-ToF MS 
Table 8.1: Identification of the cleavage products of the different peptides by ESI-ToF 
mass spectrometry after digestion with α-chymotrypsin. 
peptide fragment 
[M + H]1+ 
calculated 
[M + H]1+ 
observed 
FA Abz-KAAFAAAAK 967.5364 967.5376 
Abz-KAAF 555.2559 555.2938 
AAAAK 431.2617 431.2627 
P2-IleFA Abz-KAIleFAAAAK 1009.5463 1009.5851 
Abz-KAIleF 597.3029 597.3435 
AAAAK 431.2617 431.2647 
P2-53-F3IleFA Abz-KA-5
3-F3Ile-FAAAAK 1063.4622 1063.5577 
P1'-IleFA Abz-KAAFIleAAAK 1009.5463 1009.5825 
Abz-KAAF 555.2559 555.2951 
IleAAAK 473.3087 473.3104 
P1'-53-F3IleFA Abz-KAAF-5
3-F3Ile-AAAK 1063.4622 1063.5604 
Abz-KAAF 555.2559 555.2954 
53-F3Ile-AAAK 527.2246 527.2827 
P2'-IleFA Abz-KAAFAIleAAK 1009.5463 1009.5875 
Abz-KAAF 555.2559 555.2943 
AIleAAK 473.3087 473.3112 
P2'-53-F3IleFA Abz-KAAFA-5
3-F3Ile-AAK 1063.4622 1063.5575 
Abz-KAAF 555.2559 555.2945 
A-53-F3Ile-AAK 527.2246 527.2822 
Table 8.2: Identification of the cleavage products of the different peptides by ESI-ToF 
mass spectrometry after digestion with pepsin. 
peptide fragment 
[M + H]1+ 
calculated 
[M + H]1+ 
observed 
FA Abz-KAAFAAAAK 96.5364 967.5434 
Abz-KAAF 555.2559 555.2967 
AAAAK 431.2617 431.2617 
P2-IleFA Abz-KAIleFAAAAK 1009.5463 1009.5916 
Abz-KAIleF 597.3029 597.3442 
AAAAK 431.2617 431.2647 
P2-53-F3IleFA Abz-KA-5
3-F3Ile-FAAAAK 1063.4622 1063.5639 
P1'-IleFA Abz-KAAFIleAAAK 1009.5463 1009.5908 
Abz-KAAF 555.2559 555.2969 
IleAAAK 473.3087 437.3087 
P1'-53-F3IleFA Abz-KAAF-5
3-F3Ile-AAAK 1063.4622 1063.5634 
Abz-KAAF 555.2559 555.2969 
53-F3Ile-AAAK 527.2246 527.2843 
P2'-IleFA Abz-KAAFAIleAAK 1009.5463 1009.5889 
Abz-KAAF 555.2559 555.2970 
AIleAAK 473.3087 473.3121 
P2'-53-F3IleFA Abz-KAAFA-5
3-F3Ile-AAK 1063.4622 1063.5627 
FA-53-F3Ile-AAK 674.2930 674.3530 
Abz-KAAFA 626.2930 626.3333 
Abz-KAAF 555.2559 555.2969 
A-53-F3Ile-AAK 527.2246 527.2845 
53-F3Ile-AAK 456.1875 456.2462 
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Table 8.3: Identification of the cleavage products of the different peptides by ESI-ToF 
mass spectrometry after digestion with elastase. 
peptide fragment 
[M + H]1+ 
calculated 
[M + H]1+ 
observed 
FA Abz-KAAFAAAAK 967.5364 967.5352 
Abz-KAAFAAA 768.3672 768.4080 
Abz-KAAFAA 697.3301 697.3690 
AFAAAAK 649.3673 648.2935 
Abz-KAAFA 626.2930 626.3308 
AAAK 360.2246 360.2238 
AAK 289.1875 289.1872 
P2-IleFA Abz-KAIleFAAAAK 1009.5463 1009.5884 
Abz-KAIleFAAAA 881.4513 881.4960 
Abz-KAIleFAAA 810.4142 810.4960 
Abz-KAIleFAA 739.3771 739.4176 
Abz-KAIleFA 668.3400 668.3787 
FAAAAK 578.3301 578.3322 
AAAK 360.2246 360.2256 
AAK 289.1875 289.1880 
AK 218.1504 218.1505 
P2-53-F3IleFA Abz-KA-53-F3Ile-FAAAAK 1063.4622 1063.5576 
Abz-KA-53-F3Ile-FAAA 864.3301 864.4210 
Abz-KA-53-F3Ile-FAA 793.2930 793.3844 
Abz-KA-53-F3Ile-FA 722.2559 722.3470 
FAAAAK 578.3301 578.3271 
AAAK 360.2246 360.224 
P1'-IleFA Abz-KAAFIleAAAK 1009.5463 1009.5853 
Abz-KAAFIleAA 810.4142 810.4500 
Abz-KAAFIleA 739.3771 739.4144 
FIleAAAK 620.3771 620.3747 
P1'-53-F3IleFA Abz-KAAF-53-F3Ile-AAAK 1063.4622 1063.5578 
Abz-KAAF-53-F3Ile-AA 864.3301 864.4205 
Abz-KAAF-53-F3Ile-A 793.2930 793.3844 
AF-53-F3Ile-AAAK 745.3301 745.3814 
AAK 289.1875 289.1857 
AK 218.1504 218.1483 
P2'-IleFA Abz-KAAFAIleAAK 1009.5463 1009.5866 
Abz-KAAFAIleAA 881.4513 881.4910 
Abz-KAAFAIleA 810.4142 810.4539 
Abz-KAAFAIle 739.3771 739.4171 
FAIleAAK 620.3771 620.3687 
Abz-KAA 408.1875 408.2252 
P2'-53-F3IleFA Abz-KAAFA-53-F3Ile-AAK 1063.4622 1063.5530 
Abz-KAAFA-53-F3Ile 793.2930 793.3851 
FA-53-F3Ile-AAK 674.2930 674.3441 
Abz-KAA 408.1875 408.2233 





Table 8.4: Identification of the cleavage products of the different peptides by ESI-ToF 
mass spectrometry after digestion with proteinase K. 
peptide fragment 
[M + H]1+ 
calculated 
[M + H]1+ 
observed 
FA Abz-KAAFAAAAK 967.5364 967.5376 
AFAAAAK 649.3673 649.2762 
P2-IleFA Abz-KAIleFAAAAK 1009.5463 1009.5872 
Abz-KAIleFAAA 810.4142 810.4551 
Abz-KAIleFAA 739.3771 739.4192 
Abz-KAIleFA 668.3400 889.3806 
Abz-KAIleF 597.3029 597.3422 
AAK 289.1875 289.1891 
P2-53-F3IleFA Abz-KA-5
3-F3Ile-FAAAAK 1063.4622 1063.5604 
Abz-KA-53-F3Ile-FAAA 864.3301 864.4204 
Abz-KA-53-F3Ile-FAA 793.2930 793.3895 
Abz-KA-53-F3Ile-FA 722.2559 722.3512 
Abz-KA-53-F3Ile-F 651.2188 651.3140 
AAAAK 431.2617 430.0513 
AAK 289.1875 289.1888 
P1'-IleFA Abz-KAAFIleAAAK 1009.5463 1009.5878 
Abz-KAAFIleAA 810.4142 810.4545 
Abz-KAAFIleA 739.3771 739.4169 
FIleAAAK 620.3771 620.3795 
Abz-KAA 408.1875 408.2265 
AAK 289.1504 289.1891 
P1'-53-F3IleFA Abz-KAAF-5
3-F3Ile-AAAK 1063.4622 1063.5580 
Abz-KAAF-53-F3Ile-AA 864.3301 864.4253 
Abz-KAAF-53-F3Ile-A 793.2930 793.3853 
F-53-F3Ile-AAAK 647.2930 674.3504 
Abz-KAA 408.1875 408.2260 
AAK 289.1875 289.1880 
AK 218.1504 218.1508 
P2'-IleFA Abz-KAAFAIleAAK 1009.5463 1009.5854 
Abz-KAAFA 626.2930 626.338 
FAIleAAK 620.3771 620.3791 
Abz-KAA 408.1875 408.2260 
P2'-53-F3IleFA Abz-KAAFA-5
3-F3Ile-AAK 1063.4622 1063.5563 
FA-53-F3Ile-AAK 674.2930 674.3496 
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